T cell receptors recognizing mutated p53
By developing T cell receptors that can identify and attack mutant p53, the problem of ineffective treatment of certain metastatic cancers in the prior art has been solved, efficient identification and killing of multiple cancers, and reduced normal cells toxicity.
Patent Information
- Application Number
- CN202411117183.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2017-09-29
- Filing Date
- 2018-09-17
- Publication Date
- 2024-11-15
AI Technical Summary
Existing cancer treatments have poor prognosis for metastatic cancer, especially certain types of cancer such as pancreas, colorectal, lung, endometrium, ovarian and prostate cancer, resulting in unmet additional treatment needs.
A T-cell receptor (TCR) that can recognize and target the mutant p53 protein is developed, and mutant p53 is recognized and attacked through HLA molecular-dependent means, reducing toxicity to normal cells and improving killing efficacy against cancer cells.
The TCR can effectively identify and attack cancer cells carrying mutant p53, reduce damage to normal cells, improve treatment effect, and provide new treatment options for mutant p53-positive cancers that are unresponsive to various types of treatments, expanding immunotherapy Indications.
Smart Images

Figure CN118955684A_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This patent application claims the benefit of U.S. Provisional Patent Application No. 62 / 565,383, filed on September 29, 2017, which is incorporated herein by reference in its entirety.
[0003] STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT
[0004] This invention was made with government support from the National Cancer Institute of the National Institutes of Health under Grant No. BC010985. The government has certain rights in this invention.
[0005] Incorporation by Reference of Electronically Submitted Materials
[0006] Incorporated herein by reference in its entirety is the computer-readable nucleotide / amino acid sequence listing filed concurrently and identified as follows: a 687,555-byte ASCII (text) file named "739980_ST25.txt" dated September 7, 2018. Background of the Invention
[0008] Treatment options for some cancers can be very limited, especially when the cancer has metastasized and cannot be removed. Despite advances in treatments such as surgery, chemotherapy, and radiation therapy, many cancers (e.g., pancreatic, colorectal, lung, endometrial, ovarian, and prostate cancers) can have a poor prognosis. Therefore, there is an unmet need for additional cancer treatments. Brief description of the invention
[0010] One embodiment of the present invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for mutant human p53.
[0011] Other embodiments of the present invention provide related polypeptides and proteins involving the TCR of the present invention and related nucleic acids, recombinant expression vectors, host cells, cell populations and pharmaceutical compositions.
[0012] Additional embodiments of the invention provide methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal. BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS
[0014] Figure 1Graph showing IFN-γ (pg / mL) concentrations measured after co-culture with autologous PBLs transduced with one of the indicated TCRs from patient 4127, after co-culture with autologous dendritic cells (DCs) pulsed with decreasing concentrations (μg / mL) of the indicated WT p53-G245 peptide (wt) (unshaded bars) or mutant p53-G245S peptide (mut) (shaded bars).
[0015] Figure 2 Graph showing the percentage of 4-1BB-positive cells (%CD4+mTCRβ+) detected after co-culturing autologous PBL transduced with one of the indicated TCRs from patient 4127 with autologous dendritic cells (DCs) pulsed with decreasing concentrations (μg / mL) of WT p53-G245 peptide (wt) (unshaded bars) or mutant p53-G245S peptide (mut) (shaded bars) as indicated.
[0016] Figure 3 is a graph showing the percentage of 4-1BB positive cells (%CD4+mTCRβ+) detected after co-culturing autologous PBL transduced with one of the indicated TCRs from patient 4127 with autologous DC pulsed with one of the peptides shown in Table A.
[0017] Figure 4 is a graph showing IFN-γ (pg / mL) concentrations measured after co-culturing TILs from patient 4127 or T cells transduced with one of the indicated TCRs with COS7 cells transduced with one of the indicated HLA alleles and pulsed with DMSO or one of the indicated peptides.
[0018] Figure 5 Graph showing the percentage of 4-1BB-positive cells (% of CD4+mTCRβ+) detected after co-culturing TILs from patient 4127 or T cells transduced with one of the indicated TCRs with COS7 cells transduced with one of the indicated HLA alleles and pulsed with DMSO or one of the indicated peptides.
[0019] Figure 6 The results show that the expression of 2x10 cells / mL was measured after co-culturing TILs from patient 4127 with allogeneic (DRB3*01:01:01 or DRB3*02:02:01) APCs. 4Figure 2. Graph of the number of effector cell spots on allogeneic (DRB3*01:01:01 or DRB3*02:02:01) APCs (1) electroporated with TMG consisting of an irrelevant (IRR; left slashed empty bars), WT p53 (p53-WT; left slashed gray bars), or mutated p53 (p53-MUT; gray bars) sequence or (2) pulsed with a peptide vehicle (DMSO; right slashed empty bars) or a purified (>95% by HPLC) 25 amino acid peptide consisting of a WT p53-G245 sequence (LP-p53-wt-G245; right slashed gray bars) or mutated p53-G245S (LP-p53-mut-G245S; black bars) sequence.
[0020] Figure 7 The results show that the expression of 4127-TCR1 in cells was measured after co-culturing with allogeneic (DRB3*01:01:01 or DRB3*02:02:01) APCs per 2x10 4 Figure 2. Graph of the number of effector cell spots of allogeneic (DRB3*01:01:01 or DRB3*02:02:01) APCs (1) electroporated with TMG consisting of irrelevant (IRR; left slashed empty bars), WT p53 (p53-WT; left slashed gray bars), or mutated p53 (p53-MUT; gray bars) sequences or (2) pulsed with peptide vehicle (DMSO; right slashed empty bars) or purified (>95% by HPLC) 25 amino acid peptide consisting of WT p53-G245 sequence (LP-p53-wt-G245; right slashed gray bars) or mutated p53-G245S (LP-p53-mut-G245S; black bars) sequences.
[0021] Fig. 8A Figure 2 shows IFN-γ secretion (spots / 2×10) measured after co-culture of TILs from the infusion bag used to treat patient 4196 with Cos7 cells transfected with a TMG1 plasmid and the indicated HLA alleles. 4 cells).
[0022] Figure 8B Figure 2 shows IFN-γ secretion (spots / 2×10) measured after co-culture of TILs from the infusion bag used to treat patient 4196 with autologous DCs pulsed with the candidate minimal epitopes (HMTEVVRHC (SEQ ID NO: 530) or (SQHMTEVRH (SEQ ID NO: 531)). 4 T cells cultured alone served as a control.
[0023] Figures 9A-9DIt is a figure showing the percentage of mTCRβ+CD8+41BB+ cells detected after DC pulsed with the minimum WT (circle) or mutated (mut) (square) epitope of indicated concentration (μg / mL) and cells transduced using one of the following TCRs were co-cultured: AV12 / BV6-1 (A), AV2 / BV6-1 (B), AV6 / BV11 (C) or AV38 / BV10-3 (D). Pulsed DCs were co-cultured with untransduced (UT) cells (triangles) as controls. The results shown represent two experiments.
[0024] Figures 10A-10B It is a graph showing IFN-γ secretion (pg / mL) (A) and 4-1BB positive cell percentage (%, mTCRβ+) (B) measured after co-culturing of T2 cells pulsed with the minimally mutated epitope of the indicated concentration (μg / mL) and cells transduced using one of the following TCRs: AV12 / BV6-1 (solid triangles), AV6 / BV11 (circles) or AV38 / BV10-3 (squares). Pulsed T2 cells were co-cultured with untransduced (UT) cells (hollow triangles) as a control.
[0025] Fig.11 The results show that after co-culturing TCR-transduced cells with the specified target cell lines, every 2X10 4 Figure 2 shows the number of IFN-γ positive spots per effector cell. Effector cells were transduced with AV12 / BV6-1 (black bars), AV6 / BV11 (striped bars), or AV38 / BV10-3 (grey bars). HLA-A*02:01 transduced target cells are indicated by LS123-A2, CCRF-CEM-A2, and AU-565-A2. Peptide-pulsed target cells are indicated as (+). Target cells not pulsed with peptide are indicated by (-). Untransduced effector cells co-cultured with target cell lines (unshaded bars) were used as controls.
[0026] Fig.12 Figure 2 shows the number of 2×10 p53-positive cells detected after co-culture of patient 4238 TIL fragments F1-F24 (n=24) with autologous APCs electroporated with TMG composed of either irrelevant (IRR; open bars) or mutant p53 (p53-MUT; black bars) sequences. 4 Figure 3 is a graph showing the number of IFN-γ positive spots per effector cell.
[0027] Fig.13 Figure 2 shows the number of 2 × 10 β-cells detected after co-culture of patient 4238 TIL fragments F1-F24 (n=24) with autologous APCs pulsed with purified (>95% by HPLC) 25-amino acid peptides consisting of the peptide vehicle (DMSO; open bars) or mutant p53-R248Q (LP-p53-R248Q-MUT; black bars) sequences.4 Figure 3 is a graph showing the number of IFN-γ positive spots per effector cell.
[0028] Fig.14 Graph showing the percentage of CD8+4-1BB+ cells detected after co-culture of patient 4238 TIL fragments F1-F24 (n=24) with autologous APCs electroporated with TMG composed of irrelevant (IRR; open bars) or mutant p53 (p53-MUT; black bars) sequences.
[0029] Fig.15 Graph showing the percentage of CD8+4-1BB+ cells detected after co-culture of 4238TIL fragments F1-F24 (n=24) with autologous APCs pulsed with purified (>95% by HPLC) 25 amino acid peptides consisting of the peptide vehicle (DMSO; open bars) or mutant p53-R248Q (LP-p53-R248Q-MUT; black bars) sequence.
[0030] Fig.16 Figure 2 shows the number of TIL fragments (F1-F24, n=24) from patient 4253 measured after co-culturing with autologous APCs per 2×10 4 Figure 2. Plot of the number of IFN-γ-positive spots on effector cells of autologous APCs (1) pulsed with peptide vehicle (DMSO; empty bars), (2) pulsed with a purified (>95% by HPLC) 25-amino acid peptide consisting of the mutant p53R248W (LP-p53R248W-MUT; black bars) sequence, (3) electroporated with irrelevant TMG (TMG-IRR; gray slashed bars), or (4) electroporated with p53-mut-TMG containing the mutant p53-R248W sequence.
[0031] Fig.17 Figure 2 shows the number of TIL fragments (F1-F24, n=24) from patient 4273 measured after co-culturing with autologous APCs per 2×10 4 Figure 2. Graph of the number of IFN-γ-positive spots on effector cells of autologous APCs electroporated with TMG consisting of irrelevant (IRR; empty bars), WT p53 (p53-WT; gray bars), or mutated p53 (p53-MUT; black bars) sequences.
[0032] Fig.18 Graph showing the percentage of CD4+4-1BB+ cells detected after co-culturing TIL fragments from patient 4273 (F1-F24, n=24) with autologous APCs electroporated with TMG composed of irrelevant (IRR; empty bars), WT p53 (p53-WT; gray bars), or mutated p53 (p53-MUT; black bars) sequences.
[0033] Fig.19 Figure 2 shows the number of TIL fragments (F1-F24, n=24) from patient 4273 measured after co-culturing with autologous APCs per 2×10 4 Figure 2 shows the number of IFN-γ-positive spots on autologous APCs pulsed with peptide vehicle (DMSO; empty bars) or purified (>95% by HPLC) 25-amino acid peptides consisting of the WT p53-R248 sequence (LP-p53-R248-WT; gray bars) or the mutated p53-R248W (LP-p53-R248W-MUT; black bars) sequence.
[0034] Fig. 20 Graph showing the percentage of CD4+4-1BB+ cells detected after co-culturing TIL fragments from patient 4273 (F1-F24, n=24) with autologous APCs pulsed with peptide vehicle (DMSO; empty bars) or purified (>95% by HPLC) 25-amino acid peptide consisting of the WT p53-R248 sequence (LP-p53-R248-WT; gray bars) or mutated p53-R248W (LP-p53-R248W-MUT; black bars) sequence.
[0035] Fig.21 Figure 2 shows the number of 2x10 cells / mL measured after co-culturing autologous PBL from patient 4149 (transposed with 4149-TCRa2b1 or 4149-TCRa2b2) with autologous APCs. 4 Figure 2. Graph of the number of IFN-γ-positive spots on effector cells of autologous APCs (1) electroporated with TMG consisting of irrelevant (IRR, right diagonal black bars), WT p53 (p53-wt-TMG, left diagonal black bars), or mutated p53 (p53-mut-TMG, gray bars) sequences, or (2) pulsed with peptide vehicle (DMSO, open bars) or purified (>95% by HPLC) 25-amino acid peptide consisting of WT p53-Y220 sequence (LP-p53-Y220-WT, horizontally shaded black bars) or mutated p53-Y220C (LP-p53-Y220C-MUT, black bars). Phorbol 12-myristate 13-acetate (PMA) and ionomycin (Iono) were positive controls (gray bars).
[0036] Fig. 22Graph showing the percentage of CD4+4-1BB+ cells detected after co-culture of autologous PBL from patient 4149 transposed with TCR (4149-TCRa2b1 or 4149-TCRa2b2) with autologous APCs (1) electroporated with TMG consisting of irrelevant (IRR, right slashed black bars), WT p53 (p53-wt-TMG, left slashed black bars), or mutated p53 (p53-mut-TMG, gray bars) sequences, or (2) pulsed with peptide vehicle (DMSO, open bars) or purified (>95% by HPLC) 25-amino acid peptide consisting of WT p53-Y220 sequence (LP-p53-Y220-WT, horizontally shaded black bars) or mutated p53-Y220C (LP-p53-Y220C-MUT, black bars) sequences. PMA and Iono were positive controls (grey bars).
[0037] Fig.23 is a graph showing the percentage of 4-1BB+ cells (percentage of CD4+ T cells) detected after co-culture of TILs from patient 4149 with autologous DCs pulsed with one of the peptides in Table F.
[0038] Fig.24 Graph showing IFN-γ secretion (pg / mL) of 4149-TCRa2b2 transposed T cells co-cultured with Cos7 cells co-transfected with individual HLA alleles + / - TMG. Cells not transfected with TMG were pulsed with p53Y220C 15-mer peptide. Pulsed target cells are indicated by shaded bars. TMG transfected target cells are indicated by unshaded bars.
[0039] Fig.25 Graph showing the percentage of CD8+4-1BB+ cells detected after co-culture of TIL fragments (F2 and F24) from patient 4213 with autologous APCs pulsed with either peptide vehicle (DMSO, open bars) or a purified (>95% by HPLC) 25-amino acid peptide consisting of the mutant p53-R248Q (LP-p53-R248Q-MUT; black bars) sequence.
[0040] Fig.26 The TIL fragments (F2 and F24) of patient 4213 were co-cultured with autologous APCs and measured per 2x10 4Figure 2 shows the number of IFN-γ-positive spots of effector cells, wherein the autologous APCs were pulsed with a peptide vehicle (DMSO, open bars) or a purified (>95%, by HPLC) 25-amino acid peptide consisting of a mutant p53-R248Q (LP-p53-R248Q-MUT; black bars) sequence. The secretion of IFN-γ is represented by the open bars. The expression of 4-1BB is shown by the solid bars.
[0041] Fig. 27 The TIL fractions (F1-F24, n=24) of patient 4268 were co-cultured with autologous APCs and the number of cells per 2×10 4 Figure 2. Graph of the number of IFN-γ-positive spots on effector cells of autologous APCs electroporated with TMG consisting of irrelevant (IRR, open bars), WT p53 (p53-WT, gray bars), or mutated p53 (p53-MUT, black bars) sequences.
[0042] Fig.28 Figure 2 shows the TIL fractions (F1-F24, n=24) of patient 4268 after co-culture with autologous APCs. 4 Figure 2. Graph of the number of IFN-γ-positive spots on effector cells of autologous APCs pulsed with peptide vehicle (DMSO, open bars) or purified (>95% by HPLC) 25-amino acid peptides consisting of the WT p53-R248 sequence (LP-p53-R248-WT; gray bars) or the mutated p53-R248Q (LP-p53-R248Q-MUT; black bars) sequence.
[0043] Fig.29 Graph showing the percentage of CD4+4-1BB+ cells detected after co-culture of TIL fragments (F1-F24, n=24) from patient 4268 with autologous APCs pulsed with either peptide vehicle (DMSO, open bars) or purified (>95% by HPLC) 25-amino acid peptide consisting of the WTp53-R248 sequence (LP-p53-R248-WT; gray bars) or mutated p53-R248Q (LP-p53-R248Q-MUT; black bars) sequence.
[0044] Fig.30Graph showing the percentage of CD8+4-1BB+ cells detected after co-culture of TIL fragments (F1-F24, n=24) from patient 4268 with autologous APCs pulsed with either peptide vehicle (DMSO, open bars) or purified (>95% by HPLC) 25-amino acid peptide consisting of the WTp53-R248 sequence (LP-p53-R248-WT; gray bars) or mutated p53-R248Q (LP-p53-R248Q-MUT; black bars) sequence.
[0045] Fig.31 Figure 2 shows the number of TIL fragments (F1-F24, n=24) from patient 4266 measured after co-culture with autologous APCs per 2×10 4 Figure 2. Graph of the number of IFN-γ-positive spots per effector cell of autologous APCs electroporated with TMG consisting of irrelevant (IRR, open bars), WT p53 (p53-WT, gray bars), or mutated p53 (p53-MUT, black bars) sequences.
[0046] Fig.32 Graph showing the percentage of CD8+4-1BB+ cells detected after co-culture of TIL fragments from patient 4266 (F1-F24, n=24) with autologous APCs electroporated with TMG consisting of irrelevant (IRR, open bars), WT p53 (p53-WT, gray bars), or mutated p53 (p53-MUT, black bars) sequences.
[0047] Fig.33 Figure 2 shows the number of TIL fragments (F1-F24, n=24) from patient 4266 measured after co-culture with autologous APCs per 2×10 4 Figure 2. Graph of the number of IFN-γ-positive spots on effector cells of autologous APCs pulsed with peptide vehicle (DMSO, open bars) or purified (>95% by HPLC) 25-amino acid peptides consisting of the WT p53-R248 sequence (LP-p53-R248-WT; gray bars) or the mutated p53-R248W (LP-p53-R248W-MUT; black bars) sequence.
[0048] Fig.34Graph showing the percentage of CD8+4-1BB+ cells detected after co-culture of TIL fragments (F1-F24, n=24) from patient 4266 with autologous APCs pulsed with either peptide vehicle (DMSO, open bars) or purified (>95% by HPLC) 25-amino acid peptide consisting of the WTp53-R248 sequence (LP-p53-R248-WT; gray bars) or mutated p53-R248W (LP-p53-R248W-MUT; black bars) sequence.
[0049] Fig.35 An alignment of the amino acid sequences of nine p53 splice variants is shown. SP|P04637|P53_HUMAN(SEQ ID NO:1); SP|P04637-2|P53_HUMAN(SEQ ID NO:535); SP|P04637-3|P53_HUMAN(SEQ ID NO:536); SP|P04637-4|P53_HUMAN(SEQ ID NO:537);SP|P04637-5|P53_HUMAN(SEQ ID NO:538);SP|P04637-6|P53_HUMAN(SEQ ID NO:539);SP|P04637-7|P53_HUMAN(SEQ ID NO:540);SP|P04637-8|P53_HUMAN(SEQ ID NO:541); and SP|P04637-9|P53_HUMAN (SEQ ID NO:542).
[0050] Fig.36 is a graph showing the percentage of 4-1BB-positive cells (% of mTCRβ+) detected after co-culture of T cells transduced with 4127-037-TCR with autologous APCs pulsed with decreasing concentrations of a 25-amino acid peptide corresponding to the WT (open circles) or mutant (filled squares) p53-G245S sequence.
[0051] Figures 37A-37C Graphs showing the percentage of 4-1BB-positive cells (% of mTCRβ+) (left y-axis; diagonal bars) and IFN-γ (pg / mL) (right y-axis; black bars) measured after co-culturing T cells transduced with 4127-O37-TCR (A), 4127-TP31-G245S-TCR1 (B), or 4127-O102-TCR (C) with COS7 cells co-transfected with one of the indicated HLA alleles and pulsed with the 25-amino acid p53-G245S peptide.
[0052] Fig.38Figure 2 is a graph showing the percentage of 4-1BB-positive cells (%CD8+) measured after co-culturing TILs (fragment culture 12) from patient 4141 with autologous APCs (right y-axis; black bars) and IFN-γ (number of spots / 2X10 4 Figure 2 shows a graph of APCs transfected with TMG encoding an irrelevant mutation (TMG-IRR), a WT p53 sequence (TP53-wt-TMG), or a mutant p53 sequence (including R175H) (TP53-mut-TMG). Culture medium alone and PMA and ionomycin were negative and positive controls, respectively.
[0053] Fig.39 To show the measured 2x10 4 Figure 2 is a graph of the number of IFN-γ-positive spots per effector cell co-transfected with the indicated HLA alleles and no additional genes (HLA only; open bars), or with WT TP53 TMG (grey shaded bars) or mutant TP53 TMG containing the p53-R175H sequence (black bars).
[0054] Fig.40 Figure 2 is a graph showing IFN-γ concentrations (pg / mL) measured after co-culturing T cells expressing mock (no TCR) or 4141-TCR1a2 with T2 tumor cells (expressing HLA-A*02:01). T2 cells were pulsed with peptide vehicle (DMSO; gray bars) or purified (>95% by HPLC) peptides consisting of WT p53-R175 peptide (shaded gray bars) or mutant p53-R175H peptide (black bars). Medium alone (open bars) and PMA and ionomycin (grid bars) were negative and positive controls, respectively. Data are mean ± SEM (n = 3).
[0055] Fig.41 Graph showing the percentage of cells positively expressing one of the indicated markers after co-culture of T cells expressing 4141-TCR1a2 with Saos2 cells (p53-NULL and HLA-A*02:01+), which were either untreated (unshaded bar) or made to overexpress full-length p53R-175H protein (shaded bar). Data are mean ± SEM (n = 3). Student's two-tailed t-test was performed for each cytokine between the two cell lines for statistical analysis (***p < 0.001).
[0056] Fig.42Figure 2 is a graph showing the percentage of CD4+4-1BB-positive cells detected after co-culture of TILs (fragment culture 6 from patient 4259) with autologous APCs that were either (1) electroporated with TMG consisting of irrelevant (TMG-IRR), WT p53 (TMG-p53-WT), or mutated p53 (TMG-p53-MUT) sequences, or (2) pulsed with a peptide vehicle (DMSO) or a purified (>95% by HPLC) 25-amino acid peptide consisting of the WTp53-Y220 sequence (LP-p53-Y220-WT) or mutated p53-Y220C (LP-p53-Y220C-MUT) sequence.
[0057] Fig.43 is a graph showing the percentage of CD4+4-1BB-positive cells detected after co-culture of TIL fragment cultures from patient 4259 (no. 6) with autologous APCs pulsed with decreasing concentrations of 25-amino acid peptides corresponding to the WT p53 sequence (open circles) or mutated p53-Y220C (filled squares) at 37°C for 2 hours.
[0058] Fig.44 is a graph showing the percentage of CD4+4-1BB-positive cells detected after co-culture of TILs from patient 4259 with autologous APCs pulsed with DMSO, WTp53-Y220 peptide, or mutant p53-Y220C peptide.
[0059] Fig.45 is a graph showing the percentage of 4-1BB-positive cells (CD4+%) detected after co-culturing TIL fragment cultures from patient 4259 (no. 6) with Cos7 cells, which were co-transfected with the indicated HLA alleles from patient 4259 and pulsed with DMSO (open bars) or p53-Y220C peptide (solid bars).
[0060] Fig.46 TC#4259 target cells (endogenously expressing p53Y220C and HLA-DRB1*04:01:01) were compared with effector T cells expressing mock (no TCR, open bars) or p53-Y220C-specific TCR (4259-F6-TCR; black bars) (10 5) Figure of the percentage of 4-1BB+ cells detected after co-culture.TC#4259 cells were not incubated with any substance, or TC#4259 cells were incubated with W6 / 32 pan-HLA class I specific blocking antibody, IVA12 pan-HLA class II specific blocking antibody or mutated p53-Y220C peptide. Separate culture medium (no TC) and PMA and ionomycin were negative and positive controls, respectively. Data are mean ± SEM (n = 3). Student's two-tailed t-test was performed between designated groups for statistical analysis (**p < 0.01 and ***p < 0.001).
[0061] Fig.47 Figure 2 shows the expression of 2×10 TIL fragments (F1-F22 and F24, n=23) from patient 4285 after co-culture with autologous APCs. 4 Figure 2. Graph of the number of IFN-γ-positive spots per effector cell of autologous APCs electroporated with TMG consisting of irrelevant (IRR, open bars), WT p53 (p53-WT, gray bars), or mutated p53 (p53-MUT, black bars) sequences.
[0062] Fig.48 Figure 2 shows the expression of 2×10 TIL fragments (F1-F22 and F24, n=23) from patient 4285 after co-culture with autologous APCs. 4 Figure 2. Graph of the number of IFN-γ-positive spots per effector cell, APCs pulsed with peptide vehicle (DMSO; open bars) or purified (>95% by HPLC) 25 amino acid peptides consisting of the WT p53-R175 sequence (LP-p53-R175-WT; gray bars) or mutant p53-R175H (LP-p53-R175H-MUT; black bars).
[0063] Fig.49 is a graph showing the percentage of CD4+4-1BB-positive cells detected after co-culturing TIL fragments from patient 4285 (F1-F22 and F24, n=23) with autologous APCs electroporated with TMG composed of irrelevant (IRR, open bars), WTp53 (p53-WT, gray bars), or mutated p53 (p53-MUT, black bars) sequences.
[0064] Fig.50Graph showing the percentage of CD4+4-1BB-positive cells detected after co-culture of TIL fragments from patient 4285 (F1-F22 and F24, n=23) with autologous APCs pulsed with peptide vehicle (DMSO; open bars) or a purified (>95% by HPLC) 25 amino acid peptide consisting of the WTp53-R175 sequence (LP-p53-R175-WT; gray bars) or mutant p53-R175H (LP-p53-R175H-MUT; black bars).
[0065] Fig.51 Graph showing the percentage of 4-1BB+ cells (CD4+ percentage) detected after co-culturing TIL fragment cultures 4285-F6, 4285-F9, and 4285-F10 with Cos7 cells transfected with the indicated HLA alleles and pulsed with DMSO (peptide vehicle; gray and black diagonal bars) or mutant p53-R175H peptide (gray, grid, and black bars).
[0066] Fig.52 is a graph showing the percentage of 4-1BB+ cells (CD4+ percentage) detected after co-culturing T cells transposed with 4285-TCR1 with autologous APCs pulsed with decreasing concentrations of 25- or 15-amino acid peptides corresponding to WT (open circles and squares) or mutated (filled circles and squares) p53-R175H sequences.
[0067] Fig.53 Is a graph showing the percentage of 4-1BB+ cells (CD8+ percentage) detected after co-culturing TILs from patient 4266 with Cos7 cells co-transfected with individual HLA alleles from patient 4266 and pulsed with no peptide (empty bars), DMSO (peptide vehicle; gray bars), WT p53-R248 peptide (gray slashes) or mutated p53-R248W peptide (black bars). Data are mean ± SEM (n = 3).
[0068] Fig.54 It is a graph showing the percentage of 4-1BB+ cells detected after co-culturing T cells expressing mocks (no TCR), 4266-TCR1, 4266-TCR2, 4266-TCR3 or 4266-TCR4 with autologous APC (CD8+ percentage), wherein the autologous APC is pulsed with a peptide vehicle (DMSO; gray bar) or a purified (>95%, by HPLC) 25 amino acid peptide consisting of a WT p53-R248 sequence (slashed gray bar) or a mutated p53-R248W (black bar) sequence. The culture medium alone (empty bar) and PMA and ionomycin (grid bar) are negative and positive controls, respectively.
[0069] Fig.55 It is a figure showing the percentage (CD8+ percentage) of 4-1BB+ cells detected after T cells expressing mimics (no TCR) or p53-R248W-specific TCR (4266-TCR2, 4266-TCR3 or 4266-TCR4) in co-culture and tumor cells (TC) lines continuously passaged by immunocompromised mice (TC#4266) are established from xenografted tumor fragments excised from patient 4266 and then continuously passaged by immunocompromised mice (TC#4266).TC#4266 cells are not incubated with any substance (black bars), or TC#4266 cells are incubated with W6 / 32 pan-HLA class I specific blocking antibodies (grey bars on the right), IVA12 pan-HLA class II specific blocking antibodies (grey bars) or mutated p53-R248W peptides (grey bars on the left). Single culture medium (no TC; empty bars) and PMA and ionomycin (grey bars) are negative controls and positive controls, respectively.
[0070] Fig.56 It is a figure showing the percentage of CD4+4-1BB+ cells detected after co-culture of TIL from patient 4273 with autologous APC, and the APC is transfected with TMG encoding irrelevant mutations (grey bars), wild-type p53 sequences (grey oblique lines) or mutant p53 sequences (black bars) including p53-R248W. Culture medium alone (open bars) and PMA and ionomycin (grid bars) are respectively negative and positive controls.
[0071] Fig.57 Graph showing the percentage of CD4+4-1BB+ cells detected after co-culture of TILs from patient 4273 with autologous APCs pulsed with a 25 amino acid peptide corresponding to the wild type (open circles) or a 25 amino acid peptide from a mutation of the p53-R248W neo-epitope (filled squares). DMSO was the peptide vehicle.
[0072] Fig.58 4-1BB+ cells detected after co-culture of TILs from patient 4273 with autologous APCs, the APCs were pulsed with 15 amino acid peptides from the p53-R248W neo-epitope with 14 overlapping amino acids (amino acid substitutions are indicated in bold). DMSO was used as a peptide vehicle, culture medium alone (T cells only), and PMA and ionomycin were used as controls. 25 amino acid peptides (wtp53-R248 and mutated p53-R248W) were additional controls for the 15 amino acid peptides. The peptides were: and MNWRPILTITLEDS (SEQ ID NO:602).
[0073] Fig.59 is a graph showing the concentration of IFN-γ (pg / mL) secreted by TILs from patient 4273 after co-culture with Cos7 cells, which were co-transfected with individual HLA alleles from patient 4273 and WT (empty bars) or mutated (black bars) TP53 TMG in the presence or absence of p53-R248W neoantigen, respectively.
[0074] Fig.60 The results show that after co-culture of T cells expressing mock (no TCR) or 4273-TCR1a2 with autologous APCs, each 2x10 4 Figure 2 shows the number of IFN-γ-spots per cell of autologous APCs pulsed with peptide vehicle (DMSO; gray bars) or purified (>95% by HPLC) 25 amino acid peptides consisting of the WT p53-R248 sequence (slashed gray bars) or the mutated p53-R248W (black bars) sequence. Medium alone (empty bars) and PMA and ionomycin (grid bars) are negative and positive controls, respectively. DETAILED DESCRIPTION OF THE INVENTION
[0076] Tumor protein p53 (also known as "TP53" or "p53") acts as a tumor suppressor by, for example, regulating cell division. The p53 protein is located in the nucleus of the cell, where it binds directly to DNA. When DNA is damaged, the p53 protein is involved in determining whether the DNA will be repaired or whether the damaged cell will undergo apoptosis. If the DNA can be repaired, p53 activates other genes to restore the damage. If the DNA cannot be repaired, the p53 protein prevents the cell from dividing and signals it to undergo apoptosis. By preventing cells with mutated or damaged DNA from dividing, p53 helps prevent tumor development. Wild-type (WT) full-length p53 comprises the amino acid sequence of SEQ ID NO: 1.
[0077] Mutations in the p53 protein can reduce or eliminate the tumor suppressive function of the p53 protein. Alternatively or additionally, the p53 mutation can be a gain-of-function mutation that interferes with wild-type p53 in a dominant negative manner. The mutated p53 protein can be expressed in any of a variety of human cancers, such as, for example, cholangiocarcinoma, melanoma, colon cancer, rectal cancer, ovarian cancer, endometrial cancer, non-small cell lung cancer (NSCLC), glioblastoma, cervical cancer, head and neck cancer, breast cancer, pancreatic cancer or bladder cancer.
[0078] One embodiment of the present invention provides a kind of T cell receptor (TCR) (hereinafter referred to as "mutated p53") that is separated or purified with antigenic specificity to mutated human p53. Hereinafter, unless otherwise specified, reference to "TCR" also refers to the functional part and functional variant of TCR. The mutation of p53 is defined herein by reference to the full-length amino acid sequence WT p53 (SEQID NO:1). Therefore, the mutation of p53 is described herein by reference to the amino acid residue present at a specific position, followed by the position number, followed by the amino acid that replaces this residue in the specific mutation in question. For example, when the position is as defined by SEQ ID NO:1, the term "R175" refers to the arginine present at position 175 of SEQ ID NO:1, "R175H" means that the arginine present at position 175 of SEQ ID NO:1 is replaced by histidine, and "G245S" means that the glycine present at position 245 of SEQ ID NO:1 has been replaced by serine. P53 has nine known splice variants. The p53 mutation described herein is conservative in all nine p53 splice variants. Fig.35 An alignment of nine p53 splice variants is shown in . Thus, T cells isolated by the methods of the present invention may have antigenic specificity for any mutated p53 amino acid sequence described herein encoded by any of the nine p53 splice variants. When a position is defined as in SEQ ID NO: 1, the actual position of the amino acid sequence of a particular splice variant of p53 is defined relative to the corresponding position of SEQ ID NO: 1, and the position as defined by SEQ ID NO: 1 may be different from the actual position in the particular splice variant. Thus, for example, a mutation refers to a replacement of an amino acid residue in the amino acid sequence of a particular splice variant of p53 corresponding to a specified position of the sequence of 393 amino acids of SEQ ID NO: 1, it being understood that the actual position in the splice variant may be different.
[0079] In one embodiment of the invention, the TCR has antigenic specificity for human p53 having a mutation at position 175, 220, 245, 248, 249, 273 or 282 of SEQ ID NO: 1. The TCR may have antigenic specificity for human p53 having a mutation at position 175, 220, 245 or 248 of SEQ ID NO: 1. The p53 mutation may be any missense mutation. Thus, the mutation at position 175, 220, 245, 248, 249, 273 or 282 of SEQ ID NO: 1 may be a substitution of a natural (WT) amino acid residue present at position 175, 220, 245, 248, 249, 273 or 282 of SEQ ID NO: 1, wherein any amino acid residue other than a natural (WT) amino acid residue is present at the specific position in question. In one embodiment of the invention, the TCR has antigenic specificity for human p53 having one of the following human p53 mutations: R175H, Y220C, G245D, G245S, R248L, R248Q, R248W, R249S, R273H, R273C, R273L or R282W. SEQ ID NOSEQ ID NO The TCR may have antigenic specificity for human p53 having one of the following human p53 mutations: R175H, Y220C, G245S, R248Q or R248W. For example, the TCR of the invention may have antigenic specificity for a mutant p53 amino acid sequence selected from SEQ ID NO: 2-13.
[0080] In one embodiment of the invention, the TCR of the invention may be capable of recognizing mutant p53 in an HLA (human leukocyte antigen) molecule-dependent manner. As used herein, "HLA-molecule-dependent manner" means that the TCR generates an immune response when it binds to mutant p53 in the context of an HLA molecule expressed by the patient from which the TCR was isolated. The TCR of the invention may be capable of recognizing mutant p53 presented by an applicable HLA molecule and may bind to HLA molecules in addition to mutant p53.
[0081] The TCR of the present invention provides many advantages, including when expressed by cells for adoptive cell transfer. Mutant p53 is expressed by tumor cells, rather than by normal non-cancerous cells. Without being constrained by a particular theory or mechanism, it is believed that the TCR of the present invention advantageously targets and destroys cancer cells while minimizing or eliminating the destruction of normal non-cancerous cells, thereby, for example, reducing toxicity by minimizing or eliminating toxicity. In addition, advantageously, the TCR of the present invention can successfully treat or prevent mutation p53 positive cancers that are unresponsive to other types of treatment (e.g., chemotherapy, surgery or radiation). In addition, the TCR of the present invention can provide high affinity recognition of mutation p53, which can provide the ability to identify untreated tumor cells (e.g., tumor cells not treated with interferon (IFN)-γ, tumor cells not transfected with vectors encoding one or two mutation p53 and applicable HLA molecules, tumor cells not pulsed with p53 peptides with p53 mutations, or a combination thereof). About half of the tumors carry p53 mutations, of which about half are missense mutations, and about 30% of missense mutations occur at the following "hotspot" residues: R175H, Y220C, G245D, G245S, R248L, R248Q, R248W, R249S, R273C, R273L, R273H, and R282W. In addition, the same p53 "hotspot" mutations (e.g., R175H, Y220C, G245D, G245S, R248L, R248Q, R248W, R249S, R273H, R273C, R273L, or R282W) often occur in tumors of unrelated populations (accumulating about 30% of p53 missense mutations). Therefore, the TCR of the present invention can increase the number of patients who may be suitable for immunotherapy treatment.
[0082] As used herein, the phrase "antigen specific" means that the TCR can specifically bind to and immunorecognize mutant p53 with high affinity. For example, if about 1 x 10 4 About 1x10 5T cells secrete at least about 200 pg / mL or more (e.g., 200 pg / mL or more, 300 pg / mL or more, 400 pg / mL or more, 500 pg / mL or more, 600 pg / mL or more, 700 pg / mL or more, 1000 pg / mL or more, 5,000 pg / mL or more, 7,000 pg / mL or more, 10,000 pg / mL or more, 20,000 pg / mL or more, or a range defined by any two of the foregoing values) when co-cultured with target cells that are antigen-negative and positive for applicable HLA molecules. The TCR is considered to be "antigen specific" for mutant p53 if it is co-cultured with antigen-negative, applicable HLA molecule-positive target cells pulsed with low concentrations of mutant p53 peptide (e.g., about 0.05 ng / mL to about 5 ng / mL, 0.05 ng / mL, 0.1 ng / mL, 0.5 ng / mL, 1 ng / mL, 5 ng / mL, or a range defined by any two of the foregoing values), or (b) antigen-negative, applicable HLA molecule-positive target cells into which a nucleotide sequence encoding mutant p53 has been introduced so that the target cells express mutant p53. Cells expressing the TCR of the invention may also secrete IFN-γ when co-cultured with antigen-negative, applicable HLA molecule-positive target cells pulsed with higher concentrations of mutant p53 peptide.
[0083] Alternatively or additionally, a TCR can be considered to be "antigenic specific" for mutant p53 if T cells expressing the TCR secrete at least twice the amount of IFN-γ when co-cultured with (a) antigen-negative, applicable HLA molecule-positive target cells pulsed with a low concentration of mutant p53 peptide or (b) antigen-negative, applicable HLA molecule-positive target cells into which a nucleotide sequence encoding mutant p53 has been introduced so that the target cells express mutant p53. Negative controls can be, for example, (i) T cells expressing TCR co-cultured with the following target cells: (a) antigen-negative, HLA-positive target cells pulsed with the same concentration of irrelevant peptides (e.g., some other peptides having a different sequence from the mutant p53 peptide) or (b) antigen-negative, HLA-positive target cells into which a nucleotide sequence encoding an irrelevant peptide has been introduced so that the target cells express the irrelevant peptide, or (ii) untransduced T cells (e.g., from PBMCs, which do not express TCR) co-cultured with the following target cells: (a) antigen-negative, HLA-positive target cells pulsed with the same concentration of mutant p53 peptides or (b) antigen-negative, HLA-positive target cells into which a nucleotide sequence encoding mutant p53 has been introduced so that the target cells express mutant p53. IFN-γ secretion can be measured by methods known in the art (e.g., enzyme-linked immunosorbent assay (ELISA)).
[0084] Alternatively or additionally, a TCR may be considered "antigen-specific" for mutant p53 if at least twice as many T cells expressing the TCR secrete IFN-γ when co-cultured with target cells that are (a) antigen-negative, HLA-positive target cells pulsed with a low concentration of mutant p53 peptide or (b) antigen-negative, HLA-positive target cells into which a nucleotide sequence encoding mutant p53 has been introduced so that the target cells express mutant p53. The concentrations of peptides and negative controls may be as described herein for other aspects of the invention. The number of cells secreting IFN-γ may be measured by methods known in the art (e.g., ELISOT assay).
[0085] Alternatively or additionally, a TCR may be considered "antigen-specific" for mutant p53 if at least twice as many spots are detected by ELISPOT as those of T cells expressing the TCR when co-cultured with (a) antigen-negative, applicable HLA molecule-positive target cells pulsed with a low concentration of mutant p53 peptide or (b) antigen-negative, applicable HLA molecule-positive target cells into which a nucleotide sequence encoding mutant p53 has been introduced so that the target cells express mutant p53, wherein the number of spots is compared to the number of spots detected by ELISPOT of negative control T cells co-cultured with the same target cells. The concentrations of peptides and negative controls may be as described herein in conjunction with other aspects of the invention.
[0086] Alternatively or additionally, a TCR may be considered "antigen-specific" for mutant p53 if greater than about 50 spots are detected by ELISPOT for a TCR-expressing T cell co-cultured with the following target cells: (a) antigen-negative, applicable HLA molecule-positive target cells pulsed with a low concentration of mutant p53 peptide or (b) antigen-negative, applicable HLA molecule-positive target cells into which a nucleotide sequence encoding mutant p53 has been introduced so that the target cell expresses mutant p53. The concentration of the peptide may be as described herein for other aspects of the invention.
[0087] Alternatively or additionally, a TCR can be considered to be "antigen-specific" for mutant p53 if a T cell expressing the TCR upregulates expression of one or both of 4-1BB and OX40 (e.g., as measured by flow cytometry following stimulation with target cells expressing mutant p53).
[0088] The present invention provides a TCR comprising two polypeptides (i.e., polypeptide chains), such as an alpha (α) chain of a TCR, a beta (β) chain of a TCR, a gamma (γ) chain of a TCR, a delta (δ) chain of a TCR, or a combination thereof. The polypeptide of the TCR of the present invention may comprise any amino acid sequence, provided that the TCR has antigenic specificity for mutated p53.
[0089] In one embodiment of the invention, the TCR comprises two polypeptide chains, each of which comprises a variable region comprising a complementarity determining region (CDR) 1, CDR2 and CDR3 of the TCR. In one embodiment of the invention, the TCR comprises a first polypeptide chain and a second polypeptide chain, the first polypeptide chain comprising an alpha chain CDR1 (CDR1α), an alpha chain CDR2 (CDR2α) and an alpha chain CDR3 (CDR3α), and the second polypeptide chain comprising a beta chain CDR1 (CDR1β), a beta chain CDR2 (CDR2β) and a beta chain CDR3 (CDR3β). In one embodiment of the invention, the TCR comprises the following amino acid sequence: (1) all SEQ ID NOs: 27-32; (2) all SEQ ID NOs: 37-42; (3) all SEQ ID NOs: 47-52; (4) all SEQ ID NOs: 57-62; (5) all SEQ ID NOs: 67-72; (6) all SEQ ID NOs: 77-82; (7) all SEQ ID NOs: 87-92; (8) all SEQ ID NOs: 97-102; (9) all SEQ ID NOs: 107-112; (10) all SEQ ID NOs: 117-122; (11) all SEQ ID NOs: 127-132; (12) all SEQ ID NOs: 137-142; (13) all SEQ ID NOs: 147-152; (14) all SEQ ID NOs: 157-162; (15) all SEQ ID NO:167-172; (16) all SEQ ID NO:177-182; (17) all SEQ ID NO:187-192; (18) all SEQ ID NO:197-202; (19) all SEQ ID NO:207-212; (20) all SEQ ID NO:217-222; (21) all SEQ ID NO:227-232; (22) all SEQ ID NO:237-242; (23) all SEQ ID NO:247-252; (24) all SEQ ID NO:257-262; (25) all SEQ ID NO:267-272; (26) all SEQ ID NO:277-282; (27) all SEQ ID NO:287-292; (28) all SEQ ID NO:297-302; (29) all SEQ ID NO: 307-312; (30) all SEQ ID NO: 317-322; (31) all SEQ ID NO: 327-332; (32) all SEQ ID NO: 337-342; (33) all SEQ ID NO: 347-352;(34) all SEQ ID NOs:357-362; (35) all SEQ ID NOs:367-372; (36) all SEQ ID NOs:377-382; (37) all SEQ ID NOs:387-392; (38) all SEQ ID NOs:397-402; (39) all SEQ ID NOs:407-412; (40) all SEQ ID NOs:417-422; (41) all SEQ ID NOs:427-432; (42) all SEQ ID NOs:437-442; (43) all SEQ ID NOs:447-452; (44) all SEQ ID NOs:457-462; (45) all SEQ ID NOs:467-472; (46) all SEQ ID NOs:477-482; or (47) all SEQ ID NOs:487-492. Each of the aforementioned 47 amino acid sequence sets in this paragraph lists the 6 CDR regions of each of the 47 different TCRs that are antigenically specific for mutant human p53. The 6 amino acid sequences in each set correspond to CDR1α, CDR2α, CDR3α, CDR1β, CDR2β and CDR3β of the TCR, respectively. ;
[0090] In one embodiment of the present invention, the TCR comprises an α chain variable region amino acid sequence and a β chain variable region amino acid sequence, which together comprise one of the above-mentioned CDR sets. In this regard, the TCR may comprise the following amino acid sequences: (1) both SEQ ID NOs: 33-34; (2) both SEQ ID NOs: 43-44; (3) both SEQ ID NOs: 53-54; (4) both SEQ ID NOs: 63-64; (5) both SEQ ID NOs: 73-74; (6) both SEQ ID NOs: 83-84; (7) both SEQ ID NOs: 93-94; (8) both SEQ ID NOs: 103-104; (9) both SEQ ID NOs: 113-114; (10) both SEQ ID NOs: 123-124; (11) both SEQ ID NOs: 133-134; (12) both SEQ ID NOs: 143-144; (13) both SEQ ID NOs: 153-154; (14) both SEQ ID NOs: 163-164; (15) both SEQ ID NOs: NO:173-174; (16) SEQ ID NO:183-184; (17) SEQ ID NO:193-194; (18) SEQ ID NO:203-204; (19) SEQ ID NO:213-214; (20) SEQ ID NO:223-224; (21) SEQ ID NO:233-234; (22) SEQ ID NO:243-244; (23) SEQ ID NO:253-254; (24) SEQ ID NO:263-264; (25) SEQ ID NO:273-274; (26) SEQ ID NO:283-284; (27) SEQ ID NO:293-294; (28) SEQ ID NO:303-304; (29) SEQ ID NO:310-311; (30) SEQ ID NO:312-313; (31) SEQ ID NO:314-315; (32) SEQ ID NO:315-316 NO:313-314; (30) SEQ ID NO:323-324; (31) SEQ ID NO:333-334; (32) SEQ ID NO:343-344; (33) SEQ ID NO:353-354; (34) SEQ ID NO:363-364; (35) SEQ ID NO:373-374; (36) SEQ ID NO:383-384; (37) SEQ ID NO:393-394; (38) SEQ ID NO:403-404; (39) SEQ ID NO:413-414;(40) both SEQ ID NOs: 423-424; (41) both SEQ ID NOs: 433-434; (42) both SEQ ID NOs: 443-444; (43) both SEQ ID NOs: 453-454; (44) both SEQ ID NOs: 463-464; (45) both SEQ ID NOs: 473-474; (46) both SEQ ID NOs: 483-484; or (47) both SEQ ID NOs: 493-494. Each of the aforementioned 47 amino acid sequence sets in this paragraph lists two variable regions of each of 47 different TCRs that are antigenically specific for mutant human p53. The two amino acid sequences in each set correspond to the variable regions of the α chain and the β chain of the TCR, respectively. ;
[0091] The TCR of the present invention may further include a constant region. The constant region may be derived from any suitable species (e.g., human or mouse). In one embodiment of the present invention, TCR further includes a mouse constant region. As used herein, when referring to any component of TCR or TCR described herein (e.g., complementary determining region (CDR), variable region, constant region, α chain and / or β chain), the term "mouse" or "human" means TCR (or its components) derived from mouse or human, respectively, that is, TCRs derived from or once expressed by mouse T cells or human T cells, respectively. In one embodiment of the present invention, TCR may include mouse α chain constant region and mouse β chain constant region. Mouse α chain constant region may be modified or unmodified. As described in, for example, US2017 / 0145070, the modified mouse α chain constant region may be, for example, cysteine substituted, LVL modified, or cysteine substituted and LVL modified at the same time. Mouse β chain constant region may be modified or unmodified. The modified mouse β chain constant region can be, for example, cysteine substituted, as described, for example, in US2017 / 0145070. In one embodiment of the invention, the TCR comprises a cysteine substituted, LVL modified mouse α chain constant region comprising the amino acid sequence of SEQ ID NO: 23 or 24. In one embodiment of the invention, the TCR comprises a cysteine substituted mouse β chain constant region comprising the amino acid sequence of SEQ ID NO: 25.
[0092] In one embodiment of the invention, the TCR of the invention may comprise an α chain of a TCR and a β chain of a TCR. The α chain of a TCR may comprise a variable region of an α chain and a constant region of an α chain. This type of α chain may be paired with any β chain of a TCR. The β chain may comprise a variable region of a β chain and a constant region of a β chain. In one embodiment of the invention, the TCR comprises the following amino acid sequences: (1) both SEQ ID NOs: 35-36; (2) both SEQ ID NOs: 45-46; (3) both SEQ ID NOs: 55-56; (4) both SEQ ID NOs: 65-66; (5) both SEQ ID NOs: 75-76; (6) both SEQ ID NOs: 85-86; (7) both SEQ ID NOs: 95-96; (8) both SEQ ID NOs: 105-106; (9) both SEQ ID NOs: 115-116; (10) both SEQ ID NOs: 125-126; (11) both SEQ ID NOs: 135-136; (12) both SEQ ID NOs: 145-146; (13) both SEQ ID NOs: 155-156; (14) both SEQ ID NOs: 165-166; (15) both SEQ ID NOs: NO:175-176; (16) SEQ ID NO:185-186; (17) SEQ ID NO:195-196; (18) SEQ ID NO:205-206; (19) SEQ ID NO:215-216; (20) SEQ ID NO:225-226; (21) SEQ ID NO:235-236; (22) SEQ ID NO:245-246; (23) SEQ ID NO:255-256; (24) SEQ ID NO:265-266; (25) SEQ ID NO:275-276; (26) SEQ ID NO:285-286; (27) SEQ ID NO:295-296; (28) SEQ ID NO:305-306; (29) SEQ ID NO:310-311; (30) SEQ ID NO:312-313; (31) SEQ ID NO:314-315; (32) SEQ ID NO:315-316 NO:315-316; (30) SEQ ID NO:325-326; (31) SEQ ID NO:335-336; (32) SEQ ID NO:345-346; (33) SEQ ID NO:355-356; (34) SEQ ID NO:365-366; (35) SEQ ID NO:375-376; (36) SEQ ID NO:385-386; (37) SEQ ID NO:395-396;(38) both SEQ ID NOs: 405-406; (39) both SEQ ID NOs: 415-416; (40) both SEQ ID NOs: 425-426; (41) both SEQ ID NOs: 435-436; (42) both SEQ ID NOs: 445-446; (43) both SEQ ID NOs: 455-456; (44) both SEQ ID NOs: 465-466; (45) both SEQ ID NOs: 475-476; (46) both SEQ ID NOs: 485-486; or (47) both SEQ ID NOs: 495-496 Each of the above 47 amino acid sequence sets in this paragraph lists the α chain and β chain of each of the 47 different TCRs that are antigenically specific for mutant human p53. The two amino acid sequences in each set correspond to the α chain and β chain of the TCR, respectively. ;
[0093] The scope of the present invention includes functional variants of the TCR of the present invention as described herein. As used herein, the term "functional variant" refers to a TCR, polypeptide or protein having substantial or significant sequence identity or similarity with a parent TCR, polypeptide or protein, and the functional variant retains the biological activity of the TCR, polypeptide or protein of which it is a variant. For example, functional variants include those variants of TCR, polypeptide or protein (parent TCR, polypeptide or protein) as described herein, which retain the ability to specifically bind to mutant p53 with a similar degree, the same degree or a higher degree with the parent TCR, polypeptide or protein, and the parent TCR has antigen specificity to the mutant p53, or the parent polypeptide or protein specifically binds to the mutant p53. With respect to a parent TCR, polypeptide or protein, a functional variant may, for example, be at least about 30%, at least about 50%, at least about 75%, at least about 80%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% or more identical in amino acid sequence to the parent TCR, polypeptide or protein, respectively.
[0094] For example, a functional variant may include an amino acid sequence of a parent TCR, polypeptide or protein having at least one conservative amino acid substitution. Conservative amino acid substitutions are known in the art and include amino acid substitutions in which an amino acid having certain physical and / or chemical properties is exchanged for another amino acid having the same chemical or physical properties. For example, conservative amino acid substitutions may be acidic amino acids replacing another acidic amino acid (e.g., Asp or Glu), amino acids with non-polar side chains replacing another amino acid with non-polar side chains (e.g., Ala, Gly, Val, Ile, Leu, Met, Phe, Pro, Trp, Val, etc.), basic amino acids are replaced by another basic amino acid (Lys, Arg, etc.), amino acids with polar side chains replace another amino acid with polar side chains (Asn, Cys, Gln, Ser, Thr, Tyr, etc.), etc.
[0095] Alternatively or additionally, the functional variant may comprise an amino acid sequence of a parent TCR, polypeptide or protein having at least one non-conservative amino acid substitution. In this case, it is preferred that the non-conservative amino acid substitution does not interfere with or inhibit the biological activity of the functional variant. Preferably, the non-conservative amino acid substitution enhances the biological activity of the functional variant such that the biological activity of the functional variant is increased compared to the parent TCR, polypeptide or protein.
[0096] A TCR, polypeptide or protein can consist essentially of a specified amino acid sequence or sequences described herein, such that other components of the TCR, polypeptide or protein, such as other amino acids, do not substantially alter the biological activity of the TCR, polypeptide or protein.
[0097] The present invention also provides polypeptides comprising a functional portion of any of the TCRs described herein.The term "polypeptide" as used herein includes oligopeptides and refers to a single chain of amino acids linked by one or more peptide bonds.
[0098] With regard to the polypeptide of the present invention, the functional portion can be any part of the contiguous amino acids of the TCR that is part of the TCR, provided that the functional portion specifically binds to mutant p53. When used in reference to TCR, the term "functional portion" refers to any part or fragment of the TCR of the present invention, which retains the biological activity of the TCR of which it is a part (maternal TCR). For example, the functional portion includes those parts of the TCR that retain the ability to specifically bind to mutant p53 (e.g., in an applicable HLA molecule-dependent manner), or the ability to detect, treat or prevent cancer, to a degree similar to, the same as, or higher than that of the maternal TCR. With respect to maternal TCR, the functional portion may include, for example, about 10%, about 25%, about 30%, about 50%, about 68%, about 80%, about 90%, about 95% or more of the maternal TCR.
[0099] The functional portion may include additional amino acids at the amino terminus or carboxyl terminus or both termini of the portion, which additional amino acids are not present in the amino acid sequence of the parent TCR. Ideally, the additional amino acids do not interfere with the biological function of the functional portion, for example, specifically binding to mutated p53; and / or being able to detect cancer, treat or prevent cancer, etc. More ideally, the additional amino acids enhance the biological activity compared to the biological activity of the parent TCR.
[0100] The polypeptide may comprise a functional portion of one or both of the α chain and β chain of the TCR of the present invention, for example, a functional portion of one or more of CDR1, CDR2 and CDR3 of the variable region of the α chain and / or β chain of the TCR of the present invention. In one embodiment of the present invention, the functional portion that the polypeptide may comprise comprises the following amino acid sequences: (1) all of SEQ ID NOs: 27-32; (2) all of SEQ ID NOs: 37-42; (3) all of SEQ ID NOs: 47-52; (4) all of SEQ ID NOs: 57-62; (5) all of SEQ ID NOs: 67-72; (6) all of SEQ ID NOs: 77-82; (7) all of SEQ ID NOs: 87-92; (8) all of SEQ ID NOs: 97-102; (9) all of SEQ ID NOs: 107-112; (10) all of SEQ ID NOs: 117-122; (11) all of SEQ ID NOs: 127-132; (12) all of SEQ ID NOs: 137-142; (13) all of SEQ ID NOs: 147-152; (14) all of SEQ ID NOs: 157-162; (15) all of SEQ ID NOs: All of SEQ ID NO:167-172; (16) All of SEQ ID NO:177-182; (17) All of SEQ ID NO:187-192; (18) All of SEQ ID NO:197-202; (19) All of SEQ ID NO:207-212; (20) All of SEQ ID NO:217-222; (21) SEQ ID All of SEQ ID NO:227-232; (22) All of SEQ ID NO:237-242; (23) All of SEQ ID NO:247-252; (24) All of SEQ ID NO:257-262; (25) All of SEQ ID NO:267-272; (26) All of SEQ ID NO:277-282; (27) SEQ ID All of NO:287-292; (28) SEQ ID All of NO:297-302; (29) SEQ ID All of NO:307-312; (30) All of SEQ ID NO:317-322; (31) All of SEQ ID NO:327-332; (32) All of SEQ ID NO:337-342; (33) All of SEQ ID NO:347-352; (34) All of SEQ ID NO:357-362; (35) SEQ All of ID NO:367-372; (36) All of SEQ ID NO:377-382;(37) all of SEQ ID NOs: 387-392; (38) all of SEQ ID NOs: 397-402; (39) all of SEQ ID NOs: 407-412; (40) all of SEQ ID NOs: 417-422; (41) all of SEQ ID NOs: 427-432; (42) all of SEQ ID NOs: 437-442; (43) all of SEQ ID NOs: 447-452; (44) all of SEQ ID NOs: 457-462; (45) all of SEQ ID NOs: 467-472; (46) all of SEQ ID NOs: 477-482; or (47) all of SEQ ID NOs: 487-492.
[0101] In one embodiment of the present invention, the polypeptide of the present invention may comprise, for example, the variable region of the TCR of the present invention, which comprises a combination of the above-mentioned CDR regions. In this regard, the polypeptide may comprise the following amino acid sequences: (1) both SEQ ID NOs: 33-34; (2) both SEQ ID NOs: 43-44; (3) both SEQ ID NOs: 53-54; (4) both SEQ ID NOs: 63-64; (5) both SEQ ID NOs: 73-74; (6) both SEQ ID NOs: 83-84; (7) both SEQ ID NOs: 93-94; (8) both SEQ ID NOs: 103-104; (9) both SEQ ID NOs: 113-114; (10) both SEQ ID NOs: 123-124; (11) both SEQ ID NOs: 133-134; (12) both SEQ ID NOs: 143-144; (13) both SEQ ID NOs: 153-154; (14) both SEQ ID NOs: 163-164; (15) both SEQ ID NO:173-174; (16) SEQ ID NO:183-184; (17) SEQ ID NO:193-194; (18) SEQ ID NO:203-204; (19) SEQ ID NO:213-214; (20) SEQ ID NO:223-224; (21) SEQ ID NO:233-234; (22) SEQ ID NO:243-244; (23) SEQ ID NO:253-254; (24) SEQ ID NO:263-264; (25) SEQ ID NO:273-274; (26) SEQ ID NO:283-284; (27) SEQ ID NO:293-294; (28) SEQ ID NO:303-304; (29) SEQ ID NOs:313-314; (30) SEQ ID NOs:323-324; (31) SEQ ID NOs:333-334; (32) SEQ ID NOs:343-344; (33) SEQ ID NOs:353-354; (34) SEQ ID NOs:363-364; (35) SEQ ID NOs:373-374; (36) SEQ ID NOs:383-384; (37) SEQ ID NOs:393-394; (38) SEQ ID NOs:403-404; (39) SEQ ID NOs:413-414; (40) SEQ ID NOs:423-424;(41) both SEQ ID NOs: 433-434; (42) both SEQ ID NOs: 443-444; (43) both SEQ ID NOs: 453-454; (44) both SEQ ID NOs: 463-464; (45) both SEQ ID NOs: 473-474; (46) both SEQ ID NOs: 483-484; or (47) both SEQ ID NOs: 493-494.
[0102] In one embodiment of the present invention, the polypeptide of the present invention may further comprise the constant region of the above-mentioned TCR of the present invention. In this regard, the polypeptide may comprise (i) one of SEQ ID NOs: 23-25 or (ii) the amino acid sequence of one of SEQ ID NOs: 25 and SEQ ID NOs: 23-24.
[0103] In one embodiment of the present invention, the polypeptide of the present invention may comprise the α chain and β chain of the TCR of the present invention. In this regard, the polypeptide may comprise the following amino acid sequences: (1) both SEQ ID NOs:35-36; (2) both SEQ ID NOs:45-46; (3) both SEQ ID NOs:55-56; (4) both SEQ ID NOs:65-66; (5) both SEQ ID NOs:75-76; (6) both SEQ ID NOs:85-86; (7) both SEQ ID NOs:95-96; (8) both SEQ ID NOs:105-106; (9) both SEQ ID NOs:115-116; (10) both SEQ ID NOs:125-126; (11) both SEQ ID NOs:135-136; (12) both SEQ ID NOs:145-146; (13) both SEQ ID NOs:155-156; (14) both SEQ ID NOs:165-166; (15) SEQ ID NOs:175-176; (16) SEQ ID NOs:185-186; (17) SEQ ID NOs:195-196; (18) SEQ ID NOs:205-206; (19) SEQ ID NOs:215-216; (20) SEQ ID NOs:225-226; (21) SEQ ID NOs:235-236; (22) SEQ ID NOs:245-246; (23) SEQ ID NOs:255-256; (24) SEQ ID NOs:265-266; (25) SEQ ID NOs:275-276; (26) SEQ ID NOs:285-286; (27) SEQ ID NOs:295-296; (28) SEQ ID NOs:305-306; (29) SEQ ID NOs:310-311; (311) SEQ ID NOs:312-313; (312) SEQ ID NOs:314-315 NO:315-316; (30) SEQ ID NO:325-326; (31) SEQ ID NO:335-336; (32) SEQ ID NO:345-346; (33) SEQ ID NO:355-356; (34) SEQ ID NO:365-366; (35) SEQ ID NO:375-376; (36) SEQ ID NO:385-386; (37) SEQ ID NO:395-396; (38) SEQ ID NO:405-406; (39) SEQ ID NO:415-416; (40) SEQ ID NO:425-426; (41) SEQ ID NO:435-436;(42) both SEQ ID NOs: 445-446; (43) both SEQ ID NOs: 455-456; (44) both SEQ ID NOs: 465-466; (45) both SEQ ID NOs: 475-476; (46) both SEQ ID NOs: 485-486; or (47) both SEQ ID NOs: 495-496.
[0104] The present invention further provides proteins comprising at least one polypeptide as described herein. "Protein" means a molecule comprising one or more polypeptide chains. In one embodiment, the protein of the present invention may comprise: (1) a first polypeptide chain comprising the entire amino acid sequence of SEQ ID NOs: 27-29 and a second polypeptide chain comprising the entire amino acid sequence of SEQ ID NOs: 30-32; (2) a first polypeptide chain comprising the entire amino acid sequence of SEQ ID NOs: 37-39 and a second polypeptide chain comprising the entire amino acid sequence of SEQ ID NOs: 40-42; (3) a first polypeptide chain comprising the entire amino acid sequence of SEQ ID NOs: 47-49 and a second polypeptide chain comprising the entire amino acid sequence of SEQ ID NOs: 50-52; (4) a first polypeptide chain comprising the entire amino acid sequence of SEQ ID NOs: 57-59 and a second polypeptide chain comprising the entire amino acid sequence of SEQ ID NOs: 60-62; (5) a first polypeptide chain comprising the entire amino acid sequence of SEQ ID NOs: 67-69 and a second polypeptide chain comprising the entire amino acid sequence of SEQ ID NOs: 70-72; (6) a first polypeptide chain comprising the entire amino acid sequence of SEQ ID NOs: 77-79 and a second polypeptide chain comprising the entire amino acid sequence of SEQ ID NOs: (7) a first polypeptide chain comprising the entire amino acid sequence of SEQ ID NOs: 87-89 and a second polypeptide chain comprising the entire amino acid sequence of SEQ ID NOs: 90-92; (8) a first polypeptide chain comprising the entire amino acid sequence of SEQ ID NOs: 97-99 and a second polypeptide chain comprising the entire amino acid sequence of SEQ ID NOs: 100-102; (9) a first polypeptide chain comprising the entire amino acid sequence of SEQ ID NOs: 107-109 and a second polypeptide chain comprising the entire amino acid sequence of SEQ ID NOs: 110-112; (10) a first polypeptide chain comprising the entire amino acid sequence of SEQ ID NOs: 117-119 and a second polypeptide chain comprising the entire amino acid sequence of SEQ ID NOs: 120-122; (11) a first polypeptide chain comprising the entire amino acid sequence of SEQ ID NOs: 127-129 and a second polypeptide chain comprising the entire amino acid sequence of SEQ ID NOs: 130-132; (12) a first polypeptide chain comprising the entire amino acid sequence of SEQ ID NOs: 131-132 (13) a first polypeptide chain comprising the entire amino acid sequence of SEQ ID NOs: 137-139 and a second polypeptide chain comprising the entire amino acid sequence of SEQ ID NOs: 140-142; (14) a first polypeptide chain comprising the entire amino acid sequence of SEQ ID NOs: 147-149 and a second polypeptide chain comprising the entire amino acid sequence of SEQ ID NOs: 150-152;(14) a first polypeptide chain comprising the entire amino acid sequence of SEQ ID NOs: 157-159, and a second polypeptide chain comprising the entire amino acid sequence of SEQ ID NOs: 160-162; (15) a first polypeptide chain comprising the entire amino acid sequence of SEQ ID NOs: 167-169, and a second polypeptide chain comprising the entire amino acid sequence of SEQ ID NOs: 170-172; (16) a first polypeptide chain comprising the entire amino acid sequence of SEQ ID NOs: 177-179, and a second polypeptide chain comprising the entire amino acid sequence of SEQ ID NOs: 180-182; (17) a first polypeptide chain comprising the entire amino acid sequence of SEQ ID NOs: 187-189, and a second polypeptide chain comprising the entire amino acid sequence of SEQ ID NOs: 190-192; (18) a first polypeptide chain comprising the entire amino acid sequence of SEQ ID NOs: 197-199, and a second polypeptide chain comprising the entire amino acid sequence of SEQ ID NOs: 200-202; (19) a first polypeptide chain comprising SEQ ID NO:207-209, and a second polypeptide chain comprising the entire amino acid sequence of SEQ ID NO:210-212; (20) a first polypeptide chain comprising the entire amino acid sequence of SEQ ID NO:217-219, and a second polypeptide chain comprising the entire amino acid sequence of SEQ ID NO:220-222; (21) a first polypeptide chain comprising the entire amino acid sequence of SEQ ID NO:227-229, and a second polypeptide chain comprising the entire amino acid sequence of SEQ ID NO:230-232; (22) a first polypeptide chain comprising the entire amino acid sequence of SEQ ID NO:237-239, and a second polypeptide chain comprising the entire amino acid sequence of SEQ ID NO:240-242; (23) a first polypeptide chain comprising the entire amino acid sequence of SEQ ID NO:247-249, and a second polypeptide chain comprising the entire amino acid sequence of SEQ ID NO:250-252; (24) a first polypeptide chain comprising SEQ ID NO: NO:257-259, and a second polypeptide chain comprising the entire amino acid sequence of SEQ ID NO:260-262; (25) a first polypeptide chain comprising the entire amino acid sequence of SEQ ID NO:267-269, and a second polypeptide chain comprising the entire amino acid sequence of SEQ ID NO:270-272; (26) a first polypeptide chain comprising the entire amino acid sequence of SEQ ID NO:277-279, and a second polypeptide chain comprising the entire amino acid sequence of SEQ ID NO:280-282;(27) a first polypeptide chain comprising the entire amino acid sequence of SEQ ID NOs: 287-289, and a second polypeptide chain comprising the entire amino acid sequence of SEQ ID NOs: 290-292; (28) a first polypeptide chain comprising the entire amino acid sequence of SEQ ID NOs: 297-299, and a second polypeptide chain comprising the entire amino acid sequence of SEQ ID NOs: 300-302; (29) a first polypeptide chain comprising the entire amino acid sequence of SEQ ID NOs: 307-309, and a second polypeptide chain comprising the entire amino acid sequence of SEQ ID NOs: 310-312; (30) a first polypeptide chain comprising the entire amino acid sequence of SEQ ID NOs: 317-319, and a second polypeptide chain comprising the entire amino acid sequence of SEQ ID NOs: 320-322; (31) a first polypeptide chain comprising the entire amino acid sequence of SEQ ID NOs: 327-329, and a second polypeptide chain comprising the entire amino acid sequence of SEQ ID NOs: 330-332; (32) a first polypeptide chain comprising the entire amino acid sequence of SEQ ID NOs: NO:337-339, and a second polypeptide chain comprising the entire amino acid sequence of SEQ ID NO:340-342; (33) a first polypeptide chain comprising the entire amino acid sequence of SEQ ID NO:347-349, and a second polypeptide chain comprising the entire amino acid sequence of SEQ ID NO:350-352; (34) a first polypeptide chain comprising the entire amino acid sequence of SEQ ID NO:357-359, and a second polypeptide chain comprising the entire amino acid sequence of SEQ ID NO:360-362; (35) a first polypeptide chain comprising the entire amino acid sequence of SEQ ID NO:367-369, and a second polypeptide chain comprising the entire amino acid sequence of SEQ ID NO:370-372; (36) a first polypeptide chain comprising the entire amino acid sequence of SEQ ID NO:377-379, and a second polypeptide chain comprising the entire amino acid sequence of SEQ ID NO:380-382; (37) a first polypeptide chain comprising SEQ ID NO:387-389 and a second polypeptide chain comprising the entire amino acid sequence of SEQ ID NO:390-392; (38) a first polypeptide chain comprising the entire amino acid sequence of SEQ ID NO:397-399, and a second polypeptide chain comprising the entire amino acid sequence of SEQ ID NO:400-402; (39) a first polypeptide chain comprising the entire amino acid sequence of SEQ ID NO:407-409 and a second polypeptide chain comprising the entire amino acid sequence of SEQ ID NO:410-412;(40) a first polypeptide chain comprising the entire amino acid sequence of SEQ ID NOs: 417-419 and a second polypeptide chain comprising the entire amino acid sequence of SEQ ID NOs: 420-422; (41) a first polypeptide chain comprising the entire amino acid sequence of SEQ ID NOs: 427-429 and a second polypeptide chain comprising the entire amino acid sequence of SEQ ID NOs: 430-432; (42) a first polypeptide chain comprising the entire amino acid sequence of SEQ ID NOs: 437-439 and a second polypeptide chain comprising the entire amino acid sequence of SEQ ID NOs: 440-442; (43) a first polypeptide chain comprising the entire amino acid sequence of SEQ ID NOs: 447-449 and a second polypeptide chain comprising the entire amino acid sequence of SEQ ID NOs: 450-452; (44) a first polypeptide chain comprising the entire amino acid sequence of SEQ ID NOs: 457-459 and a second polypeptide chain comprising the entire amino acid sequence of SEQ ID NOs: 460-462; (45) a first polypeptide chain comprising the entire amino acid sequence of SEQ ID NOs: NO:467-469, and a second polypeptide chain comprising the entire amino acid sequence of SEQ ID NO:470-472; (46) a first polypeptide chain comprising the entire amino acid sequence of SEQ ID NO:477-479, and a second polypeptide chain comprising the entire amino acid sequence of SEQ ID NO:480-482; or (47) a first polypeptide chain comprising the entire amino acid sequence of SEQ ID NO:487-489, and a second polypeptide chain comprising the entire amino acid sequence of SEQ ID NO:490-492. ;
[0105] In one embodiment of the present invention, the protein comprises: (1) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO:33 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO:34; (2) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO:43 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO:44; (3) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO:53 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO:54; (4) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO:63 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO:64; (5) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO:73 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO:74; (6) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO:83 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO:84; (7) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO:93 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO:94; (8) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO:103 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO:114; NO:104; (9) a first polypeptide chain comprising an amino acid sequence of SEQ ID NO:113 and a second polypeptide chain comprising an amino acid sequence of SEQ ID NO:114; (10) a first polypeptide chain comprising an amino acid sequence of SEQ ID NO:123 and a second polypeptide chain comprising an amino acid sequence of SEQ ID NO:124; (11) a first polypeptide chain comprising an amino acid sequence of SEQ ID NO:133 and a second polypeptide chain comprising an amino acid sequence of SEQ ID NO:134; (12) a first polypeptide chain comprising an amino acid sequence of SEQ ID NO:143 and a second polypeptide chain comprising an amino acid sequence of SEQ ID NO:144; (13) a first polypeptide chain comprising an amino acid sequence of SEQ ID NO:153 and a second polypeptide chain comprising an amino acid sequence of SEQ ID NO:154; (14) a first polypeptide chain comprising an amino acid sequence of SEQ ID NO:163 and a second polypeptide chain comprising an amino acid sequence of SEQ ID NO:164; (15) a first polypeptide chain comprising an amino acid sequence of SEQ ID NO:173 and a second polypeptide chain comprising an amino acid sequence of SEQ ID NO:174 (16) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 183 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 184;(17) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 193 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 194; (18) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 203 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 204; (19) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 213 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 214; (20) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 223 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 224; (21) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 233 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 234; (22) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 243 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 244; (23) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 253 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 254; (24) NO:263 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO:264; (25) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO:273 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO:274; (26) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO:283 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO:284; (27) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO:293 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO:294; (28) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO:303 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO:304; (29) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO:313 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO:314; (30) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO:323 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO:324; (31) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO:324 (32) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 343 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 344;(33) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 353 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 354; (34) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 363 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 364; (35) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 373 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 374; (36) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 383 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 384; (37) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 393 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 394; (38) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 403 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 404; (39) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 413 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 414; (40) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 414 NO:423 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO:424; (41) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO:433 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO:434; (42) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO:443 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO:444; (43) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO:453 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO:454; (44) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO:463 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO:464; (45) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO:473 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO:474; (46) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO:483 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO:484; or (47) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO:484 A first polypeptide chain comprising the amino acid sequence of SEQ ID NO:493 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO:494. ;
[0106] In one embodiment of the present invention, the protein comprises: (1) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO:35 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO:36; (2) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO:45 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO:46; (3) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO:55 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO:56; (4) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO:65 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO:66; (5) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO:75 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO:76; (6) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO:85 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO:86; (7) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO:95 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO:96; (8) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO:105 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO:110 NO:106; (9) a first polypeptide chain comprising an amino acid sequence of SEQ ID NO:115 and a second polypeptide chain comprising an amino acid sequence of SEQ ID NO:116; (10) a first polypeptide chain comprising an amino acid sequence of SEQ ID NO:125 and a second polypeptide chain comprising an amino acid sequence of SEQ ID NO:126; (11) a first polypeptide chain comprising an amino acid sequence of SEQ ID NO:135 and a second polypeptide chain comprising an amino acid sequence of SEQ ID NO:136; (12) a first polypeptide chain comprising an amino acid sequence of SEQ ID NO:145 and a second polypeptide chain comprising an amino acid sequence of SEQ ID NO:146; (13) a first polypeptide chain comprising an amino acid sequence of SEQ ID NO:155 and a second polypeptide chain comprising an amino acid sequence of SEQ ID NO:156; (14) a first polypeptide chain comprising an amino acid sequence of SEQ ID NO:165 and a second polypeptide chain comprising an amino acid sequence of SEQ ID NO:166; (15) a first polypeptide chain comprising an amino acid sequence of SEQ ID NO:175 and a second polypeptide chain comprising an amino acid sequence of SEQ ID NO:180 (16) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 185 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 186;(17) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 195 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 196; (18) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 205 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 206; (19) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 215 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 216; (20) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 225 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 226; (21) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 235 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 236; (22) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 245 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 246; (23) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 255 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 256; (24) NO:265 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO:266; (25) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO:275 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO:276; (26) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO:285 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO:286; (27) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO:295 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO:296; (28) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO:305 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO:306; (29) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO:315 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO:316; (30) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO:325 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO:326; (31) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO:330 (32) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 345 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 346;(33) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 355 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 356; (34) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 365 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 366; (35) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 375 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 376; (36) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 385 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 386; (37) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 395 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 396; (38) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 405 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 406; (39) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 415 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 416; (40) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 416 NO:425 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO:426; (41) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO:435 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO:436; (42) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO:445 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO:446; (43) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO:455 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO:456; (44) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO:465 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO:466; (45) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO:475 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO:476; (46) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO:485 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO:486; or (47) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO:486 A first polypeptide chain comprising the amino acid sequence of SEQ ID NO:495 and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO:496. ;
[0107] The protein of the present invention can be a TCR. Alternatively, if the first and / or second polypeptide chain of the protein also comprises other amino acid sequences, such as amino acid sequences encoding immunoglobulins or a portion thereof, the protein of the present invention can be a fusion protein. In this regard, the present invention also provides a fusion protein comprising at least one polypeptide of the present invention as described herein and at least one other polypeptide. Other polypeptides may exist as separate polypeptides of the fusion protein, or may exist as polypeptides, which are expressed in the same frame (in series) with a polypeptide of the present invention as described herein. Other polypeptides may encode any peptide or protein molecule or a portion thereof, including but not limited to immunoglobulins, CD3, CD4, CD8, MHC molecules, CD1 molecules, such as CD1a, CD1b, CD1c, CD1d, etc.
[0108] The fusion protein may comprise one or more copies of a polypeptide of the present invention and / or one or more copies of other polypeptides. For example, the fusion protein may comprise 1, 2, 3, 4, 5 or more copies of a polypeptide of the present invention and / or other polypeptides. Suitable methods for preparing fusion proteins are known in the art and include, for example, recombinant methods.
[0109] In some embodiments of the invention, the TCR, polypeptide and protein of the present invention may be expressed as a single protein comprising a connecting peptide connecting an alpha chain and a beta chain. In this regard, the TCR, polypeptide and protein of the present invention may further comprise a connector peptide. The connecting peptide may advantageously promote the expression of recombinant TCR, polypeptide and / or protein in a host cell. The connecting peptide may comprise any suitable amino acid sequence. For example, the connecting peptide may comprise the amino acid sequence of SEQ ID NO:26. When a construct including a connecting peptide is expressed by a host cell, the connecting peptide may be cleaved to produce separate alpha and beta chains. In one embodiment of the invention, a TCR, polypeptide or protein may comprise an amino acid sequence comprising a full-length alpha chain, a full-length beta chain, and a connecting peptide between the alpha and beta chains.
[0110] The protein of the present invention may be a recombinant antibody or an antigen-binding portion thereof, which comprises at least one polypeptide of the present invention described herein. As used herein, "recombinant antibody" refers to a recombinant (e.g., genetically engineered) protein comprising at least one polypeptide of the present invention and a polypeptide chain of an antibody or an antigen-binding portion thereof. The polypeptide of an antibody or an antigen-binding portion thereof may be a heavy chain, a light chain, a variable region or a constant region of a heavy chain or a light chain, a single-chain variable region fragment (scFv), or an Fc, Fab, or F(ab)2' fragment of an antibody, etc. The polypeptide chain of an antibody or an antigen-binding portion thereof may exist as a separate polypeptide of a recombinant antibody. Alternatively, the polypeptide chain of an antibody or an antigen-binding portion thereof may exist as a polypeptide, which is expressed in the same frame (in series) as the polypeptide of the present invention. The polypeptide of an antibody or an antigen-binding portion thereof may be a polypeptide of any antibody or any antibody fragment, including any antibody and antibody fragment described herein.
[0111] The TCR, polypeptides and proteins of the present invention can have any length, i.e., can contain any number of amino acids, provided that the TCR, polypeptide or protein maintains its biological activity, such as the ability to specifically bind to mutant p53, the ability to detect cancer in a mammal, or the ability to treat or prevent cancer in a mammal, etc. For example, the polypeptide can be in the range of about 50 to about 5000 amino acids in length, such as 50, 70, 75, 100, 125, 150, 175, 200, 300, 400, 500, 600, 700, 800, 900, 1000 or more amino acids. In this regard, the polypeptides of the present invention also include oligopeptides.
[0112] The TCR, polypeptides and proteins of the present invention may comprise synthetic amino acids to replace one or more naturally occurring amino acids. Such synthetic amino acids are known in the art and include, for example, aminocyclohexanecarboxylic acid, norleucine, α-amino n-decanoic acid, homoserine, S-acetylaminomethyl-cysteine, trans-3- and trans-4-hydroxyproline, 4-aminophenylalanine, 4-nitrophenylalanine, 4-chlorophenylalanine, 4-carboxyphenylalanine, β-phenylserine β-hydroxyphenylalanine, phenylglycine, α-naphthylalanine, cyclohexylalanine, cyclohexylglycine, indole-2-carboxy Acid, 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, aminomaleic acid, aminomaleic acid monoamide, N'-benzyl-N'-methyl-lysine, N',N'-dibenzyl-lysine, 6-hydroxylysine, ornithine, α-aminocyclopentanecarboxylic acid, α-aminocyclohexanecarboxylic acid, α-aminocycloheptanecarboxylic acid, α-(2-amino-2-borane)-carboxylic acid, α,β-diaminobutyric acid, α,β-diaminopropionic acid, homophenylalanine and α-tert-butylglycine.
[0113] The TCRs, polypeptides and proteins of the invention may be glycosylated, amidated, carboxylated, phosphorylated, esterified, N-acylated, cyclized, e.g. via disulfide bonds, or converted into acid addition salts and / or optionally dimerized or polymerized, or conjugated.
[0114] The TCRs, polypeptides, and / or proteins of the present invention can be obtained by methods known in the art (e.g., de novo synthesis). In addition, polypeptides and proteins can be recombinantly produced using standard recombinant methods using the nucleic acids described herein. For example, see Green and Sambrook, Molecular Cloning:A Laboratory Manual ,4 thed., Cold Spring Harbor Press, Cold Spring Harbor, NY (2012). Alternatively, the TCRs, polypeptides and / or proteins described herein may be commercially synthesized by companies such as Synpep (Dublin, CA), Peptide Technologies Corp. (Gaithersburg, MD) and Peptide Systems (San Diego, CA). In this regard, the TCRs, polypeptides and proteins of the present invention may be synthesized, recombinant, isolated and / or purified.
[0115] One embodiment of the present invention provides a nucleic acid comprising a nucleotide sequence encoding any TCR, polypeptide or protein described herein. "Nucleic acid" as used herein includes "polynucleotide", "oligonucleotide" and "nucleic acid molecule", and generally means a polymer of DNA or RNA, which may be single-stranded or double-stranded, which may contain natural, non-natural or changed nucleotides, and may contain natural, non-natural or changed internucleotides, such as phosphoramidate links or thiophosphate links, rather than the phosphodiester found between the nucleotides of unmodified oligonucleotides. In one embodiment, nucleic acid comprises complementary DNA (cDNA). It is usually preferred that nucleic acid does not include any insertion, deletion, inversion and / or substitution. However, in some instances, as discussed herein, it may be applicable to nucleic acid comprising one or more insertions, deletions, inversions and / or substitutions.
[0116] Preferably, the nucleic acid of the present invention is recombinant. As used herein, the term "recombinant" refers to (i) molecules constructed outside of living cells by connecting natural or synthetic nucleic acid fragments to nucleic acid molecules that can replicate in living cells, or (ii) molecules produced by replication of those described in (i) above. For purposes of this article, replication can be in vitro replication or in vivo replication.
[0117] Nucleic acids can be constructed based on chemical synthesis and / or enzyme ligation reactions using procedures known in the art. For example, see Green and Sambrook et al., supra. For example, nucleic acids can be chemically synthesized using naturally occurring nucleotides or various modified nucleotides (e.g., thiophosphate derivatives and acridine substituted nucleotides) designed to increase the biological stability of the molecule or improve the physical stability of the duplex formed after hybridization. Examples of modified nucleotides that can be used to produce nucleic acids include, but are not limited to, 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxymethyl)uracil, 5-carboxymethylaminomethyl-2-thiouracil, 5-carboxymethylaminomethyluracil, dihydrouracil, β-D-galactoquinoline, inosine, N 6-Isopentenyl adenine, 1-methylguanine, 1-methyllinoside, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N 6 -substituted adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, β-D-mannoside, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N 6 -isopentenyl adenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-hydroxyacetic acid methyl ester, 3-(3-amino-3-N-2-carboxypropyl) uracil and 2,6-diaminopurine. Alternatively, one or more nucleic acids of the present invention can be purchased from companies such as Macromolecular Resources (Fort Collins, CO) and Synthegen (Houston, TX).
[0118] In one embodiment of the invention, nucleic acid comprises a codon optimized nucleotide sequence encoding any TCR, polypeptide or protein described herein. Without being constrained by any particular theory or mechanism, the codon optimization of nucleotide sequence is considered to improve the translation efficiency of mRNA transcripts. Codon optimization of nucleotide sequence may involve replacing natural codons with another codon encoding the same amino acid, but can be translated by tRNA that is more easily available in cells, thereby improving translation efficiency. The optimization of nucleotide sequence can also reduce the secondary mRNA structure that interferes with translation, thereby improving translation efficiency.
[0119] The present invention also provides a nucleic acid comprising a nucleotide sequence that is complementary to the nucleotide sequence of any nucleic acid described herein or a nucleotide sequence that hybridizes under stringent conditions to the nucleotide sequence of any nucleic acid described herein.
[0120] Nucleotide sequences that hybridize under stringent conditions are preferably hybridized under high stringency conditions. The "high stringency conditions" means that the nucleotide sequence specifically hybridizes to the target sequence (the nucleotide sequence of any nucleic acid described herein) in an amount that can be more strongly detected than non-specific hybridization. High stringency conditions include conditions that can distinguish polynucleotides with precise complementary sequences or containing only a few scattered mismatches from random sequences, and the random sequences just have a few small regions (e.g., 3-10 bases) that match the nucleotide sequence. This small complementary region is easier to melt than the full-length complement of 14-17 bases or more bases, and high stringency hybridization makes them easy to distinguish. Relatively high stringency conditions will include (for example) low salt and / or high temperature conditions provided by about 0.02-0.1MNaCl or its equivalent at a temperature of about 50-70°C. Such high stringency conditions tolerate very few mismatches (if any) between the nucleotide sequence and the template or target chain, and are particularly suitable for detecting the expression of any TCR of the present invention. It is generally understood that the conditions can be made more stringent by increasing the amount of formamide.
[0121] The present invention also provides nucleic acids comprising a nucleotide sequence that is at least about 70% or more, such as about 80%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98% or about 99% identical to any of the nucleic acids described herein. In this regard, the nucleic acid can consist essentially of any of the nucleotide sequences described herein.
[0122] The nucleic acid of the present invention can be incorporated into a recombinant expression vector. In this regard, the present invention provides a recombinant expression vector comprising any nucleic acid of the present invention. In one embodiment of the present invention, the recombinant expression vector comprises a nucleotide sequence encoding an alpha chain, a beta chain and a connecting peptide.
[0123] For the purposes of this article, the term "recombinant expression vector" means a genetically modified oligonucleotide or polynucleotide construct that allows a host cell to express RNA, protein, polypeptide or peptide when the construct comprises a nucleotide sequence encoding mRNA, protein, polypeptide or peptide and the vector contacts a cell under conditions sufficient to allow the mRNA, protein, polypeptide or peptide to be expressed in the cell. The vector of the present invention is not naturally occurring as a whole. However, portions of the vector may be naturally occurring. The recombinant expression vector of the present invention may comprise any type of nucleotide, including but not limited to DNA and RNA, which may be single-stranded or double-stranded partially obtained or synthesized from a natural source, and may contain natural, non-natural or altered nucleotides. The recombinant expression vector may comprise naturally occurring, non-naturally occurring internucleotide links or both types of links. Preferably, non-naturally occurring or altered nucleotides or internucleotide links do not hinder transcription or replication of the vector.
[0124] The recombinant expression vector of the present invention can be any suitable recombinant expression vector, and can be used for transformation or transfection of any suitable host cell. Suitable vectors include those designed for propagation and amplification or for expression or for the above-mentioned two vectors, such as plasmid and virus. The vector can be selected from transposon / transposase series, pUC series (Fermentas Life Sciences), pBluescript series (Stratagene, LaJolla, CA), pET series (Novagen, Madison, WI), pGEX series (Pharmacia Biotech, Uppsala, Sweden) and pEX series (Clontech, Palo Alto, CA). Phage vectors can also be used, such as λ GT10, λ GT11, λ ZapII (Stratagene), λ EMBL4 and λ NM1149. The example of plant expression vector includes pBI01, pBI101.2, pBI101.3, pBI121 and pBIN19 (Clontech). Examples of animal expression vectors include PEUK-Cl, pMAM and pMAMneo (Clontech). Preferably, the recombinant expression vector is a transposon vector or a viral vector, such as a retroviral vector.
[0125] The recombinant expression vectors of the present invention can be prepared using standard recombinant DNA techniques such as those described by Green and Sambrook et al. (supra). Circular or linear expression vector constructs can be prepared to include a replication system that functions in a prokaryotic or eukaryotic host cell. The replication system can be derived from ColE1, 2μ plasmid, λ, SV40, bovine papilloma virus, etc.
[0126] Ideally, recombinant expression vectors contain regulatory sequences, such as transcriptional and translational start and stop codons, that are specific for the type of host cell (e.g., bacteria, fungi, plants, or animals) into which the vector is to be introduced, as appropriate and taking into account whether the vector is DNA- or RNA-based.
[0127] The recombinant expression vector may include one or more marker genes that can be used to select transformed or transfected host cells. Marker genes include biocide resistance, such as antibiotic resistance, heavy metals, etc. Complementation in auxotrophic host cells to provide prototrophy, etc. Marker genes suitable for the expression vector of the present invention include, for example, neomycin / G418 resistance genes, hygromycin resistance genes, histidine resistance genes, tetracycline resistance genes, and ampicillin resistance genes.
[0128] The recombinant expression vector may comprise a natural or non-natural promoter operably linked to a nucleotide sequence encoding a TCR, a polypeptide or a protein or a nucleotide sequence complementary or hybridized to a nucleotide sequence encoding a TCR, a polypeptide or a protein. The selection of promoters, for example, strong, weak, inducible, tissue-specific and development-specific promoters, is within the ordinary skill of the art. Similarly, the combination of nucleotide sequence and promoter is also within the skill of the art. Promoters may be non-viral promoters, such as human elongation factor-1α promoters, or viral promoters, such as cytomegalovirus (CMV) promoters, SV40 promoters, RSV promoters, and promoters found in the long terminal repeats of mouse stem cell viruses.
[0129] The recombinant expression vector of the present invention can be designed for transient expression, stable expression or both. In addition, the recombinant expression vector can be used for constitutive expression or inducible expression.
[0130] In addition, recombinant expression vectors can be prepared to include suicide genes. As used herein, the term "suicide gene" refers to a gene that causes the cell expressing the suicide gene to die. The suicide gene can be a gene that makes the cell expressing the gene sensitive to an agent (e.g., a drug), and causes the cell to die when the cell contacts or is exposed to the agent. Suicide genes are known in the art and include, for example, herpes simplex virus (HSV) thymidine kinase (TK) gene, cytosine deaminase, purine nucleoside phosphorylase, and nitroreductase.
[0131] Another embodiment of the present invention further provides a host cell comprising any recombinant expression vector described herein. As used herein, the term "host cell" refers to any type of cell that may comprise a recombinant expression vector of the present invention. The host cell may be a eukaryotic cell, such as a plant, an animal, a fungus or an algae, or may be a prokaryotic cell, such as a bacterium or a protozoan. The host cell may be a cultured cell or a primary cell, i.e., directly isolated from an organism (e.g., a human). The host cell may be an adherent cell or a suspension cell, i.e., a cell that grows in suspension. Suitable host cells are known in the art and include, for example, DH5α Escherichia coli cells, Chinese hamster ovary cells, monkey VERO cells, COS cells, HEK293 cells, etc. In order to amplify or replicate the recombinant expression vector, the host cell is preferably a prokaryotic cell, such as a DH5 cell. In order to produce a recombinant TCR, a polypeptide or a protein, the host cell is preferably a mammalian cell. Most preferably, the host cell is a human cell. Although the host cell may be any cell type, may be from any type of tissue, and may be a cell at any stage of development, the host cell is preferably a peripheral blood lymphocyte (PBL) or a peripheral blood mononuclear cell (PBMC). More preferably, the host cell is a T cell.
[0132] For the purposes of this article, T cells can be any T cells, such as cultured T cells, such as primary T cells; or T cells from cultured T cell lines, such as Jurkat, SupT1, etc.; or T cells obtained from mammals. If obtained from mammals, T cells can be obtained from a variety of sources, including but not limited to blood, bone marrow, lymph nodes, thymus, or other tissues or fluids. T cells can also be enriched or purified. Preferably, the T cells are human T cells. T cells can be any type of T cells and can be T cells at any stage of development, including but not limited to CD4+ / CD8+ double positive T cells, CD4+ helper T cells such as Th1 and Th2 cells, CD4+T cells, CD8+T cells (such as cytotoxic T cells), tumor infiltrating lymphocytes (TILs), memory T cells (such as central memory T cells and effector memory T cells), initial T cells, etc.
[0133] The present invention also provides a cell group comprising at least one host cell described herein. The cell group may be a heterogeneous population, comprising a host cell comprising any recombinant expression vector described and at least one other cell, such as a host cell (such as a T cell) or a cell other than a T cell that does not comprise any recombinant expression vector, such as a B cell, a macrophage, a neutrophil, an erythrocyte, a hepatocyte, an endothelial cell, an epithelial cell, a muscle cell, a brain cell, etc. Alternatively, the cell group may be a substantially homogeneous population, wherein the population mainly comprises a host cell (for example, substantially consisting of it), and the host cell comprises a recombinant expression vector. The population may also be a clonal population of a cell, wherein all cells of the population are clones of a single host cell comprising a recombinant expression vector, so that all cells of the population comprise a recombinant expression vector. In one embodiment of the present invention, the cell group is a clonal population comprising a host cell, and the host cell comprises a recombinant expression vector as described herein.
[0134] In one embodiment of the invention, the number of cells in the population can be rapidly expanded. The number of T cells can be expanded by any method known in the art, for example, U.S. Patent 8,034,334; U.S. Patent 8,383,099; U.S. Patent Application Publication No. 2012 / 0244133; Dudley et al., J. Immunother., 26: 332-42 (2003); and Riddell et al., J. Immunol. Methods, 128: 189-201 (1990). In one embodiment, the number of T cells is expanded by culturing T cells with OKT3 antibody, IL-2 and feeding PBMC (e.g., irradiated allogeneic PBMC).
[0135] The TCRs, polypeptides, proteins, nucleic acids, recombinant expression vectors and host cells (including populations thereof) of the present invention may be isolated and / or purified. As used herein, the term "isolated" means removed from its natural environment. As used herein, the term "purified" means increased purity, wherein "purity" is a relative term and need not be interpreted as absolute purity. For example, the purity may be at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, or may be about 100%.
[0136] The TCR, polypeptides, proteins, nucleic acids, recombinant expression vectors and host cells (including populations thereof) of the present invention, which are collectively referred to as "TCR materials of the present invention" hereinafter, can be formulated as compositions, such as pharmaceutical compositions. In this regard, the present invention provides pharmaceutical compositions comprising any of the TCRs, polypeptides, proteins, nucleic acids, expression vectors and host cells (including populations thereof) described herein and a pharmaceutically acceptable carrier. The pharmaceutical composition of the present invention containing any TCR material of the present invention may contain more than one TCR material of the present invention, such as polypeptides and nucleic acids, or two or more different TCRs. Alternatively, the pharmaceutical composition may contain the TCR material of the present invention in combination with another pharmaceutically active agent or drug, such as a chemotherapeutic agent, such as asparaginase, busulfan, carboplatin, cisplatin, daunorubicin, doxorubicin, fluorouracil, gemcitabine, hydroxyurea, methotrexate, paclitaxel, rituximab, vinblastine, vincristine, etc.
[0137] Preferably, the carrier is a pharmaceutically acceptable carrier. With respect to pharmaceutical compositions, the carrier may be any carrier conventionally used for the particular TCR material of the present invention under consideration. Methods for preparing administrable compositions are known or apparent to those skilled in the art and are described in more detail in, for example, Remington: The Science and Practice of Pharmacy, 22nd Ed., Pharmaceutical Press (2012). Preferably, a medically acceptable carrier is one that does not have harmful side effects or toxicity under the conditions of use.
[0138] The choice of carrier will be determined in part by the specific TCR material of the present invention and the specific method for administering the TCR material of the present invention. Therefore, there are various suitable formulations of the pharmaceutical composition of the present invention. Suitable formulations may include any formulation for parenteral, subcutaneous, intravenous, intramuscular, intraarterial, intrathecal, intratumoral or interperitoneal administration. More than one approach can be used to administer the TCR material of the present invention, and in some cases, a specific approach can provide a more immediate and more effective response than another approach.
[0139] Preferably, the TCR material of the present invention is administered by, for example, intravenous injection. When the TCR material of the present invention is a host cell expressing the TCR of the present invention, the pharmaceutically acceptable carrier of the injection cell may include any isotonic carrier, such as physiological saline (about 0.90% w / v NaCl aqueous solution, about 300mOsm / L NaCl aqueous solution or about 9.0g NaCl / liter of water), Normosol R electrolyte solution (Abbott, Chicago, IL), PLASMA-LYTE A (Baxter, Deerfield, IL), about 5% glucose aqueous solution or Ringer's lactate. In one embodiment, human serum albumin is added with the pharmaceutically acceptable carrier.
[0140] For the purposes of the present invention, the amount or dosage of the TCR material of the present invention administered (e.g., the number of cells when the TCR material of the present invention is one or more cells) should be sufficient to produce a therapeutic or preventive response to an individual or animal within a reasonable time frame. For example, the dose of the TCR material of the present invention should be sufficient to bind to a cancer antigen (e.g., a mutated p53), or to detect, treat, or prevent cancer within about 2 hours or more (e.g., 12 to 24 hours or more) from the time of administration. In certain embodiments, the time period may even be longer. The dosage will be determined by the effectiveness of the specific TCR material of the present invention and the condition of the animal (e.g., a human) and the weight of the animal (e.g., a human) to be treated.
[0141] Many analyses for determining the dosage are known in the art. For the purposes of the present invention, an analysis including the following can be used to determine the starting dose for administration to a mammal: in a group of mammals, each of which is given different doses of T cells, comparing the extent of target cell lysis when a given dose of the T cells is administered to a mammal, or the extent of IFN-γ secreted by T cells expressing the TCR, polypeptide or protein of the present invention. The extent of target cell lysis or the extent of IFN-γ secreted when a specific dose is administered can be analyzed by methods known in the art.
[0142] The dosage of the TCR material of the invention is also determined by the presence, nature, and extent of any adverse side effects that may accompany the administration of a particular TCR material of the invention. Typically, the attending physician will determine the dosage of the TCR material of the invention for each individual patient, taking into account factors such as age, weight, general health, diet, sex, the TCR material of the invention to be administered, the route of administration, and the severity of the cancer being treated. In one embodiment in which the TCR material of the invention is a cell population, the number of cells administered per infusion may vary, for example, about 1x10 6 To about 1x10 12 In some embodiments, less than 1×10 6 cells.
[0143] It will be readily appreciated by those of ordinary skill in the art that the inventive TCR materials of the present invention can be modified in any number of ways so as to improve the therapeutic or preventive effects of the TCR materials of the present invention by modification. For example, the TCR materials of the present invention may be coupled to chemotherapeutic agents directly or indirectly via bridging. The practice of coupling compounds to chemotherapeutic agents is known in the art. Those of ordinary skill in the art recognize that sites on the TCR materials of the present invention that are not necessary for the function of the TCR materials of the present invention are ideal sites for connecting bridging and / or chemotherapeutic agents, provided that once the bridging and / or chemotherapeutic agents are connected to the TCR materials of the present invention, they will not interfere with the function of the TCR materials of the present invention, i.e., the ability to bind to or detect, treat or prevent cancer with mutant p53.
[0144] It is expected that the pharmaceutical composition, TCR, polypeptide, protein, nucleic acid, recombinant expression vector, host cell or cell group of the present invention can be used for the method of treating or preventing cancer. Without being bound by a particular theory, it is believed that the TCR of the present invention specifically binds to the p53 of mutation, so that when expressed by cells, TCR (or related polypeptide or protein of the present invention) can mediate the immune response of the target cell expressing mutant p53. In this regard, embodiments of the present invention provide a method for treating or preventing cancer in mammals, which comprises administering to mammals any pharmaceutical composition, TCR, polypeptide or protein described herein, comprising any nucleic acid or recombinant expression vector or any host cell or cell group encoding any TCR, polypeptide or protein described herein, with an amount effective for treating or preventing cancer in mammals, comprising encoding any TCR described herein, polypeptide or protein nucleotide sequence.
[0145] Embodiments of the present invention provide any pharmaceutical composition, TCR, polypeptide or protein described herein, any nucleic acid or recombinant expression vector comprising a nucleotide sequence encoding any TCR, polypeptide, protein described herein, or any host cell or cell population comprising a recombinant vector encoding any TCR, polypeptide or protein described herein for use in treating or preventing cancer in a mammal.
[0146] As used herein, the terms "treatment" and "prevention" and words derived therefrom do not necessarily mean 100% or complete treatment or prevention. Rather, there are varying degrees of treatment or prevention, which those skilled in the art recognize as having potential benefits or therapeutic effects. In this regard, the methods of the present invention can provide any level of cancer treatment or prevention in a mammal. In addition, the treatment or prevention provided by the methods of the present invention may include the treatment or prevention of one or more conditions or symptoms of the cancer being treated or prevented. For example, treatment or prevention may include promoting tumor regression. In addition, for purposes herein, "prevention" may include delaying the onset of cancer or its symptoms or conditions. Alternatively or additionally, "prevention" may include preventing or delaying the recurrence of cancer or its symptoms or conditions.
[0147] Embodiments of the present invention also provide a method for detecting the presence of cancer in a mammal. The method comprises (i) contacting a sample comprising one or more cells from a mammal with any TCR, polypeptide, protein, nucleic acid, recombinant expression vector, host cell, cell population or pharmaceutical composition of the present invention as described herein, thereby forming a complex, and detecting the complex, wherein the detection of the complex indicates the presence of cancer in the mammal.
[0148] Regarding the methods of the present invention for detecting cancer in mammals, the cell sample may be a sample comprising whole cells, lysates thereof, or fractions of whole cell lysates, such as nuclear or cytoplasmic fractions, total protein fractions, or nucleic acid fractions.
[0149] For the purpose of the detection methods of the present invention, for mammals, contacting can be performed in vitro or in vivo. Preferably, the contacting is in vitro.
[0150] In addition, the complex can be detected by any of a variety of means known in the art. For example, the TCR, polypeptide, protein, nucleic acid, recombinant expression vector, host cell or cell population of the invention described herein can be labeled with a detectable label, for example, a radioisotope, a fluorophore (e.g., fluorescein isothiocyanate (FITC), phycoerythrin (PE)), an enzyme (e.g., alkaline phosphatase, horseradish peroxidase) and an element particle (e.g., gold particle).
[0151] For the purposes of the methods of the invention, wherein a host cell or population of cells is administered, the cells may be allogeneic or autologous to the mammal. Preferably, the cells are autologous to the mammal.
[0152] For the purposes of the methods of the present invention, the cancer can be any cancer, including acute lymphocytic cancer, acute myeloid leukemia, alveolar rhabdomyosarcoma, bone cancer, brain cancer, breast cancer, anal cancer, anal canal or anorectal cancer, eye cancer, intrahepatic bile duct cancer, joint cancer, neck cancer, gallbladder or pleural cancer, nose, nasal cavity or middle ear cancer, oral cancer, vaginal cancer, vulvar cancer, chronic lymphocytic leukemia, chronic myeloid cancer, colon cancer, colorectal cancer, endometrial cancer, esophageal cancer, Cervical cancer, gastrointestinal carcinoid, glioma, Hodgkin's lymphoma, hypopharyngeal cancer, kidney cancer, laryngeal cancer, liver cancer, lung cancer, malignant mesothelioma, melanoma, multiple myeloma, nasopharyngeal cancer, non-Hodgkin's lymphoma, oropharyngeal cancer, ovarian cancer, penile cancer, pancreatic cancer, peritoneal, omental and mesenteric cancer, pharyngeal cancer, prostate cancer, rectal cancer, kidney cancer, skin cancer, small intestine cancer, soft tissue cancer, stomach cancer, testicular cancer, thyroid cancer, uterine cancer, ureteral cancer and bladder cancer. In a preferred embodiment, the cancer is a cancer expressing mutant p53. The cancer may express p53 with mutations at any one or more of positions 175, 220, 245, 248, 249, 273 and 282 of SEQ ID NO: 1. The cancer may express p53 with one or more of the following human p53 mutations: R175H, Y220C, G245D, G245S, R248L, R248Q, R248W, R249S, R273H, R273C, R273L, and R282W. Preferably, the cancer is an epithelial cancer or bile duct cancer, melanoma, colon cancer, rectal cancer, ovarian cancer, endometrial cancer, non-small cell lung cancer (NSCLC), glioblastoma, cervical cancer, head and neck cancer, breast cancer, pancreatic cancer, or bladder cancer.
[0153] The mammal mentioned in the method of the present invention can be any mammal. As used herein, the term "mammal" refers to any mammal, including but not limited to mammals of the order Rodentia, such as mice and hamsters, and mammals of the order Lagomorpha, such as rabbits. Preferably, the mammal is from the order Carnivora, including Felis (cats) and Canis (dogs). More preferably, the mammal is from the order Artiodactyla, including Bovines (cows) and Swines (pigs); or from the order Persodactyla, including Equines (horses). Most preferably, the mammal belongs to the order Primates, Ceboids, or Simoids (monkeys) or the order Anthropoids (humans and apes). A particularly preferred mammal is a human.
[0154] The following examples further illustrate the present invention but, of course, should not be construed in any way as limiting its scope. Example
[0155] The amino acid sequences listed in Tables 1-3 were used in the experiments described in the following examples. In Tables 1-2, "LP" stands for "Long Peptide". In Table 3, "TMG" stands for "Tandem Minigene".
[0156] Table 1
[0157]
[0158] Table 2 lists the wild-type forms of the peptides of Table 1.
[0159] Table 2
[0160]
[0161] Table 3
[0162]
[0163]
[0164] Example 1
[0165] This example demonstrates the isolation and specific reactivity of four TCRs from patient 4127 against mutant p53.
[0166] Combination Figure 1-7 , 36 and 37A-37C were performed on patient 4127. The mutant p53 reactive T cells of this patient were identified by the method described in U.S. Patent Application No. 2017 / 0224800 ("Tran Method"). The method for isolating a single TCR is described as follows.
[0167] use Figure 1 Autologous PBL were transduced with one of the TCRs shown in Figure 2 and tested 2 weeks later. Autologous DCs were cultured at 3 x 10 4 10 cells / well were plated and pulsed overnight with decreasing concentrations of WT p53-G245 peptide (wt) or mutant p53-G245S peptide (mut). 3x 10 4 The transduced T cells were co-cultured overnight at 37°C. The supernatant was harvested and used for IFN-γ ELISA. The IFN-γ ELISA results are shown in Figure 1 4-1BB expression was determined by FACS gating: lymphocytes\PI(neg)CD3 + \CD3 + MTCR + \CD8(neg)CD4 + The FACS results are shown in Figure 2 .
[0168] use Figure 3The autologous PBL were transduced with a TCR as shown in Figure 2 Co-cultures were performed as described in , but DCs were pulsed with DMSO (peptide vehicle) or one of the 15-mer p53-G245S peptides with 14 amino acids of overlap as shown in Table A. Figure 2 The results are shown in Figure 3 .
[0169] Table A
[0170]
[0171] Cos7 cells (2.5 x 10 per well) 4 T cells (10 ng / mL) were plated on the wells of a flat-bottom 96-well plate. 20 hours later, the cells were co-transfected with individual HLA alleles. 20 hours later, the cells were pulsed with 10 μg / mL of p53G245S-15-mer peptide at 37°C for 3 hours. After washing, T cells (10 5 ) were added to the wells and co-cultured at 37°C overnight (20 hours). IFN-γ secretion was detected by ELISA. Prediction by NetMHCIIpan: cbs.dtu.dk / services / NetMHCIIpan / . 4-1BB expression was measured by FACS. FACS gates were set as follows: lymphocytes → live cells (PI negative) → CD3+ (T cells) → CD4+ (4127-TIL) or CD4+mTCR+ (TCR-transduced T cells). Results are shown in Figure 4-5 and Table B.
[0172] Table B
[0173]
[0174] In the NCI HLA database, 1367 of 3719 patients with DRB_ (37%) expressed DRB3*02, and 5 / 9 (56%) of patients with endometrial and ovarian cancer from the NCI-SB (National Cancer Institute Surgical Branch) expressed DRB3*02. According to the allelefrequencies.net website, the reported DRB3*02 allele frequencies are very high. For example, this website reports the frequency of the DRB3*02 allele to be 0.3447 in the US NMDP Middle East or North Coast of Africa population.
[0175] TILs from patient 4127 were co-cultured with allogeneic (DRB3*01:01:01 or DRB3*02:02:01) antigen presenting cells (APCs) that were (1) electroporated with a tandem minigene (TMG) consisting of an irrelevant, WT p53, or mutant p53 sequence, or (2) pulsed with a peptide vehicle (DMSO) or a purified (>95% by high performance liquid chromatography (HPLC)) 25 amino acid peptide consisting of a WT p53-G245S sequence or a mutant p53-G245S sequence. Co-culture was performed overnight at 37°C. IFN-γ secretion was assessed using an ELISPOT assay. Results are shown in Figure 6 middle.
[0176] T cells specific for p53-G245S and expressing 4127-TCR1 were co-cultured with allogeneic APCs, e.g. Figure 6 The results are shown in Figure 7 middle.
[0177] Autologous APCs were pulsed with decreasing concentrations of a 25-amino acid peptide corresponding to the WT p53-G245 or mutant p53-G245S sequence. T cells transduced with 4127-O37-TCR from patient 4127 were co-cultured with peptide-pulsed APCs at 37°C overnight. After gating on lymphocytes (lymphocytes → single cells → live cells) → CD3+MTCR+, 4-1BB expression was evaluated by flow cytometry. Results are shown in Fig.36 .
[0178] Cos7 cells (2.5x10 4 100 μg / well) were plated on the wells of a flat-bottom 96-well plate. The next day, the cells were co-transfected with a single HLA allele from patient 4127. The next day, the 25 amino acid p53-G245S peptide was pulsed on the transfected Cos7 cells. Excess peptide was washed away. T cells were transduced with a TCR from patient 4127. Transduced T cells (2×10 4 The co-cultures were incubated overnight at 37°C. IFN-γ secretion was evaluated by ELISA. After gating lymphocytes (monocytes) and live cells (CD3+MTCR+), 4-1BB expression was evaluated by flow cytometry. Results are shown in Figures 37A-37C .
[0179] The sequence of TCR 4127-TP53-G245S-TCR1 isolated from patient 4127 is as follows. From the amino terminus, the first underlined region is CDR1β (SEQ ID NO: 30), the second underlined region is CDR2β (SEQ ID NO: 31), the third underlined region is CDR3β (SEQ ID NO: 32), the fourth underlined region is CDR1α (SEQ ID NO: 27), the fifth underlined region is CDR2α (SEQ ID NO: 28), and the sixth underlined region is CDR3α (SEQ ID NO: 29). The bold region is a connector (SEQ ID NO: 26). From the amino terminus, the first italic region is the β chain constant region (SEQ ID NO: 25), and the second italic region is the α chain constant region (SEQ ID NO: 23). The β chain variable region (SEQ ID NO: 34) includes a sequence starting from the amino terminus and ending just before the β chain constant region begins. The alpha chain variable region (SEQ ID NO: 33) includes the sequence starting immediately after the linker and ending just before the start of the alpha chain constant region. The full-length beta chain (SEQ ID NO: 36) includes the sequence starting from the amino terminus and ending just before the start of the linker. The full-length alpha chain (SEQ ID NO: 35) includes the sequence starting immediately after the linker and ending at the carboxyl terminus.
[0180] Cancer reactive T cells were identified as follows. TCRs were isolated as follows.
[0181] TCR Name:4127-TP 53-G245S-TCR1
[0182] Identification of P53 mutation: G245S
[0183] Method: Tran method
[0184] Co-culture to identify TCR: Co-culture 4127-F10 TIL fraction with G245S long peptide and sort CD4+41BB+ TIL cells (single cell RT-PCR only)
[0185] Methods used to identify TCRs: single-cell RT-PCR (see below), Adaptive Pairseq (4127-F10 fragment), 5' RACE from TIL clone O71
[0186] Abundance of TCR among all paired TCRs: 31.3% (observed 5 times in 16 pairs)
[0187] TCR direction: β-α
[0188] Expression vector: γ-retrovirus
[0189]
[0190] The statistical data of TCR 4127-TP53-G245S-TCR1 of patient 4127 are shown in Table 4 below.
[0191] Table 4
[0192] parameter # frequency Total number of holes 96 100% CDR3α type 6 6.3% CDR3β 13 13.5% 4127-TP3-G245S-TCR1 pair 5 5.2% Total paired TCR 16 16.7%
[0193] The sequence of TCR 4127-TP53-G245S-TCR4 isolated from patient 4127 is as follows. From the amino terminus, the first underlined region is CDR1β (SEQ ID NO: 40), the second underlined region is CDR2β (SEQ ID NO: 41), the third underlined region is CDR3β (SEQ ID NO: 42), the fourth underlined region is CDR1α (SEQ ID NO: 37), the fifth underlined region is CDR2α (SEQ ID NO: 38), and the sixth underlined region is CDR3α (SEQ ID NO: 39). The bold region is a connector (SEQ ID NO: 26). From the amino terminus, the first italic region is the β chain constant region (SEQ ID NO: 25), and the second italic region is the α chain constant region (SEQ ID NO: 23). The β chain variable region (SEQ ID NO: 44) includes a sequence starting from the amino terminus and ending just before the β chain constant region begins. The alpha chain variable region (SEQ ID NO: 43) includes a sequence starting immediately after the linker and ending just before the start of the alpha chain constant region. The full-length beta chain (SEQ ID NO: 46) includes a sequence starting from the amino terminus and ending just before the start of the linker. The full-length alpha chain (SEQ ID NO: 45) includes a sequence starting immediately after the linker and ending at the carboxyl terminus.
[0194] Cancer reactive T cells were identified as follows. TCRs were isolated as follows.
[0195] TCR Name:4127-TP 53-G245S-TCR4
[0196] Identification of P53 mutation: G245S
[0197] Method: Tran method
[0198] Co-culture to identify TCR: Co-culture 4127-F10 TIL fraction with G245S long peptide and sort CD4+41BB+ TIL cells (single cell RT-PCR only)
[0199] Methods used to identify TCRs: Single-cell RT-PCR (see below), Adaptive Pairseq (4127-F10 fragment)
[0200] Abundance of TCR among all paired TCRs: 12.5% (observed 2 times in 16 pairs)
[0201] TCR direction: β-α
[0202] Expression vector: γ-retrovirus
[0203]
[0204] The statistical data of TCR 4127-TP53-G245S-TCR4 of patient 4127 are shown in Table 5 below.
[0205] Table 5
[0206] parameter # frequency Total number of holes 96 100% CDR3α gene 2 2.1% CDR3β gene 39 40.6% 4127-TP53-G245S-TCR4 pair 2 2.1% Total paired TCR 16 16.7%
[0207] The sequence of TCR4127_O102_TCR isolated from patient 4127 is as follows. From the amino terminus, the first underlined region is CDR1β (SEQ ID NO: 50), the second underlined region is CDR2β (SEQ ID NO: 51), the third underlined region is CDR3β (SEQ ID NO: 52), the fourth underlined region is CDR1α (SEQ ID NO: 47), the fifth underlined region is CDR2α (SEQ ID NO: 48), and the sixth underlined region is CDR3α (SEQ ID NO: 49). The bold region is a connector (SEQ ID NO: 26). From the amino terminus, the first italic region is the β chain constant region (SEQ ID NO: 25), and the second italic region is the α chain constant region (SEQ ID NO: 23). The β chain variable region (SEQ ID NO: 54) includes a sequence starting from the amino terminus and ending before the β chain constant region begins. The alpha chain variable region (SEQ ID NO: 53) includes a sequence starting immediately after the linker and ending just before the start of the alpha chain constant region. The full-length beta chain (SEQ ID NO: 56) includes a sequence starting at the amino terminus and ending just before the start of the linker. The full-length alpha chain (SEQ ID NO: 55) includes a sequence starting immediately after the linker and ending at the carboxyl terminus.
[0208] Cancer reactive T cells were identified as follows. TCRs were isolated as follows.
[0209] TCR Name:4127_O102_TCR
[0210] Identification of p53 mutation: G245S
[0211] Method: Tran method
[0212] Co-culture to identify TCR: Not performed. TCR was directly identified from RNA of T cell clone (O102) using 5' RACE. Clones were developed by sorting OX 40+ T cells and establishing T cell clones by limiting dilution, and T cell clones were screened using the Tran method.
[0213] Methods for identifying TCR: 5' RACE, cloning of O102 from TIL
[0214] Abundance of TCR among all paired TCRs: 100% T cell clones (not applicable)
[0215] TCR orientation: α-β
[0216] Expression vector: γ-retrovirus
[0217]
[0218] The sequence of TCR 4127-037-TCR isolated from patient 4127 is as follows. Starting from the amino terminus, the first underlined region is CDR1β (SEQ ID NO: 460), the second underlined region is CDR2β (SEQ ID NO: 461), the third underlined region is CDR3β (SEQ ID NO: 462), the fourth underlined region is CDR1α (SEQ ID NO: 457), the fifth underlined region is CDR2α (SEQ ID NO: 458), and the sixth underlined region is CDR3α (SEQ ID NO: 459).
[0219] The bold region is the linker (SEQ ID NO: 26). Starting from the amino terminus, the first italic region is the beta chain constant region (SEQ ID NO: 25), and the second italic region is the alpha chain constant region (SEQ ID NO: 23). The beta chain variable region (SEQ ID NO: 464) includes a sequence starting from the amino terminus and ending before the start of the beta chain constant region. The alpha chain variable region (SEQ ID NO: 463) includes a sequence starting immediately after the linker and ending before the start of the alpha chain constant region. The full-length beta chain (SEQ ID NO: 466) includes a sequence starting from the amino terminus to the end before the start of the linker. The full-length alpha chain (SEQ ID NO: 465) includes a sequence starting immediately after the linker and ending at the carboxyl terminus.
[0220] Cancer reactive T cells were identified as follows. TCRs were isolated as follows.
[0221] TCR Name:4127-O37-TCR
[0222] Identification of p53 mutation: G245S
[0223] Method: Tran method
[0224] Co-culture to identify TCR: Not performed. TCR was directly identified from genomic DNA of T cell clone (O37) using adaptive TCRAD and TCRB measurements (next generation sequencing (NGS) platform). O37 clone was developed by sorting OX 40+ T cells and establishing T cell clones by limiting dilution. T cell clones were screened using the Tran method.
[0225] Methods for identifying TCRs: Adaptive TCR sequencing (NGS) of TIL clone O37
[0226] TCR abundance among all paired TCRs: 100% T cell clones (n / a)
[0227] TCR direction: β-α
[0228] Expression vector: γ-retrovirus
[0229]
[0230] Example 2
[0231] This example demonstrates the isolation and specific reactivity of three anti-mutant p53 TCRs from patient 4196.
[0232] Patient 4196 was subjected to the experiment as described in Figures 8-11. The p53 reactive T cells of this patient were identified by the Tran method as described in U.S. Patent Application No. 2017 / 0224800. Individual TCRs were isolated using the Fluidigm method. The statistical data of patient 4196 are shown in Table D.
[0233] Characterization of p53-responsive cells: Challenges in identifying minimal epitopes: The first predicted peptide with the mutant amino acid p53 R 175H is shown in Table C.
[0234] Table C
[0235] HLA HLA-A0201 Peptides HMTEVVRHC (SEQ ID NO:530) core HMTEVVRHC (SEQ ID NO:530) Affinity (nM) 7826.06 %grade 13.00
[0236] MG1 vs 4196-Rx1 TIL: COS7 cells were transfected with plasmids for TMG1 and HLA alleles. Cells were co-cultured with 4196Rx1 TIL infusion bags for 20 hours (h). Results are shown in Fig. 8A .
[0237] Pulsing P53-R175H minimal peptide versus 4196-Rx1 TIL: Autologous DCs on day 4 for 2 hours using candidate minimal epitopes (HMTEVVRHC (SEQ ID NO: 530) or (SQHMTEVRH (SEQ ID NO: 531)). Cells were washed and co-cultured with 4196Rx1 TIL infusion bag for 20 hours. Results are shown in Figure 8B .
[0238] A*02:01 restricted TP 53 tetramer can be used to isolate TP 53 reactive cells from TIL infusion bags: There is limited technology to isolate TP 53 reactive cells using 4-1BB+ sorting after co-culture with TP53 peptide. To isolate TP 53 reactive cells, A*02:01-TP 53 tetramer was generated. An irrelevant tetramer (A*02:01-gp 100) was generated as a control. FACS analysis was performed by gating on live CD3+, CD8+ cells. For A*02:01-TP 53 tetramer, 14.9% of p53 tetramer+ cells were detected. For A*02:01-gp 100 tetramer, 0.7% of p53 tetramer+ cells were detected.
[0239] Isolation and characterization of TP53 reactive cells: The strategy for the isolation and characterization of TP53 reactive cells was as follows: (1) FACS was used to sort tetramer positive cells as described above. (2) Single cell PCR was performed. (3) Vβ extracellular sequence determination was performed.
[0240] Several candidate clones for TP53 TCR were identified using single cell PCR, as shown in Table D. TCR-1a and TCR-1b were alternative candidate clones.
[0241] Table D
[0242]
[0243] Plasmids encoding candidate TCRs were cloned using the MSGV1 vector. Retroviral transduction was used to introduce the TCRs into donor lymphocytes.
[0244] On day 4, the HPLC grade minimal epitope was pulsed for 2 h on A*02:01 DC. DC cells were co-cultured with TCR-transduced cells for 20 h. Results are shown in Figures 9A-9D Three distinct A*02:01-restricted TP53 receptors were identified.
[0245] T2 cells were thawed and allowed to rest for 24 hours before being pulsed with decreasing concentrations of the HPLC minimal epitope for 2 hours. The cells were then washed and co-cultured with TP53TCR-transduced cells for 17 hours. Figures 10A-10B .
[0246] The following parental tumor cell lines were transduced with HLA-A*02:01: colon line – LS123 (ATCC CCL-255), which has R175H but unknown HLA-A2 status; leukemia cell line: CCRF-CEM (ATCC CRM-CCL-119, leukemia), which has R175H but unknown HLA-A2 status; breast line: AU-565 (ATCC CRL-2351, breast adenocarcinoma), which has R175H but unknown HLA-A2 status; melanoma cell line: MEL 624, which endogenously expresses HLA-A2 and wt R175.
[0247] On the morning of co-culture, targeted transduced tumor cells were harvested and plated (1 x 10 5 cells / well). On target cells, R175H minimal epitope (HPLC, 5 μg / mL) was pulsed for 2 h. Cells were washed twice and incubated with 2×10 4 TP53TCR transduced cells were co-cultured for 20 hours (patient 4196). Responses were read using IFN-γ ELISPOT. Results are shown in Fig.11 Additional experimental data on target cell HLA-A2 and TP53 expression and TCR reactivity of this example are provided in Example 15.
[0248] TCR4196_AV12-1_with_BV6-1 isolated from patient 4196 is as follows. Starting from the amino terminus, the first underlined region is CDR1β (SEQ ID NO: 70), the second underlined region is CDR2β (SEQ ID NO: 71), the third underlined region is CDR3β (SEQ ID NO: 72), the fourth underlined region is CDR1α (SEQ ID NO: 67), the fifth underlined region is CDR2α (SEQ ID NO: 68), and the sixth underlined region is CDR3α (SEQ ID NO: 69). The bold region is a connector (SEQ ID NO: 26). Starting from the amino terminus, the first italic region is the β chain constant region (SEQ ID NO: 25), and the second italic region is the α chain constant region (SEQ ID NO: 24). The β chain variable region (SEQ ID NO: 74) includes a sequence starting from the amino terminus and ending before the β chain constant region begins. The alpha chain variable region (SEQ ID NO: 73) includes the sequence starting immediately after the linker and ending just before the start of the alpha chain constant region. The full-length beta chain (SEQ ID NO: 76) includes the sequence starting from the amino terminus and ending just before the start of the linker. The full-length alpha chain (SEQ ID NO: 75) includes the sequence starting immediately after the linker and ending at the carboxyl terminus.
[0249] Cancer-reactive T cells were identified as follows.
[0250] TCR Name:4196_AV12-1_with_BV6-1
[0251] Identification of p53 mutation: R175H
[0252] Method: Tran method
[0253]
[0254] TCR 4196_AV38-1_with_BV10-3 isolated from patient 4196 is as follows. From the amino terminus, the first underlined region is CDR1β (SEQ ID NO: 80), the second underlined region is CDR2β (SEQ ID NO: 81), the third underlined region is CDR3β (SEQ ID NO: 82), the fourth underlined region is CDR1α (SEQ ID NO: 77), the fifth underlined region is CDR2α (SEQ ID NO: 78), and the sixth underlined region is CDR3α (SEQ ID NO: 79). The bold region is a connector (SEQ ID NO: 26). From the amino terminus, the first italic region is the β chain constant region (SEQ ID NO: 25), and the second italic region is the α chain constant region (SEQ ID NO: 24). The β chain variable region (SEQ ID NO: 84) includes a sequence starting from the amino terminus and ending before the β chain constant region begins. The α chain variable region (SEQ ID NO: 83) includes the sequence starting immediately after the linker and ending before the start of the α chain constant region. The full-length β chain (SEQ ID NO: 86) includes the sequence starting from the amino terminus and ending before the start of the linker. The full-length α chain (SEQ ID NO: 85) includes the sequence starting immediately after the linker and ending at the carboxyl terminus.
[0255] Cancer-reactive T cells were identified as follows.
[0256] TCR Name:4196_AV38-1_with_BV10-3
[0257] Identification of p53 mutation: R175H
[0258] Method: Tran method
[0259]
[0260]
[0261] TCR4196_AV6_with_BV11-2 isolated from patient 4196 is described below. Starting from the amino terminus, the first underlined region is CDR1β (SEQ ID NO: 90), the second underlined region is CDR2β (SEQ ID NO: 91), the third underlined region is CDR3β (SEQ ID NO: 92), the fourth underlined region is CDR1α (SEQ ID NO: 87), the fifth underlined region is CDR2α (SEQ ID NO: 88), and the sixth underlined region is CDR3α (SEQ ID NO: 89). The bold region is a connector (SEQ ID NO: 26). Starting from the amino terminus, the first italic region is the β chain constant region (SEQ ID NO: 25), and the second italic region is the α chain constant region (SEQ ID NO: 24). The β chain variable region (SEQ ID NO: 94) includes a sequence starting from the amino terminus and ending before the β chain constant region begins. The alpha chain variable region (SEQ ID NO: 93) includes the sequence starting immediately after the linker and ending before the start of the alpha chain constant region. The full-length beta chain (SEQ ID NO: 96) includes the sequence starting from the amino terminus and ending before the start of the linker. The full-length alpha chain (SEQ ID NO: 95) includes the sequence starting immediately after the linker and ending at the carboxyl terminus.
[0262] Cancer-reactive T cells were identified as follows.
[0263] TCR Name:4196_AV6_with_BV11-2
[0264] Identification of p53 mutation: R175H
[0265] Method: Tran method
[0266]
[0267] Example 3
[0268] This example demonstrates the isolation of 11 anti-mutant p53 TCRs from patient 4238.
[0269] As for Figure 12-15 The experiment was conducted on patient 4238.
[0270] TIL fragments from patient 4238 (F1-F24, n=24) were co-cultured with autologous APCs electroporated with TMG consisting of irrelevant or mutant p53 sequences. Co-cultures were incubated overnight at 37°C. IFN-γ secretion was assessed using an ELISPOT assay. Results are shown in Fig.12After setting gates for lymphocytes → live cells (PI negative) → CD3+ (T cells), the expression of 4-1BB was evaluated by flow cytometry. Fig.14 .
[0271] TIL fragments from patient 4238 (F1-F24, n=24) were co-cultured with autologous APCs pulsed with either a peptide vehicle (DMSO) or a purified 25 amino acid peptide consisting of the mutant p53-R248Q sequence (>95% by HPLC). Co-cultures were incubated overnight at 37°C. IFN-γ secretion was assessed using an ELISPOT assay. Results are shown in Fig.13 After setting gates for lymphocytes → live cells (PI negative) → CD3+ (T cells), the expression of 4-1BB was evaluated by flow cytometry. Fig.15 .
[0272] TIL fragments F10, F11 and F17 are the source of TCR after CD8+41BB+F17 sorting.
[0273] The sequence of TCR4238-F10-TCR1 isolated from patient 4238 is as follows. Starting from the amino terminus, the first underlined region is CDR1α (SEQ ID NO: 207), the second underlined region is CDR2α (SEQ ID NO: 208), the third underlined region is CDR3α (SEQ ID NO: 209), the fourth underlined region is CDR1β (SEQ ID NO: 210), the fifth underlined region is CDR2β (SEQ ID NO: 211), and the sixth underlined region is CDR3β (SEQ ID NO: 212). The bold region is a connector (SEQ ID NO: 26). Starting from the amino terminus, the first italic region is the α chain constant region (SEQ ID NO: 23), and the second italic region is the β chain constant region (SEQ ID NO: 25). The α chain variable region (SEQ ID NO: 213) includes a sequence starting from the amino terminus and ending before the start of the α chain constant region. The variable region of the beta chain (SEQ ID NO: 214) includes a sequence starting immediately after the linker and ending before the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 215) includes a sequence starting from the amino terminus and ending before the start of the linker. The full-length beta chain (SEQ ID NO: 216) includes a sequence starting immediately after the linker and ending at the carboxyl terminus.
[0274] Cancer reactive T cells were identified using the following screening method. The method used to isolate TCRs is described below.
[0275] TCR Name:4238-F10-TCR1
[0276] Identification of p53 mutation: R248Q
[0277] Screening method: Universal screening for p53 "hotspot" mutations
[0278] Co-culture to identify TCR: co-culture 4238-F10 with R248 Q long peptide, sorting CD8+41BB+NMT
[0279] Methods for identifying TCRs: single-cell reverse transcriptase polymerase chain reaction (RT-PCR)
[0280] Abundance of TCR among all paired TCRs: 25.0% (observed 3 times in 12 pairs)
[0281] TCR orientation: α-β
[0282] Expression vector: SB transposon
[0283]
[0284] The statistics of TCR 4238-F10-TCR1 of patient 4238 are shown in Table 6 below.
[0285] Table 6
[0286] parameter # frequency Total number of holes 96 100% CDR3α 4 4.2% CDR3β 4 4.2% 4238-F10-TCR1 pair 3 3.1% Total paired TCR 12 12.5%
[0287] The sequence of TCR4238-F10-TCR2 isolated from patient 4238 is as follows. Starting from the amino terminus, the first underlined region is CDR1α (SEQ ID NO: 217), the second underlined region is CDR2α (SEQ ID NO: 218), the third underlined region is CDR3α (SEQ ID NO: 219), the fourth underlined region is CDR1β (SEQ ID NO: 220), the fifth underlined region is CDR2β (SEQ ID NO: 221), and the sixth underlined region is CDR3β (SEQ ID NO: 222). The bold region is the linker (SEQ ID NO: 26). Starting from the amino terminus, the first italic region is the α chain constant region (SEQ ID NO: 23), and the second italic region is the β chain constant region (SEQ ID NO: 25). The α chain variable region (SEQ ID NO: 223) includes a sequence starting from the amino terminus and ending before the start of the α chain constant region. The variable region of the beta chain (SEQ ID NO: 224) includes a sequence that starts immediately after the linker and ends before the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 225) includes a sequence that starts from the amino terminus and ends before the start of the linker. The full-length beta chain (SEQ ID NO: 226) includes a sequence that starts immediately after the linker and ends at the carboxyl terminus.
[0288] Cancer reactive T cells were identified using the following screening method. The method used to isolate TCRs is described below.
[0289] TCR Name:4238-F10-TCR2
[0290] Identification of p53 mutation: R248Q
[0291] Screening method: Universal screening for p53 "hotspot" mutations
[0292] Co-culture to identify TCR: co-culture 4238-F10 with R248 Q long peptide and sort CD8+41BB+ T cells
[0293] Methods for identifying TCRs: single-cell RT-PCR
[0294] Abundance of TCR among all paired TCRs: 25.0% (observed 3 times in 12 pairs)
[0295] TCR orientation: α-β
[0296] Expression vector: SB transposon
[0297]
[0298] The statistics of TCR 4238-F10-TCR2 of patient 4238 are shown in Table 7 below.
[0299] Table 7
[0300] parameter # frequency Total number of holes 96 100% CDR3α 4 4.2% CDR3β 4 4.2% 4238-F10-TCR2 pair 3 3.1% Total paired TCR 12 12.5%
[0301] The sequence of TCR4238-F10-TCR3 isolated from patient 4238 is as follows. Starting from the amino terminus, the first underlined region is CDR1α (SEQ ID NO: 227), the second underlined region is CDR2α (SEQ ID NO: 228), the third underlined region is CDR3α (SEQ ID NO: 229), the fourth underlined region is CDR1β (SEQ ID NO: 230), the fifth underlined region is CDR2β (SEQ ID NO: 231), and the sixth underlined region is CDR3β (SEQ ID NO: 232). The bold region is a connector (SEQ ID NO: 26). Starting from the amino terminus, the first italic region is the α chain constant region (SEQ ID NO: 23), and the second italic region is the β chain constant region (SEQ ID NO: 25). The α chain variable region (SEQ ID NO: 233) includes a sequence starting from the amino terminus and ending before the start of the α chain constant region. The variable region of the beta chain (SEQ ID NO: 234) includes a sequence that starts immediately after the linker and ends before the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 235) includes a sequence that starts at the amino terminus and ends before the start of the linker. The full-length beta chain (SEQ ID NO: 236) includes a sequence that starts immediately after the linker and ends at the carboxyl terminus.
[0302] The following screening method was used to identify cancer reactive T cells. The method used to isolate TCRs is described below.
[0303] TCR Name:4238-F10-TCR3
[0304] Identification of p53 mutation: R248Q
[0305] Screening method: Universal screening for p53 "hotspot" mutations
[0306] Co-culture to identify TCR: co-culture 4238-F10 with R248 Q long peptide and sort CD8+41BB+ T cells
[0307] Methods for identifying TCRs: single-cell RT-PCR
[0308] Abundance of TCR among all paired TCRs: 58.3.0% (observed 7 times in 12 pairs)
[0309] TCR orientation: α-β
[0310] Expression vector: SB transposon
[0311]
[0312] The statistics of TCR 4238-F10-TCR3 of patient 4238 are shown in Table 8 below.
[0313] Table 8
[0314] parameter # frequency Total number of holes 96 100% CDR3α 16 16.7% CDR3β 26 27.1% 4238-F10-TCR3 pairs 7 7.3% Total paired TCR 12 12.5%
[0315] The sequence of TCR4238-F10-TCR4 isolated from patient 4238 is as follows. Starting from the amino terminus, the first underlined region is CDR1α (SEQ ID NO: 237), the second underlined region is CDR2α (SEQ ID NO: 238), the third underlined region is CDR3α (SEQ ID NO: 239), the fourth underlined region is CDR1β (SEQ ID NO: 240), the fifth underlined region is CDR2β (SEQ ID NO: 241), and the sixth underlined region is CDR3β (SEQ ID NO: 242). The bold region is the linker (SEQ ID NO: 26). Starting from the amino terminus, the first italic region is the α chain constant region (SEQ ID NO: 23), and the second italic region is the β chain constant region (SEQ ID NO: 25). The α chain variable region (SEQ ID NO: 243) includes a sequence starting from the amino terminus to the end before the start of the α chain constant region. The variable region of the beta chain (SEQ ID NO: 244) includes a sequence that starts immediately after the linker and ends before the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 245) includes a sequence that starts from the amino terminus and ends before the start of the linker. The full-length beta chain (SEQ ID NO: 246) includes a sequence that starts immediately after the linker and ends at the carboxyl terminus.
[0316] Cancer reactive T cells were identified using the following screening method. The method used to isolate TCRs is described below.
[0317] TCR Name:4238-F10-TCR4
[0318] Identification of p53 mutation: R248Q
[0319] Screening method: Universal screening for p53 "hotspot" mutations
[0320] Co-culture to identify TCR: co-culture 4238-F10 with R248 Q long peptide and sort CD8+41BB+ T cells
[0321] Methods for identifying TCRs: single-cell RT-PCR
[0322] Abundance of TCR among all paired TCRs: 58.3.0% (observed 7 times in 12 pairs)
[0323] TCR orientation: α-β
[0324] Expression vector: SB transposon
[0325]
[0326] The statistics of TCR 4238-F10-TCR4 of patient 4238 are shown in Table 9 below.
[0327] Table 9
[0328] parameter # frequency Total number of holes 96 100% CDR3α 16 16.7% CDR3β 26 27.1% 4238-F10-TCR4 pairs 7 7.3% Total paired TCR 12 12.5%
[0329] The sequence of TCR4238-F11-TCR1 isolated from patient 4238 is as follows. Starting from the amino terminus, the first underlined region is CDR1α (SEQ ID NO: 247), the second underlined region is CDR2α (SEQ ID NO: 248), the third underlined region is CDR3α (SEQ ID NO: 249), the fourth underlined region is CDR1β (SEQ ID NO: 250), the fifth underlined region is CDR2β (SEQ ID NO: 251), and the sixth underlined region is CDR3β (SEQ ID NO: 252). The bold region is a connector (SEQ ID NO: 26). Starting from the amino terminus, the first italic region is the α chain constant region (SEQ ID NO: 23), and the second italic region is the β chain constant region (SEQ ID NO: 25). The α chain variable region (SEQ ID NO: 253) includes a sequence starting from the amino terminus and ending before the α chain constant region begins. The variable region of the beta chain (SEQ ID NO: 254) includes a sequence starting immediately after the linker and ending before the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 255) includes a sequence starting from the amino terminus and ending before the start of the linker. The full-length beta chain (SEQ ID NO: 256) includes a sequence starting immediately after the linker and ending at the carboxyl terminus.
[0330] Cancer reactive T cells were identified using the following screening method. The method used to isolate TCRs is described below.
[0331] TCR Name:4238-F11-TCR1
[0332] Identification of p53 mutation: R248Q
[0333] Screening method: Universal screening for p53 "hotspot" mutations
[0334] Co-culture to identify TCR: co-culture 4238-F10 with R248 Q long peptide and sort CD8+41BB+ T cells
[0335] Methods for identifying TCRs: single-cell RT-PCR
[0336] Abundance of TCR among all paired TCRs: 25.0% (observed 3 times in 12 pairs)
[0337] TCR orientation: α-β
[0338] Expression vector: SB transposon
[0339]
[0340] The statistics of TCR 4238-F11-TCR1 of patient 4238 are shown in Table 10 below.
[0341] Table 10
[0342] parameter # frequency Total number of holes 96 100% CDR3α 5 5.2% CDR3β 3 3.1% 4238-F11-TCR1 pair 3 3.1% Total paired TCR 12 12.5%
[0343] The sequence of TCR4238-F11-TCR2 isolated from patient 4238 is as follows. Starting from the amino terminus, the first underlined region is CDR1α (SEQ ID NO: 257), the second underlined region is CDR2α (SEQ ID NO: 258), the third underlined region is CDR3α (SEQ ID NO: 259), the fourth underlined region is CDR1β (SEQ ID NO: 260), the fifth underlined region is CDR2β (SEQ ID NO: 261), and the sixth underlined region is CDR3β (SEQ ID NO: 262). The bold region is a connector (SEQ ID NO: 262). Starting from the amino terminus, the first italic region is the α chain constant region (SEQ ID NO: 23), and the second italic region is the β chain constant region (SEQ ID NO: 25). The α chain variable region (SEQ ID NO: 263) includes a sequence starting from the amino terminus and ending before the α chain constant region begins. The variable region of the beta chain (SEQ ID NO: 264) includes a sequence starting immediately after the linker and ending before the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 265) includes a sequence starting from the amino terminus and ending before the start of the linker. The full-length beta chain (SEQ ID NO: 266) includes a sequence starting immediately after the linker and ending at the carboxyl terminus.
[0344] The following screening method was used to identify cancer reactive T cells. The method used to isolate TCRs is described below.
[0345] TCR Name:4238-F11-TCR2
[0346] Identification of p53 mutation: R248Q
[0347] Screening method: Universal screening for p53 "hotspot" mutations
[0348] Co-culture to identify TCR: co-culture 4238-F11 with R248 Q long peptide and sort CD8+41BB+ T cells
[0349] Methods for identifying TCRs: single-cell RT-PCR
[0350] Abundance of TCR among all paired TCRs: 25.0% (observed 3 times in 12 pairs)
[0351] TCR orientation: α-β
[0352] Expression vector: SB transposon
[0353]
[0354] The statistics of TCR 4238-F11-TCR2 of patient 4238 are shown in Table 11 below.
[0355] Table 11
[0356] parameter # frequency Total number of holes 96 100% CDR3α 5 5.2% CDR3β 8 8.3% 4238-F11-TCR2 pair 3 3.1% Total paired TCR 12 12.5%
[0357] The sequence of TCR4238-F11-TCR3 isolated from patient 4238 is as follows. Starting from the amino terminus, the first underlined region is CDR1α (SEQ ID NO: 267), the second underlined region is CDR2α (SEQ ID NO: 268), the third underlined region is CDR3α (SEQ ID NO: 269), the fourth underlined region is CDR1β (SEQ ID NO: 270), the fifth underlined region is CDR2β (SEQ ID NO: 271), and the sixth underlined region is CDR3β (SEQ ID NO: 272). The bold region is the linker (SEQ ID NO: 26). Starting from the amino terminus, the first italic region is the α chain constant region (SEQ ID NO: 23), and the second italic region is the β chain constant region (SEQ ID NO: 25). The α chain variable region (SEQ ID NO: 273) includes a sequence starting from the amino terminus and ending before the start of the α chain constant region. The variable region of the beta chain (SEQ ID NO: 274) includes a sequence starting immediately after the linker and ending before the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 275) includes a sequence starting from the amino terminus and ending before the start of the linker. The full-length beta chain (SEQ ID NO: 276) includes a sequence starting immediately after the linker and ending at the carboxyl terminus.
[0358] The following screening method was used to identify cancer reactive T cells. The method used to isolate TCRs is described below.
[0359] TCR Name:4238-F11-TCR3
[0360] Identification of p53 mutation: R248Q
[0361] Screening method: Universal screening for p53 "hotspot" mutations
[0362] Co-culture to identify TCR: co-culture 4238-F11 with R248 Q long peptide and sort CD8+41BB+ T cells
[0363] Methods for identifying TCRs: single-cell RT-PCR
[0364] Abundance of TCR among all paired TCRs: 16.7% (observed 2 times in 12 pairs)
[0365] TCR orientation: α-β
[0366] Expression vector: SB transposon
[0367]
[0368] The statistics of TCR 4238-F11-TCR3 of patient 4238 are shown in Table 12 below.
[0369] Table 12
[0370] parameter # frequency Total number of holes 96 100% CDR3α 4 4.2% CDR3β 2 2.1% 4238-F11-TCR3 pairs 2 2.1% Total paired TCR 12 12.5%
[0371] The sequence of TCR4238-F11-TCR4 isolated from patient 4238 is as follows. Starting from the amino terminus, the first underlined region is CDR1α (SEQ ID NO: 277), the second underlined region is CDR2α (SEQ ID NO: 278), the third underlined region is CDR3α (SEQ ID NO: 279), the fourth underlined region is CDR1β (SEQ ID NO: 280), the fifth underlined region is CDR2β (SEQ ID NO: 281), and the sixth underlined region is CDR3β (SEQ ID NO: 282). The bold region is the linker (SEQ ID NO: 26). Starting from the amino terminus, the first italic region is the α chain constant region (SEQ ID NO: 23), and the second italic region is the β chain constant region (SEQ ID NO: 25). The α chain variable region (SEQ ID NO: 283) includes a sequence starting from the amino terminus and ending before the start of the α chain constant region. The variable region of the beta chain (SEQ ID NO: 284) includes the sequence starting immediately after the linker and ending before the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 285) includes the sequence starting from the amino terminus and ending before the start of the linker. The full-length beta chain (SEQ ID NO: 286) includes the sequence starting immediately after the linker and ending at the carboxyl terminus.
[0372] The following screening method was used to identify cancer reactive T cells. The method used to isolate TCRs is described below.
[0373] TCR Name:4238-F11-TCR4
[0374] Identification of p53 mutation: R248Q
[0375] Screening method: Universal screening for p53 "hotspot" mutations
[0376] Co-culture to identify TCR: co-culture 4238-F11 with R248 Q long peptide and sort CD8+41BB+ T cells
[0377] Methods for identifying TCRs: single-cell RT-PCR
[0378] Abundance of TCR among all paired TCRs: 16.7% (observed 2 times in 12 pairs)
[0379] TCR orientation: α-β
[0380] Expression vector: SB transposon
[0381]
[0382]
[0383] The statistics of TCR 4238-F11-TCR4 of patient 4238 are shown in Table 13 below.
[0384] Table 13
[0385] parameter # frequency Total number of holes 96 100% CDR3α 4 4.2% CDR3β 2 2.1% 4238-F11-TCR4 pair 2 2.1% Total paired TCR 12 12.5%
[0386] The sequence of TCR4238-F17-TCR1 isolated from patient 4238 is as follows. Starting from the amino terminus, the first underlined region is CDR1α (SEQ ID NO: 287), the second underlined region is CDR2α (SEQ ID NO: 288), the third underlined region is CDR3α (SEQ ID NO: 289), the fourth underlined region is CDR1β (SEQ ID NO: 290), the fifth underlined region is CDR2β (SEQ ID NO: 291), and the sixth underlined region is CDR3β (SEQ ID NO: 292). The bold region is a connector (SEQ ID NO: 26). Starting from the amino terminus, the first italic region is the α chain constant region (SEQ ID NO: 23), and the second italic region is the β chain constant region (SEQ ID NO: 25). The α chain variable region (SEQ ID NO: 293) includes a sequence starting from the amino terminus and ending before the start of the α chain constant region. The variable region of the beta chain (SEQ ID NO: 294) includes a sequence that starts immediately after the linker and ends before the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 295) includes a sequence that starts from the amino terminus and ends before the start of the linker. The full-length beta chain (SEQ ID NO: 296) includes a sequence that starts immediately after the linker and ends at the carboxyl terminus.
[0387] The following screening method was used to identify cancer reactive T cells. The method used to isolate TCRs is described below.
[0388] TCR Name:4238-F17-TCR1
[0389] Identification of p53 mutation: R248Q
[0390] Screening method: Universal screening for p53 "hotspot" mutations
[0391] Co-culture to identify TCR: co-culture 4238-F11 with R248 Q long peptide and sort CD8+41BB+ T cells
[0392] Methods for identifying TCRs: single-cell RT-PCR
[0393] Abundance of TCR among all paired TCRs: 33.3% (observed 2 times in 6 pairs)
[0394] TCR orientation: α-β
[0395] Expression vector: SB transposon
[0396]
[0397] The statistics of TCR 4238-F17-TCR1 of patient 4238 are shown in Table 14 below.
[0398] Table 14
[0399] parameter # frequency Total number of holes 96 100% CDR3α 3 3.1% CDR3β 2 2.1% 4238-F17-TCR1 pair 2 2.1% Total paired TCR 6 6.3%
[0400] The sequence of TCR4238-F17-TCR2 isolated from patient 4238 is as follows. Starting from the amino terminus, the first underlined region is CDR1α (SEQ ID NO: 297), the second underlined region is CDR2α (SEQ ID NO: 298), the third underlined region is CDR3α (SEQ ID NO: 299), the fourth underlined region is CDR1β (SEQ ID NO: 300), the fifth underlined region is CDR2β (SEQ ID NO: 301), and the sixth underlined region is CDR3β (SEQ ID NO: 302). The bold region is a connector (SEQ ID NO: 26). Starting from the amino terminus, the first italic region is the α chain constant region (SEQ ID NO: 23), and the second italic region is the β chain constant region (SEQ ID NO: 25). The α chain variable region (SEQ ID NO: 303) includes a sequence starting from the amino terminus and ending before the start of the α chain constant region. The variable region of the beta chain (SEQ ID NO: 304) includes a sequence that starts immediately after the linker and ends before the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 305) includes a sequence that starts from the amino terminus and ends before the start of the linker. The full-length beta chain (SEQ ID NO: 306) includes a sequence that starts immediately after the linker and ends at the carboxyl terminus.
[0401] The following screening method was used to identify cancer reactive T cells. The method used to isolate TCRs is described below.
[0402] TCR Name:4238-F17-TCR2
[0403] Identification of p53 mutation: R248Q
[0404] Screening method: Universal screening for p53 "hotspot" mutations
[0405] Co-culture to identify TCR: co-culture 4238-F11 with R248 Q long peptide and sort CD8+41BB+ T cells
[0406] Methods for identifying TCRs: single-cell RT-PCR
[0407] Abundance of TCR among all paired TCRs: 33.3% (observed 2 times in 6 pairs)
[0408] TCR orientation: α-β
[0409] Expression vector: SB transposon
[0410]
[0411]
[0412] The statistics of TCR 4238-F17-TCR2 of patient 4238 are shown in Table 15 below.
[0413] Table 15
[0414] parameter # frequency Total number of holes 96 100% CDR3α 6 6.3% CDR3β 2 2.1% 4238-F17-TCR2 pair 2 2.1% Total paired TCR 6 6.3%
[0415] The sequence of TCR4238-F17-TCR3 isolated from patient 4238 is as follows. Starting from the amino terminus, the first underlined region is CDR1α (SEQ ID NO: 307), the second underlined region is CDR2α (SEQ ID NO: 308), the third underlined region is CDR3α (SEQ ID NO: 309), the fourth underlined region is CDR1β (SEQ ID NO: 310), the fifth underlined region is CDR2β (SEQ ID NO: 311), and the sixth underlined region is CDR3β (SEQ ID NO: 312). The bold region is a connector (SEQ ID NO: 26). Starting from the amino terminus, the first italic region is the α chain constant region (SEQ ID NO: 23), and the second italic region is the β chain constant region (SEQ ID NO: 25). The α chain variable region (SEQ ID NO: 313) includes a sequence starting from the amino terminus and ending before the start of the α chain constant region. The variable region of the beta chain (SEQ ID NO: 314) includes a sequence that starts immediately after the linker and ends before the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 315) includes a sequence that starts from the amino terminus and ends before the start of the linker. The full-length beta chain (SEQ ID NO: 316) includes a sequence that starts immediately after the linker and ends at the carboxyl terminus.
[0416] The following screening method was used to identify cancer reactive T cells. The method used to isolate TCRs is described below.
[0417] TCR Name:4238-F17-TCR3
[0418] Identification of p53 mutation: R248Q
[0419] Screening method: Universal screening for p53 "hotspot" mutations
[0420] Co-culture to identify TCR: co-culture 4238-F11 with R248 Q long peptide and sort CD8+41BB+ T cells
[0421] Methods for identifying TCRs: single-cell RT-PCR
[0422] Abundance of TCR among all paired TCRs: 33.3% (observed 2 times in 6 pairs)
[0423] TCR orientation: α-β
[0424] Expression vector: SB transposon
[0425]
[0426] The statistics of TCR 4238-F17-TCR3 of patient 4238 are shown in Table 16 below.
[0427] Table 16
[0428]
[0429]
[0430] Example 4
[0431] This example demonstrates the isolation of two anti-mutant p53 TCRs from patient 4253.
[0432] according to Fig.16 As described, the experiment was performed on patient 4253.
[0433] TIL fragments from patients (F1-F24; n=24) were co-cultured with autologous APCs that were (1) pulsed with peptide vehicle (DMSO), (2) pulsed with a purified 25 amino acid peptide consisting of the mutant p53-R248W sequence (>95% by HPLC), (3) electroporated with an irrelevant TMG, or (4) electroporated with p53-mut-TMG containing the mutant p53-R248W sequence. Co-cultures were incubated overnight at 37°C. IFN-γ secretion was assessed by ELISPOT. Results are shown in Fig.16 F15 was chosen for TCR sorting because it responds to both p53-mut-TMG and p53-R248W long peptides.
[0434] The sequence of TCR4253-TIL-TCR1 isolated from patient 4253 is as follows. From the amino terminus, the first underlined region is CDR1α (SEQ ID NO: 187), the second underlined region is CDR2α (SEQ ID NO: 188), the third underlined region is CDR3α (SEQ ID NO: 189), the fourth underlined region is CDR1β (SEQ ID NO: 190), the fifth underlined region is CDR2β (SEQ ID NO: 191), and the sixth underlined region is CDR3β (SEQ ID NO: 192). The bold region is a connector (SEQ ID NO: 26). From the amino terminus, the first italic region is the α chain constant region (SEQ ID NO: 23), and the second italic region is the β chain constant region (SEQ ID NO: 25). The α chain variable region (SEQ ID NO: 193) includes a sequence starting from the amino terminus and ending before the α chain constant region begins. The variable region of the beta chain (SEQ ID NO: 194) includes a sequence starting immediately after the linker and ending before the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 195) includes a sequence starting from the amino terminus and ending before the start of the linker. The full-length beta chain (SEQ ID NO: 196) includes a sequence starting immediately after the linker and ending at the carboxyl terminus.
[0435] The following screening method was used to identify cancer reactive T cells. The method used to isolate TCRs is described below.
[0436] TCR Name: 4253-TIL-TCR1
[0437] Identification of p53 mutation: R248W
[0438] Methods: A simplified universal screen for p53 "hotspot" mutations (only mutant TMG and R248W long peptides were evaluated)
[0439] Co-culture to identify TCR: co-culture 4253-F15 with p53-R248W long peptide and sort CD3+41BB+ T cells
[0440] Methods for identifying TCRs: single-cell RT-PCR
[0441] Abundance of TCR among all paired TCRs: 5.6% (2 observed in 36 pairs)
[0442] TCR orientation: α-β
[0443] Expression vector: SB transposon
[0444]
[0445] The TCR 4253-TIL-TCR1 statistics of patient 4253 are shown in Table 17 below.
[0446] Table 17
[0447] parameter # frequency Total number of holes 55 100% CDR3α 3 5.5% CDR3β 2 3.6% 4253-TIL-TCR1 pair 2 3.6% Total paired TCR 36 65.5%
[0448] The sequence of TCR 4253-TIL-TCR2 isolated from patient 4253 is as follows. From the amino terminus, the first underlined region is CDR1α (SEQ ID NO: 197), the second underlined region is CDR2α (SEQ ID NO: 198), the third underlined region is CDR3α (SEQ ID NO: 199), the fourth underlined region is CDR1β (SEQ ID NO: 200), the fifth underlined region is CDR2β (SEQ ID NO: 201), and the sixth underlined region is CDR3β (SEQ ID NO: 202). The bold region is a connector (SEQ ID NO: 26). From the amino terminus, the first italic region is the α chain constant region (SEQ ID NO: 23), and the second italic region is the β chain constant region (SEQ ID NO: 25). The α chain variable region (SEQ ID NO: 203) includes a sequence starting from the amino terminus and ending before the α chain constant region begins. The variable region of the beta chain (SEQ ID NO: 204) includes a sequence that starts immediately after the linker and ends before the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 205) includes a sequence that starts from the amino terminus and ends before the start of the linker. The full-length beta chain (SEQ ID NO: 206) includes a sequence that starts immediately after the linker and ends at the carboxyl terminus.
[0449] The following screening method was used to identify cancer reactive T cells. The method used to isolate TCRs is described below.
[0450] TCR Name:4253-TIL-TCR2
[0451] Identification of p53 mutation: R248W
[0452] Methods: A simplified universal screen for p53 "hotspot" mutations (only mutant TMG and R248W long peptides were evaluated)
[0453] Co-culture to identify TCR: co-culture 4253-F15 with p53-R248W long peptide and sort CD3+41BB+ T cells
[0454] Methods for identifying TCRs: single-cell RT-PCR
[0455] Abundance of TCRs among all paired TCRs: 91.7% (33 observed in 36 pairs)
[0456] TCR orientation: α-β
[0457] Expression vector: SB transposon
[0458]
[0459] The statistics of TCR 4253-TIL-TCR2 of patient 4253 are shown in Table 18 below.
[0460] Table 18
[0461] parameter # frequency Total number of holes 55 100% CDR3α 35 63.6% CDR3β 33 60.0% 4253-TIL-TCR2 pair 33 60.0% Total paired TCR 36 65.5%
[0462] Example 5
[0463] This example identifies mutant p53-resistant T cells in patient 4273 by co-culturing autologous APCs induced to express mutant p53 within autologous T cells ("universal screen for p53 hotspot mutations"). This example also demonstrates the isolation of two mutant p53-resistant TCRs from patient 4273.
[0464] according to Figure 17-20 Experiments were performed on patient 4273 as described in 56-60.
[0465] TIL fragments from patient 4273 (F1-F24, n=24) were co-cultured with autologous APCs electroporated with TMG consisting of irrelevant, WT p53 or mutant p53 sequences. Co-cultures were incubated overnight at 37°C. IFN-γ secretion was assessed using an ELISPOT assay. Results are shown in Fig.17 . The expression of 4-1BB was evaluated by flow cytometry after setting gates for lymphocytes → live cells (PI negative) → CD3+ (T cells). The results are shown in Fig.18 .
[0466] TIL fragments from patient 4273 (F1-F24, n=24) were co-cultured with autologous APCs pulsed with either a peptide vehicle (DMSO) or a purified (>95% by HPLC) 25 amino acid peptide consisting of either the WT p53-R248 sequence or the mutant p53-R248W sequence. Co-cultures were incubated overnight at 37°C. IFN-γ secretion was assessed using an ELISPOT assay. Results are shown in Fig.19 . The expression of 4-1BB was evaluated by flow cytometry after setting gates for lymphocytes → live cells (PI negative) → CD3+ (T cells). The results are shown in Fig. 20 .
[0467] For patient 4273, F15 was the most reactive fragment, and F15 responded equally to LP and TMG, mainly CD4 T cells. So 4273-F15 was co-cultured with APC pulsed with R248W LP, and the next day the CD4+41BB+ T cells were sorted as single cells into the wells of a 96-well PCR plate, one cell per well. The PCR plate had RT-PCR solution in each well to amplify the TCRα and β CDR3 regions in the same solution. The microplate was then split into two 96-well PCR plates, and a second PCR reaction was performed to amplify either CDR3α or CDR3β as a separate reaction. The PCR products of each well (a total of 192 PCR products mapped to each well-α or β) were sequenced by Sanger sequencing. The nucleotide sequence was entered into IMGT / V-QUEST (imgt.org / iView / vest) livret=0&Option=Human TcR), IgBlast (ncbi.nlm.nih.gov / igblast / igblast.cgi?CMD=Web and SEARCH_TYPE=TCR and LINK_LOC=igtab), and translated by Expasy (web.exasy.org / transf / ). The variable family was determined based on the translated sequence and fused to CDR3 and the junction region (J or DJ). The variable sequence was fused to the mouse constant sequence, and the reconstructed TCRα and TCRβ were connected by furin-flexible-P2A (RAKR-SGSG-ATNFSLLKQAGDVEENPGP) (SEQ ID NO:26). The sequence was then synthesized de novo as DNA and cloned into an expression vector (gamma retrovirus or SLEEPING BEAUTY (SB) transposon (University of Minnesota, Minneapolis, MN)). T cells are then made to express the TCR using standard viral transduction or non-viral transposition protocols, and T cells expressing the murinized TCR are tested against the putative peptide (eg, by detection of the mouse TCR beta constant chain).
[0468] Autologous APCs were transfected with TMG encoding irrelevant mutations, WT p53 sequences, or mutated p53 sequences (including p53-R248W). Culture medium alone and PMA and ionomycin were used as negative and positive controls, respectively. TILs from patient 4273 (fragment cultures 8 and 15) were co-cultured with TMG-transfected APCs at 37°C overnight. After gating for lymphocytes → live cells (PI negative) → CD3+ (T cells), the expression of 4-1BB was evaluated by flow cytometry. The results are shown in Fig.56 middle.
[0469] Autologous APCs were pulsed with a 25 amino acid peptide corresponding to the WT or mutated p53-R248W neoepitope at 37°C for 2 hours. TILs specific for p53-R248W from patient 4273 (fragment culture 15) were co-cultured with peptide-pulsed APCs at 37°C overnight. DMSO was the peptide vehicle. For lymphocytes → live cells (PI negative) → CD3+ (T cells), the expression of 4-1BB was evaluated by flow cytometry after setting the gate. The results are shown in Fig.57 middle.
[0470] Autologous APCs were pulsed with a 15 amino acid peptide that overlapped 14 amino acids from the p53-R248W neoepitope. TILs specific for p53-R248W from patient 4273 (fragment culture 15) were co-cultured with peptide-pulsed APCs at 37°C overnight. DMSO was the peptide vehicle, and culture medium alone (T cells only) and PMA and ionomycin were controls. A 25 amino acid peptide (wt p53-R248 and mutated p53-R248W) was an additional control for the 15 amino acid peptide. After gating for lymphocytes → live cells (PI negative) → CD3+ (T cells) → CD4+CD8-, the expression of 4-1BB was evaluated by flow cytometry. The results are shown in Fig.58 middle.
[0471] Cos7 cells (2.5 x 10 per well) 4 The next day, the cells were co-transfected with individual HLA alleles from patient 4273 and WT or mutated TP53 TMG with or without the p53-R248W neoantigen. The next day, TILs from patient 4273 specific for p53-R248W (fragment culture 15) were co-cultured with transfected Cos7 cells overnight at 37°C. IFN-γ secretion was evaluated by ELISA. The results are shown in Fig.59 middle.
[0472] T cells expressing mock (no TCR) or 4273-TCR1a2 were co-cultured with autologous APCs pulsed with peptide vehicle (DMSO) or purified (>95% by HPLC) 25 amino acid peptides consisting of wild-type p53-R248 sequence or mutated p53-R248W sequence. Medium alone and PMA and ionomycin were negative and positive controls, respectively. Co-culture was performed overnight at 37°C. IFN-γ secretion was evaluated by ELISPOT. Results are shown in Fig.60 middle.
[0473] The sequence of TCR 4273-TP53-R248W-TCR1a1 isolated from patient 4273 is shown below. Starting from the amino terminus, the first underlined region is CDR1α (SEQ ID NO: 437), the second underlined region is CDR2α (SEQ ID NO: 438), the third underlined region is CDR3α (SEQ ID NO: 439), the fourth underlined region is CDR1β (SEQ ID NO: 440), the fifth underlined region is CDR2β (SEQ ID NO: 441), and the sixth underlined region is CDR3β (SEQ ID NO: 442). The bold region is the linker (SEQ ID NO: 26). Starting from the amino terminus, the first italicized region is the α chain constant region (SEQ ID NO: 23) and the second italicized region is the β chain constant region (SEQ ID NO: 25). The alpha chain variable region (SEQ ID NO: 443) comprises a sequence starting from the amino terminus and ending just before the start of the alpha chain constant region. The beta chain variable region (SEQ ID NO: 444) comprises a sequence starting immediately after the linker and ending just before the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 445) comprises a sequence starting from the amino terminus and ending just before the start of the linker. The full-length beta chain (SEQ ID NO: 446) comprises a sequence starting immediately after the linker and ending at the carboxyl terminus.
[0474] TCR Name:4273-TP53-R248W-TCR1a1
[0475] Identification of P53 mutation: R248W
[0476] Methods: Universal screening for p53 "hotspot" mutations
[0477]
[0478] The sequence of TCR 4273-TP53-R248W-TCR1a2 isolated from patient 4273 is shown below. Starting from the amino terminus, the first underlined region is CDR1α (SEQ ID NO: 447), the second underlined region is CDR2α (SEQ ID NO: 448), the third underlined region is CDR3α (SEQ ID NO: 449), the fourth underlined region is CDR1β (SEQ ID NO: 450), the fifth underlined region is CDR2β (SEQ ID NO: 451), and the sixth underlined region is CDR3β (SEQ ID NO: 452). The bold region is the linker (SEQ ID NO: 26). Starting from the amino terminus, the first italicized region is the α chain constant region (SEQ ID NO: 23) and the second italicized region is the β chain constant region (SEQ ID NO: 25). The alpha chain variable region (SEQ ID NO: 453) comprises a sequence starting from the amino terminus and ending just before the start of the alpha chain constant region. The beta chain variable region (SEQ ID NO: 454) comprises a sequence starting immediately after the linker and ending just before the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 455) comprises a sequence starting from the amino terminus and ending just before the start of the linker. The full-length beta chain (SEQ ID NO: 456) comprises a sequence starting immediately after the linker and ending at the carboxyl terminus.
[0479] TCR Name:4273-TP53-R248W-TCR1a2
[0480] Identification of P53 mutation: R248W
[0481] Methods: Universal screening for p53 "hotspot" mutations
[0482]
[0483]
[0484] Table 19 below lists the statistics of TCR of patient 4273. In Table 19, after co-culture with mutated p53 protein (TMG or peptide), there are always 96 wells sorted with 41BB+T cells. 77 wells have production pairs (meaning having (1) sequence and (2) no stop codon in the sequence), with a pairing frequency of 80.2%. 43 of those pairs are CDR3A / CDR3B combinations to constitute 4273-TP53-R248W-TCR1a1 (55.8% of production pairs). 30 of those pairs are CDR3A / CDR3B combinations to constitute 4273-TP53-R248W-TCR1a2 (39% of production pairs). Overall, in 96 wells, CDR3A and CDR3B of 4273-TP53-R248W-TCR1a1 were found 50 times and 83 times, respectively. Overall, CDR3A and CDR3B of 4273-TP53-R248W-TCR1a2 were found 33 and 83 times, respectively, in 96 wells.
[0485] Table 19
[0486]
[0487] Example 6
[0488] This example demonstrates the identification of anti-mutated p53 T cells in patient 4149. This example also demonstrates the isolation and specific reactivity of an anti-mutated p53 TCR from patient 4149.
[0489] like Figure 21-24 Experiments were performed as described for patient 4149. TCRs were discovered using the Tran method. TCRs were then used to validate the "universal screening for p53 hotspot mutations" method.
[0490] TCRs (4149-TCRa2b1 or 4149-TCRa2b2) were transposed into autologous PBL from patient 4149 and co-cultured with autologous APCs that were (1) electroporated with TMG consisting of an irrelevant, WT p53, or mutated p53 sequence, or (2) pulsed with a peptide vehicle (DMSO) or a purified (>95% by HPLC) 25-amino acid peptide consisting of a WT p53-Y220 sequence or a mutated p53-Y220C sequence. A combination of PMA and ionomycin was a positive control. Co-culture was performed overnight at 37°C. IFN-γ secretion was assessed using an ELISPOT assay. Results are shown in Fig.21 After setting gates for lymphocytes → live cells (PI negative) → CD3+ (T cells) → CD4+mTCR+ (TCR transposition T cells), the expression of 4-1BB was evaluated by flow cytometry. The results are shown in Fig. 22 middle.
[0491] The percentage of CD4+4-1BB+ cells was determined by TCRAD deep sequencing and TCRB deep sequencing. The results are shown in Table E.
[0492] Table E
[0493]
[0494] Putative p53 identified by 4149-F11 Y220C Mapping of minimal epitopes: Autologous DCs were pulsed with peptide (10 μg / mL) and incubated overnight in GM-CSF and IL-4. TILs were incubated in 500 CU / mL IL-2 for 2-3 days. 2x10 4 TIL and 10 5 The target cells were co-cultured overnight at 37°C. IFN-γ was measured by ELISPOT. The results are shown in Table 10. 4-1BB expression was measured by FACS using gated lymphocytes\PI(neg)CD3+\CD3+CD4+. The results are shown in Fig.23 middle.
[0495] Table F
[0496]
[0497] Cos7 cells (2.5 x 10 per well) 4 ) were plated on wells of a flat-bottom 96-well plate. 20 hours later, cells were co-transfected with individual HLA alleles with or without TMG. 20 hours later, autologous DC cells were transfected in parallel with TMG. All HLA class II alleles were co-transfected in one set of wells with or without TMG. Cells not transfected with TMG were pulsed with 10 μg / mL of p53-Y220C 15-mer peptide at 37°C for 2-3 hours. After washing, 4149-TCRa2b2-transposed T cells (10 5 ) were added to the wells and co-cultured overnight at 37°C. IFN-γ secretion was measured by ELISA. The results are shown in Fig.24 In. Prediction by NetMHCIIpan (Table G): cbs.dtu.dk / services / NetMHCIIpan / .
[0498] Table G
[0499]
[0500] DRB3*02 expression was detected in 1367 (37%) of 3719 DRB_ patients in the NCI HLA database and in 5 (56%) of 9 endometrial and ovarian cancer patients in NCI-SB. The reported frequency of the DRB3*02 allele is very high, as described in Example 1.
[0501] The sequence of TCR 4149TCRa2b2 isolated from patient 4149 is shown below. Starting from the amino terminus, the first underlined region is CDR1α (SEQ ID NO: 57), the second underlined region is CDR2α (SEQ ID NO: 58), the third underlined region is CDR3α (SEQ ID NO: 59), the fourth underlined region is CDR1β (SEQ ID NO: 60), the fifth underlined region is CDR2β (SEQ ID NO: 61), and the sixth underlined region is CDR3β (SEQ ID NO: 62). The bold region is the linker (SEQ ID NO: 26). Starting from the amino terminus, the first italicized region is the α chain constant region (SEQ ID NO: 23) and the second italicized region is the β chain constant region (SEQ ID NO: 25). The α chain variable region (SEQ ID NO: 63) includes a sequence starting from the amino terminus and ending just before the start of the α chain constant region. The beta chain variable region (SEQ ID NO: 64) comprises a sequence starting immediately after the linker and ending just before the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 65) comprises a sequence starting at the amino terminus and ending just before the start of the linker. The full-length beta chain (SEQ ID NO: 66) comprises a sequence starting immediately after the linker and ending at the carboxyl terminus.
[0502] Cancer reactive T cells were identified using the screening methods listed below. The patient's p53 reactive cells were identified by the Transcreening method described in US Application 2017 / 0224800.
[0503] TCR Name:4149TCRa2b2
[0504] Identification of P53 mutation: Y220C
[0505] Screening method: Universal screening for validation of p53 "hotspot" mutations
[0506] Co-culture to identify TCR: Co-culture 4149-F11 TIL fragments with p53-Y220C long peptide and sort CD4+41BB+ T cells
[0507] Method for identifying TCRs: frequency pairing. CD4+41BB+ sorted T cells were expanded in REP (Rapid Expansion Protocol) and the resulting T cell cultures were subjected to TCRAD (α) and TCRB (β) deep sequencing by Adaptive Biotechnologies. In the 4 total TCR matrices, the first two TCRαs were paired with the first two TCRβs. The second TCRα and the second TCRβ were reactive TCRs, hence the TCRα2b2 designation.
[0508] The abundance of TCR among all TCRs is as follows
[0509] TCR orientation: α-β
[0510] Expression vector: SB transposon
[0511]
[0512] The statistical data of TCR 4149TCRa2b2 of patient 4149 are shown in Table 20 below.
[0513] Table 20
[0514]
[0515] Example 7
[0516] This example demonstrates the identification of anti-mutated p53 T cells in patient 4213 by co-culturing autologous APCs induced to express mutant p53 within autologous T cells ("universal screening for p53 hotspot mutations"). This example also demonstrates the isolation of 12 anti-mutated p53 TCRs from patient 4213.
[0517] like Figure 25-26 Experiments were performed as described for patient 4213.
[0518] TIL fragments (F2 and F24) from patient 4213 were co-cultured with autologous APC pulsed with a peptide vehicle (DMSO) or a purified (>95%, by HPLC) 25-amino acid peptide consisting of a mutated p53-R248Q sequence. Co-culture was performed overnight at 37°C. After gating for lymphocytes → live cells (PI negative) → CD3+ (T cells), the expression of 4-1BB was evaluated by flow cytometry. The results are shown in Fig.25 CD8+4-1BB+ T cells were sorted into wells of a 96-well plate. TCRs were identified using single-cell RT-PCR.
[0519] CD4+T cells were derived from peripheral blood lymphocytes of patient 4213. CD4+T cell cultures were co-cultured with autologous APC pulsed with a peptide vehicle (DMSO) or a purified (>95%, by HPLC) 25-amino acid peptide consisting of a mutated p53-R248Q sequence. Co-culture was performed overnight at 37°C. IFN-γ secretion was evaluated by ELISPOT. After gating for lymphocytes → live cells (PI negative) → CD3+ (T cells), the expression of 4-1BB was evaluated by flow cytometry. The results are shown in Fig.26 CD4+41BB+ T cells were sorted into wells of a 96-well plate. TCRs were identified using single-cell RT-PCR.
[0520] The sequence of 4213-F2-TCR1 isolated from patient 4213 is shown below. Starting from the amino terminus, the first underlined region is CDR1α (SEQ ID NO: 317), the second underlined region is CDR2α (SEQ ID NO: 318), the third underlined region is CDR3α (SEQ ID NO: 319), the fourth underlined region is CDR1β (SEQ ID NO: 320), the fifth underlined region is CDR2β (SEQ ID NO: 321), and the sixth underlined region is CDR3β (SEQ ID NO: 322). The bold region is a linker (SEQ ID NO: 26). Starting from the amino terminus, the first italicized region is the α chain constant region (SEQ ID NO: 23) and the second italicized region is the β chain constant region (SEQ ID NO: 25). The α chain variable region (SEQ ID NO: 323) includes a sequence starting from the amino terminus and ending just before the start of the α chain constant region. The beta chain variable region (SEQ ID NO: 324) comprises a sequence starting immediately after the linker and ending just before the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 325) comprises a sequence starting from the amino terminus and ending just before the start of the linker. The full-length beta chain (SEQ ID NO: 326) comprises a sequence starting immediately after the linker and ending at the carboxyl terminus.
[0521] Cancer reactive T cells were identified using the screening methods listed below. The method used to isolate TCRs is shown below.
[0522] TCR Name:4213-F2-TCR1
[0523] Identification of P53 mutation: R248Q
[0524] Screening method: Universal screening for p53 "hotspot" mutations
[0525] Co-culture to identify TCR: co-culture 4213-F2 with R248Q long peptide and sort CD8+41BB+ T cells
[0526] Methods for identifying TCRs: single-cell RT-PCR
[0527] Abundance of TCR among all paired TCRs: 8.3% (observed 2 times in 24 pairs)
[0528] TCR orientation: α-β
[0529] Expression vector: SB transposon
[0530]
[0531] The statistical data of TCR 4213-F2-TCR1 of patient 4213 are shown in Table 21 below.
[0532] Table 21
[0533] parameter # frequency Total hole 96 100% CDR3α 3 3.1% CDR3β 8 8.3% 4213-F2-TCR1 pair 2 2.1% Total paired TCR 24 25.0%
[0534] The sequence of 4213-F2-TCR2 isolated from patient 4213 is shown below. From the amino terminus, the first underlined region is CDR1α (SEQ ID NO: 327), the second underlined region is CDR2α (SEQ ID NO: 328), the third underlined region is CDR3α (SEQ ID NO: 329), the fourth underlined region is CDR1β (SEQ ID NO: 330), the fifth underlined region is CDR2β (SEQ ID NO: 331), and the sixth underlined region is CDR3β (SEQ ID NO: 332). The bold region is a linker (SEQ ID NO: 26). From the amino terminus, the first italicized region is the α chain constant region (SEQ ID NO: 23) and the second italicized region is the β chain constant region (SEQ ID NO: 25). The α chain variable region (SEQ ID NO: 333) includes a sequence starting from the amino terminus and ending just before the start of the α chain constant region. The beta chain variable region (SEQ ID NO: 334) comprises a sequence starting immediately after the linker and ending just before the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 335) comprises a sequence starting from the amino terminus and ending just before the start of the linker. The full-length beta chain (SEQ ID NO: 336) comprises a sequence starting immediately after the linker and ending at the carboxyl terminus.
[0535] Cancer reactive T cells were identified using the screening methods listed below. The method used to isolate TCRs is shown below.
[0536] TCR Name:4213-F2-TCR2
[0537] Identification of P53 mutation: R248Q
[0538] Screening method: Universal screening for p53 "hotspot" mutations
[0539] Co-culture to identify TCR: co-culture 4213-F2 with R248Q long peptide and sort CD8+41BB+ T cells
[0540] Methods for identifying TCRs: single-cell RT-PCR
[0541] Abundance of TCR among all paired TCRs: 12.5% (observed 3 times in 24 pairs)
[0542] TCR orientation: α-β
[0543] Expression vector: SB transposon
[0544]
[0545]
[0546] The statistical data of TCR 4213-F2-TCR2 of patient 4213 are shown in Table 22 below.
[0547] Table 22
[0548] parameter # frequency Total hole 96 100% CDR3α 4 4.2% CDR3β 4 4.2% 4213-F2-TCR2 pair 3 3.1% Total paired TCR 24 25.0%
[0549] The sequence of 4213-F2-TCR3 isolated from patient 4213 is shown below. From the amino terminus, the first underlined region is CDR1α (SEQ ID NO: 337), the second underlined region is CDR2α (SEQ ID NO: 338), the third underlined region is CDR3α (SEQ ID NO: 339), the fourth underlined region is CDR1β (SEQ ID NO: 340), the fifth underlined region is CDR2β (SEQ ID NO: 341), and the sixth underlined region is CDR3β (SEQ ID NO: 342). The bold region is a linker (SEQ ID NO: 26). From the amino terminus, the first italicized region is the α chain constant region (SEQ ID NO: 23) and the second italicized region is the β chain constant region (SEQ ID NO: 25). The α chain variable region (SEQ ID NO: 343) includes a sequence starting from the amino terminus and ending just before the start of the α chain constant region. The beta chain variable region (SEQ ID NO: 344) comprises a sequence starting immediately after the linker and ending just before the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 345) comprises a sequence starting from the amino terminus and ending just before the start of the linker. The full-length beta chain (SEQ ID NO: 346) comprises a sequence starting immediately after the linker and ending at the carboxyl terminus.
[0550] Cancer reactive T cells were identified using the screening methods listed below. The method used to isolate TCRs is shown below.
[0551] TCR Name:4213-F2-TCR3
[0552] Identification of P53 mutation: R248Q
[0553] Screening method: Universal screening for p53 "hotspot" mutations
[0554] Co-culture to identify TCR: co-culture 4213-F2 with R248Q long peptide and sort CD8+41BB+ T cells
[0555] Methods for identifying TCRs: single-cell RT-PCR
[0556] Abundance of TCRs among all paired TCRs: 70.8% (observed 17 times in 24 pairs)
[0557] TCR orientation: α-β
[0558] Expression vector: SB transposon
[0559]
[0560] The statistical data of TCR 4213-F2-TCR3 of patient 4213 are shown in Table 23 below.
[0561] Table 23
[0562] parameter # frequency Total hole 96 100% CDR3α 19 19.8% CDR3β 42 43.8% 4213-F2-TCR3 pairs 17 17.7% Total paired TCR 24 25.0%
[0563] The sequence of 4213-F24-TCRa1 isolated from patient 4213 is shown below. Starting from the amino terminus, the first underlined region is CDR1α (SEQ ID NO: 347), the second underlined region is CDR2α (SEQ ID NO: 348), the third underlined region is CDR3α (SEQ ID NO: 349), the fourth underlined region is CDR1β (SEQ ID NO: 350), the fifth underlined region is CDR2β (SEQ ID NO: 351), and the sixth underlined region is CDR3β (SEQ ID NO: 352). The bold region is the linker (SEQ ID NO: 26). Starting from the amino terminus, the first italicized region is the α chain constant region (SEQ ID NO: 23) and the second italicized region is the β chain constant region (SEQ ID NO: 25). The α chain variable region (SEQ ID NO: 353) includes a sequence starting from the amino terminus and ending just before the start of the α chain constant region. The beta chain variable region (SEQ ID NO: 354) comprises a sequence starting immediately after the linker and ending just before the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 355) comprises a sequence starting from the amino terminus and ending just before the start of the linker. The full-length beta chain (SEQ ID NO: 356) comprises a sequence starting immediately after the linker and ending at the carboxyl terminus.
[0564] Cancer reactive T cells were identified using the screening methods listed below. The method used to isolate TCRs is shown below.
[0565] TCR Name:4213-F24-TCRa1
[0566] Identification of P53 mutation: R248Q
[0567] Screening method: Universal screening for p53 "hotspot" mutations
[0568] Co-culture to identify TCR: Co-culture 4213-F24 and R248Q long peptide, sort CD8+41BB+ T cells
[0569] Methods for identifying TCRs: single-cell RT-PCR
[0570] Abundance of TCR among all paired TCRs: 15.9% (observed 7 times in 44 pairs)
[0571] TCR orientation: α-β
[0572] Expression vector: SB transposon
[0573]
[0574] The statistical data of TCR 4213-F24-TCRa1 of patient 4213 are shown in Table 24 below.
[0575] Table 24
[0576] parameter # frequency Total hole 96 100% CDR3α 7 7.3% CDR3β 80 83.3% 4213-F24-TCRa1 pair 7 7.3% Total paired TCR 44 45.8%
[0577] The sequence of 4213-F24-TCRa2 isolated from patient 4213 is shown below. Starting from the amino terminus, the first underlined region is CDR1α (SEQ ID NO: 357), the second underlined region is CDR2α (SEQ ID NO: 358), the third underlined region is CDR3α (SEQ ID NO: 359), the fourth underlined region is CDR1β (SEQ ID NO: 360), the fifth underlined region is CDR2β (SEQ ID NO: 361), and the sixth underlined region is CDR3β (SEQ ID NO: 362). The bold region is the linker (SEQ ID NO: 26). Starting from the amino terminus, the first italicized region is the α chain constant region (SEQ ID NO: 23) and the second italicized region is the β chain constant region (SEQ ID NO: 25). The α chain variable region (SEQ ID NO: 363) includes a sequence starting from the amino terminus and ending just before the start of the α chain constant region. The beta chain variable region (SEQ ID NO: 364) comprises a sequence starting immediately after the linker and ending just before the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 365) comprises a sequence starting from the amino terminus and ending just before the start of the linker. The full-length beta chain (SEQ ID NO: 366) comprises a sequence starting immediately after the linker and ending at the carboxyl terminus.
[0578] Cancer reactive T cells were identified using the screening methods listed below. The method used to isolate TCRs is shown below.
[0579] TCR Name:4213-F24-TCRa2
[0580] Identification of P53 mutation: R248Q
[0581] Screening method: Universal screening for p53 "hotspot" mutations
[0582] Co-culture to identify TCR: Co-culture 4213-F24 and R248Q long peptide, sort CD8+41BB+ T cells
[0583] Methods for identifying TCRs: single-cell RT-PCR
[0584] Abundance of TCRs among all paired TCRs: 84.1% (observed 37 times in 44 pairs)
[0585] TCR orientation: α-β
[0586] Expression vector: SB transposon
[0587]
[0588]
[0589] The statistical data of TCR 4213-F24-TCRa2 of patient 4213 are shown in Table 25 below.
[0590] Table 25
[0591] parameter # frequency Total hole 96 100% CDR3α 39 40.6% CDR3β 80 83.3% 4213-F24-TCRa2 pair 37 38.5% Total paired TCR 44 45.8%
[0592] The sequence of 4213-PBL-TCR1 isolated from patient 4213 is shown below. Starting from the amino terminus, the first underlined region is CDR1α (SEQ ID NO: 367), the second underlined region is CDR2α (SEQ ID NO: 368), the third underlined region is CDR3α (SEQ ID NO: 369), the fourth underlined region is CDR1β (SEQ ID NO: 370), the fifth underlined region is CDR2β (SEQ ID NO: 371), and the sixth underlined region is CDR3β (SEQ ID NO: 372). The bold region is the linker (SEQ ID NO: 26). Starting from the amino terminus, the first italicized region is the α chain constant region (SEQ ID NO: 23) and the second italicized region is the β chain constant region (SEQ ID NO: 25). The α chain variable region (SEQ ID NO: 373) includes a sequence starting from the amino terminus and ending just before the start of the α chain constant region. The beta chain variable region (SEQ ID NO: 374) comprises a sequence starting immediately after the linker and ending just before the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 375) comprises a sequence starting at the amino terminus and ending just before the start of the linker. The full-length beta chain (SEQ ID NO: 376) comprises a sequence starting immediately after the linker and ending at the carboxyl terminus.
[0593] Cancer reactive T cells were identified using the screening methods listed below. The method used to isolate TCRs is shown below.
[0594] TCR Name:4213-PBL-TCR1
[0595] Identification of P53 mutation: R248Q
[0596] Screening method: Universal screening for p53 "hotspot" mutations
[0597] Co-culture to identify TCR: CD4+ memory T cells after in vitro sensitization with R248Q long peptide were co-cultured with R248Q long peptide, and CD4+41BB+ T cells were sorted
[0598] Methods for identifying TCRs: single-cell RT-PCR
[0599] Abundance of TCR among all paired TCRs: 9.5% (observed 6 times in 63 pairs)
[0600] TCR orientation: α-β
[0601] Expression vector: SB transposon
[0602]
[0603] The statistical data of TCR 4213-PBL-TCR1 of patient 4213 are shown in Table 26 below.
[0604] Table 26
[0605] parameter # frequency Total hole 192 100% CDR3α 9 4.7% CDR3β 6 3.1% 4213-PBL-TCR1 pair 6 3.1% Total paired TCR 63 32.8%
[0606] The sequence of 4213-PBL-TCR2 isolated from patient 4213 is shown below. Starting from the amino terminus, the first underlined region is CDR1α (SEQ ID NO: 377), the second underlined region is CDR2α (SEQ ID NO: 378), the third underlined region is CDR3α (SEQ ID NO: 379), the fourth underlined region is CDR1β (SEQ ID NO: 380), the fifth underlined region is CDR2β (SEQ ID NO: 381), and the sixth underlined region is CDR3β (SEQ ID NO: 382). The bold region is the linker (SEQ ID NO: 26). Starting from the amino terminus, the first italicized region is the α chain constant region (SEQ ID NO: 23) and the second italicized region is the β chain constant region (SEQ ID NO: 25). The α chain variable region (SEQ ID NO: 383) includes a sequence starting from the amino terminus and ending before the start of the α chain constant region. The beta chain variable region (SEQ ID NO:384) comprises a sequence that starts immediately after the linker and ends just before the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO:385) comprises a sequence that starts at the amino terminus and ends just before the start of the linker. The full-length beta chain (SEQ ID NO:386) comprises a sequence that starts immediately after the linker and ends at the carboxyl terminus.
[0607] Cancer reactive T cells were identified using the screening methods listed below. The method used to isolate TCRs is shown below.
[0608] TCR Name:4213-PBL-TCR2
[0609] Identification of P53 mutation: R248Q
[0610] Screening method: Universal screening for p53 "hotspot" mutations
[0611] Co-culture to identify TCR: CD4+ memory T cells after in vitro sensitization with R248Q long peptide were co-cultured with R248Q long peptide, and CD4+41BB+ T cells were sorted
[0612] Methods for identifying TCRs: single-cell RT-PCR
[0613] Abundance of TCR among all paired TCRs: 7.9% (observed 5 times in 63 pairs)
[0614] TCR orientation: α-β
[0615] Expression vector: SB transposon
[0616]
[0617]
[0618] The statistical data of TCR 4213-PBL-TCR2 of patient 4213 are shown in Table 27 below.
[0619] Table 27
[0620] parameter # frequency Total hole 192 100% CDR3α 8 4.2% CDR3β 8 4.2% 4213-PBL-TCR2 pair 5 2.6% Total paired TCR 63 32.8%
[0621] The sequence of 4213-PBL-TCR3 isolated from patient 4213 is shown below. Starting from the amino terminus, the first underlined region is CDR1α (SEQ ID NO: 387), the second underlined region is CDR2α (SEQ ID NO: 388), the third underlined region is CDR3α (SEQ ID NO: 389), the fourth underlined region is CDR1β (SEQ ID NO: 390), the fifth underlined region is CDR2β (SEQ ID NO: 391), and the sixth underlined region is CDR3β (SEQ ID NO: 392). The bold region is the linker (SEQ ID NO: 26). Starting from the amino terminus, the first italicized region is the α chain constant region (SEQ ID NO: 23) and the second italicized region is the β chain constant region (SEQ ID NO: 25). The α chain variable region (SEQ ID NO: 393) includes a sequence starting from the amino terminus and ending just before the start of the α chain constant region. The beta chain variable region (SEQ ID NO: 394) comprises a sequence starting immediately after the linker and ending just before the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 395) comprises a sequence starting from the amino terminus and ending just before the start of the linker. The full-length beta chain (SEQ ID NO: 396) comprises a sequence starting immediately after the linker and ending at the carboxyl terminus.
[0622] Cancer reactive T cells were identified using the screening methods listed below. The method used to isolate TCRs is shown below.
[0623] TCR Name:4213-PBL-TCR3
[0624] Identification of P53 mutation: R248Q
[0625] Screening method: Universal screening for p53 "hotspot" mutations
[0626] Co-culture to identify TCR: CD4+ memory T cells after in vitro sensitization with R248Q long peptide were co-cultured with R248Q long peptide, and CD4+41BB+ T cells were sorted
[0627] Methods for identifying TCRs: single-cell RT-PCR
[0628] Abundance of TCR among all paired TCRs: 6.3% (observed 4 times in 63 pairs)
[0629] TCR orientation: α-β
[0630] Expression vector: SB transposon
[0631]
[0632] The statistical data of TCR 4213-PBL-TCR3 of patient 4213 are shown in Table 28 below.
[0633] Table 28
[0634]
[0635]
[0636] The sequence of 4213-PBL-TCR4a1 isolated from patient 4213 is shown below. Starting from the amino terminus, the first underlined region is CDR1α (SEQ ID NO: 397), the second underlined region is CDR2α (SEQ ID NO: 398), the third underlined region is CDR3α (SEQ ID NO: 399), the fourth underlined region is CDR1β (SEQ ID NO: 400), the fifth underlined region is CDR2β (SEQ ID NO: 401), and the sixth underlined region is CDR3β (SEQ ID NO: 402). The bold region is the linker (SEQ ID NO: 26). Starting from the amino terminus, the first italicized region is the α chain constant region (SEQ ID NO: 23) and the second italicized region is the β chain constant region (SEQ ID NO: 25). The α chain variable region (SEQ ID NO: 403) includes a sequence starting from the amino terminus and ending just before the start of the α chain constant region. The beta chain variable region (SEQ ID NO: 404) comprises a sequence starting immediately after the linker and ending just before the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 405) comprises a sequence starting at the amino terminus and ending just before the start of the linker. The full-length beta chain (SEQ ID NO: 406) comprises a sequence starting immediately after the linker and ending at the carboxyl terminus.
[0637] Cancer reactive T cells were identified using the screening methods listed below. The method used to isolate TCRs is shown below.
[0638] TCR Name: 4213-PBL-TCR4a1
[0639] Identification of P53 mutation: R248Q
[0640] Screening method: Universal screening for p53 "hotspot" mutations
[0641] Co-culture to identify TCR: CD4+ memory T cells after in vitro sensitization with R248Q long peptide were co-cultured with R248Q long peptide and CD4+41BB+ T cells were sorted
[0642] Methods for identifying TCRs: single-cell RT-PCR
[0643] Abundance of TCR among all paired TCRs: 3.2% (observed 2 times in 63 pairs)
[0644] TCR orientation: α-β
[0645] Expression vector: SB transposon
[0646]
[0647] The statistical data of TCR 4213-PBL-TCR4a1 of patient 4213 are shown in Table 29 below.
[0648] Table 29
[0649] parameter # frequency Total hole 192 100% CDR3α 2 1.0% CDR3β 36 18.8% 4213-PBL-TCR4a1 pair 2 1.0% Total paired TCR 63 32.8%
[0650] The sequence of 4213-PBL-TCR4a2 isolated from patient 4213 is shown below. Starting from the amino terminus, the first underlined region is CDR1α (SEQ ID NO: 407), the second underlined region is CDR2α (SEQ ID NO: 408), the third underlined region is CDR3α (SEQ ID NO: 409), the fourth underlined region is CDR1β (SEQ ID NO: 410), the fifth underlined region is CDR2β (SEQ ID NO: 411), and the sixth underlined region is CDR3β (SEQ ID NO: 412). The bold region is the linker (SEQ ID NO: 26). Starting from the amino terminus, the first italicized region is the α chain constant region (SEQ ID NO: 23) and the second italicized region is the β chain constant region (SEQ ID NO: 25). The α chain variable region (SEQ ID NO: 413) includes a sequence starting from the amino terminus and ending just before the start of the α chain constant region. The beta chain variable region (SEQ ID NO: 414) comprises a sequence starting immediately after the linker and ending just before the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 415) comprises a sequence starting from the amino terminus and ending just before the start of the linker. The full-length beta chain (SEQ ID NO: 416) comprises a sequence starting immediately after the linker and ending at the carboxyl terminus.
[0651] Cancer reactive T cells were identified using the screening methods listed below. The method used to isolate TCRs is shown below.
[0652] TCR Name:4213-PBL-TCR4a2
[0653] Identification of P53 mutation: R248Q
[0654] Screening method: Universal screening for p53 "hotspot" mutations
[0655] Co-culture to identify TCR: CD4+ memory T cells after in vitro sensitization with R248Q long peptide were co-cultured with R248Q long peptide and CD4+41BB+ T cells were sorted
[0656] Methods for identifying TCRs: single-cell RT-PCR
[0657] Abundance of TCR among all paired TCRs: 3.2% (observed 2 times in 63 pairs)
[0658] TCR orientation: α-β
[0659] Expression vector: SB transposon
[0660]
[0661]
[0662] The statistical data of TCR 4213-PBL-TCR4a2 of patient 4213 are shown in Table 30 below.
[0663] Table 30
[0664] parameter # frequency Total hole 192 100% CDR3α 2 1.0% CDR3β 36 18.8% 4213-PBL-TCR4a2 pair 2 1.0% Total paired TCR 63 32.8%
[0665] The sequence of 4213-PBL-TCR4a3 isolated from patient 4213 is shown below. Starting from the amino terminus, the first underlined region is CDR1α (SEQ ID NO: 417), the second underlined region is CDR2α (SEQ ID NO: 418), the third underlined region is CDR3α (SEQ ID NO: 419), the fourth underlined region is CDR1β (SEQ ID NO: 420), the fifth underlined region is CDR2β (SEQ ID NO: 421), and the sixth underlined region is CDR3β (SEQ ID NO: 422). The bold region is the linker (SEQ ID NO: 26). Starting from the amino terminus, the first italicized region is the α chain constant region (SEQ ID NO: 23) and the second italicized region is the β chain constant region (SEQ ID NO: 25). The α chain variable region (SEQ ID NO: 423) includes a sequence starting from the amino terminus and ending just before the start of the α chain constant region. The beta chain variable region (SEQ ID NO: 424) comprises a sequence starting immediately after the linker and ending just before the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 425) comprises a sequence starting at the amino terminus and ending just before the start of the linker. The full-length beta chain (SEQ ID NO: 426) comprises a sequence starting immediately after the linker and ending at the carboxyl terminus.
[0666] Cancer reactive T cells were identified using the screening methods listed below. The method used to isolate TCRs is shown below.
[0667] TCR Name:4213-PBL-TCR4a3
[0668] Identification of P53 mutation: R248Q
[0669] Screening method: Universal screening for p53 "hotspot" mutations
[0670] Co-culture to identify TCR: CD4+ memory T cells after in vitro sensitization with R248Q long peptide were co-cultured with R248Q long peptide and CD4+41BB+ T cells were sorted
[0671] Methods for identifying TCRs: single-cell RT-PCR
[0672] Abundance of TCR among all paired TCRs: 4.8% (observed 3 times in 63 pairs)
[0673] TCR orientation: α-β
[0674] Expression vector: SB transposon
[0675]
[0676] The statistical data of TCR 4213-PBL-TCR4a3 of patient 4213 are shown in Table 31 below.
[0677] Table 31
[0678] parameter # frequency Total hole 192 100% CDR3α 4 2.1% CDR3β 36 18.8% 4213-PBL-TCR4a3 pair 3 1.6% Total paired TCR 63 32.8%
[0679] The sequence of 4213-PBL-TCR4a4 isolated from patient 4213 is shown below. Starting from the amino terminus, the first underlined region is CDR1α (SEQ ID NO: 427), the second underlined region is CDR2α (SEQ ID NO: 428), the third underlined region is CDR3α (SEQ ID NO: 429), the fourth underlined region is CDR1β (SEQ ID NO: 430), the fifth underlined region is CDR2β (SEQ ID NO: 431), and the sixth underlined region is CDR3β (SEQ ID NO: 432). The bold region is the linker (SEQ ID NO: 26). Starting from the amino terminus, the first italicized region is the α chain constant region (SEQ ID NO: 23) and the second italicized region is the β chain constant region (SEQ ID NO: 25). The α chain variable region (SEQ ID NO: 433) includes a sequence starting from the amino terminus and ending just before the start of the α chain constant region. The beta chain variable region (SEQ ID NO: 434) comprises a sequence starting immediately after the linker and ending just before the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 435) comprises a sequence starting at the amino terminus and ending just before the start of the linker. The full-length beta chain (SEQ ID NO: 436) comprises a sequence starting immediately after the linker and ending at the carboxyl terminus.
[0680] Cancer reactive T cells were identified using the screening methods listed below. The method used to isolate TCRs is shown below.
[0681] TCR Name:4213-PBL-TCR4a4
[0682] Identification of P53 mutation: R248Q
[0683] Screening method: Universal screening for p53 "hotspot" mutations
[0684] Co-culture to identify TCR: CD4+ memory T cells after in vitro sensitization with R248Q long peptide were co-cultured with R248Q long peptide and CD4+41BB+ T cells were sorted
[0685] Methods for identifying TCRs: single-cell RT-PCR
[0686] Abundance of TCR among all paired TCRs: 3.2% (observed 2 times in 63 pairs)
[0687] TCR orientation: α-β
[0688] Expression vector: SB transposon
[0689]
[0690]
[0691] The statistical data of TCR 4213-PBL-TCR4a4 of patient 4213 are shown in Table 32 below.
[0692] Table 32
[0693] parameter # frequency Total hole 192 100% CDR3α 2 1.0% CDR3β 36 18.8% 4213-PBL-TCR4a3 pair 2 1.0% Total paired TCR 63 32.8%
[0694] Example 8
[0695] This example demonstrates the identification of anti-mutated p53 T cells in patient 4268 by co-culturing autologous APCs induced to express mutated p53 within autologous T cells ("universal screening for p53 hotspot mutations"). This example also demonstrates the isolation of five anti-mutated p53 TCRs from patient 4268.
[0696] For patient 4268 Figure 27-30 The experiments were performed as described.
[0697] TIL fragments from patient 4268 (F1-F24, n=24) were co-cultured with autologous APCs electroporated with TMG consisting of irrelevant, WT p53, or mutated p53 sequences. Co-culture was performed overnight at 37°C. IFN-γ secretion was evaluated using an ELISPOT assay. Results are shown in Fig. 27 middle.
[0698] TIL fragments from patient 4268 (F1-F24, n=24) were co-cultured with autologous APC pulsed with either peptide vehicle (DMSO) or purified (>95% by HPLC) 25-amino acid peptides consisting of WT p53-R248 sequence or mutated p53-R248Q sequence. Co-culture was performed overnight at 37°C. IFN-γ secretion was evaluated using an ELISPOT assay. Results are shown in Fig.28 middle.
[0699] TIL fragments from patient 4268 (F1-F24, n = 24) were co-cultured with autologous APC pulsed with a peptide vehicle (DMSO) or a purified (> 95%, by HPLC) 25-amino acid peptide consisting of a wt p53-R248 sequence or a mutated p53-R248Q sequence. Co-culture was performed overnight at 37°C. After gating for lymphocytes → live cells (PI negative) → CD3+ (T cells), the expression of 4-1BB was evaluated by flow cytometry. The results are shown in Fig.29 TIL fragments F18 and F19 are the source of TCRs after sorting CD4+41BB+ T cells.
[0700] TIL fragments from patient 4268 (F1-F24, n = 24) were co-cultured with autologous APC pulsed with a peptide vehicle (DMSO) or a purified (> 95%, by HPLC) 25-amino acid peptide consisting of a wt p53-R248 sequence or a mutated p53-R248Q sequence. Co-culture was performed overnight at 37°C. After gating for lymphocytes → live cells (PI negative) → CD3+ (T cells), the expression of 4-1BB was evaluated by flow cytometry. The results are shown in Fig.30 TIL fragments F7, F8 and F15 are the source of TCRs after sorting CD8+4-1BB+ T cells.
[0701] The sequence of 4268-TCR1 isolated from patient 4268 is shown below. Starting from the amino terminus, the first underlined region is CDR1α (SEQ ID NO: 137), the second underlined region is CDR2α (SEQ ID NO: 138), the third underlined region is CDR3α (SEQ ID NO: 139), the fourth underlined region is CDR1β (SEQ ID NO: 140), the fifth underlined region is CDR2β (SEQ ID NO: 141), and the sixth underlined region is CDR3β (SEQ ID NO: 142). The bold region is the linker (SEQ ID NO: 26). Starting from the amino terminus, the first italicized region is the α chain constant region (SEQ ID NO: 23) and the second italicized region is the β chain constant region (SEQ ID NO: 25). The α chain variable region (SEQ ID NO: 143) includes a sequence starting from the amino terminus and ending just before the start of the α chain constant region. The beta chain variable region (SEQ ID NO: 144) comprises a sequence that starts immediately after the linker and ends just before the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 145) comprises a sequence that starts at the amino terminus and ends just before the start of the linker. The full-length beta chain (SEQ ID NO: 146) comprises a sequence that starts immediately after the linker and ends at the carboxyl terminus.
[0702] Cancer reactive T cells were identified using the screening methods listed below. The method used to isolate TCRs is shown below.
[0703] TCR Name:4268-TCR1
[0704] Identification of P53 mutation: R248Q
[0705] Methods: Universal screening for p53 "hotspot" mutations
[0706] Co-culture to identify TCR: Co-culture 4268-F7 and 4268-F8 with p53-R248Q long peptide and sort CD8+41BB+ T cells
[0707] Methods for identifying TCRs: single-cell RT-PCR
[0708] Abundance of TCRs among all paired TCRs: 78.7% (observed 48 times in 61 pairs)
[0709] TCR orientation: α-β
[0710] Expression vector: SB transposon
[0711]
[0712] The statistical data of TCR 4268-TCR1 of patient 4268 are shown in Table 33 below.
[0713] Table 33
[0714]
[0715]
[0716] The sequence of 4268-TCR2 isolated from patient 4268 is shown below. Starting from the amino terminus, the first underlined region is CDR1α (SEQ ID NO: 147), the second underlined region is CDR2α (SEQ ID NO: 148), the third underlined region is CDR3α (SEQ ID NO: 149), the fourth underlined region is CDR1β (SEQ ID NO: 150), the fifth underlined region is CDR2β (SEQ ID NO: 151), and the sixth underlined region is CDR3β (SEQ ID NO: 152). The bold region is the linker (SEQ ID NO: 26). Starting from the amino terminus, the first italicized region is the α chain constant region (SEQ ID NO: 23) and the second italicized region is the β chain constant region (SEQ ID NO: 25). The α chain variable region (SEQ ID NO: 153) includes a sequence starting from the amino terminus and ending before the start of the α chain constant region. The beta chain variable region (SEQ ID NO: 154) comprises a sequence starting immediately after the linker and ending just before the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 155) comprises a sequence starting at the amino terminus and ending just before the start of the linker. The full-length beta chain (SEQ ID NO: 156) comprises a sequence starting immediately after the linker and ending at the carboxyl terminus.
[0717] Cancer reactive T cells were identified using the screening methods listed below. The method used to isolate TCRs is shown below.
[0718] TCR Name:4268-TCR2
[0719] Identification of P53 mutation: R248Q
[0720] Methods: Universal screening for p53 "hotspot" mutations
[0721] Co-culture to identify TCR: Co-culture 4268-F7 and 4268-F8 with p53-R248Q long peptide and sort CD8+41BB+ T cells
[0722] Methods for identifying TCRs: single-cell RT-PCR
[0723] Abundance of TCR among all paired TCRs: 6.6% (observed 4 times in 61 pairs)
[0724] TCR orientation: α-β
[0725] Expression vector: SB transposon
[0726]
[0727] The statistical data of TCR 4268-TCR2 of patient 4268 are shown in Table 34 below.
[0728] Table 34
[0729] parameter # frequency Total hole 96 100% CDR3α 6 6.3% CDR3β 4 4.2% 4268-TCR2 pair 4 4.2% Total paired TCR 61 63.5%
[0730] The sequence of 4268-TCR3 isolated from patient 4268 is shown below. Starting from the amino terminus, the first underlined region is CDR1α (SEQ ID NO: 157), the second underlined region is CDR2α (SEQ ID NO: 158), the third underlined region is CDR3α (SEQ ID NO: 159), the fourth underlined region is CDR1β (SEQ ID NO: 160), the fifth underlined region is CDR2β (SEQ ID NO: 161), and the sixth underlined region is CDR3β (SEQ ID NO: 162). The bold region is the linker (SEQ ID NO: 26). Starting from the amino terminus, the first italicized region is the α chain constant region (SEQ ID NO: 23) and the second italicized region is the β chain constant region (SEQ ID NO: 25). The α chain variable region (SEQ ID NO: 163) includes a sequence starting from the amino terminus and ending before the start of the α chain constant region. The beta chain variable region (SEQ ID NO: 164) comprises a sequence starting immediately after the linker and ending just before the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 165) comprises a sequence starting at the amino terminus and ending just before the start of the linker. The full-length beta chain (SEQ ID NO: 166) comprises a sequence starting immediately after the linker and ending at the carboxyl terminus.
[0731] Cancer reactive T cells were identified using the screening methods listed below. The method used to isolate TCRs is shown below.
[0732] TCR Name:4268-TCR3
[0733] Identification of P53 mutation: R248Q
[0734] Methods: Universal screening for p53 "hotspot" mutations
[0735] Co-culture to identify TCR: Co-culture 4268-F15 with p53-R248Q long peptide and sort CD8+41BB+ T cells
[0736] Methods for identifying TCRs: single-cell RT-PCR
[0737] Abundance of TCRs among all paired TCRs: 88.6% (observed 31 times in 35 pairs)
[0738] TCR orientation: α-β
[0739] Expression vector: SB transposon
[0740]
[0741] The statistical data of TCR 4268-TCR3 of patient 4268 are shown in Table 35 below.
[0742] Table 35
[0743] parameter # frequency Total hole 96 100% CDR3α 42 43.8% CDR3β 37 38.5% 4268-TCR3 pair 31 32.3% Total paired TCR 35 36.5%
[0744] The sequence of 4268-TCR4 isolated from patient 4268 is shown below. Starting from the amino terminus, the first underlined region is CDR1α (SEQ ID NO: 167), the second underlined region is CDR2α (SEQ ID NO: 168), the third underlined region is CDR3α (SEQ ID NO: 169), the fourth underlined region is CDR1β (SEQ ID NO: 170), the fifth underlined region is CDR2β (SEQ ID NO: 171), and the sixth underlined region is CDR3β (SEQ ID NO: 172). The bold region is the linker (SEQ ID NO: 26). Starting from the amino terminus, the first italicized region is the α chain constant region (SEQ ID NO: 23) and the second italicized region is the β chain constant region (SEQ ID NO: 25). The α chain variable region (SEQ ID NO: 173) includes a sequence starting from the amino terminus and ending just before the start of the α chain constant region. The beta chain variable region (SEQ ID NO: 174) comprises a sequence starting immediately after the linker and ending just before the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 175) comprises a sequence starting at the amino terminus and ending just before the start of the linker. The full-length beta chain (SEQ ID NO: 176) comprises a sequence starting immediately after the linker and ending at the carboxyl terminus.
[0745] Cancer reactive T cells were identified using the screening methods listed below. The method used to isolate TCRs is shown below.
[0746] TCR Name:4268-TCR4
[0747] Identification of P53 mutation: R248Q
[0748] Methods: Universal screening for p53 "hotspot" mutations
[0749] Co-culture to identify TCR: Co-culture 4268-F18 with p53-R248Q long peptide and sort CD4+41BB+ T cells
[0750] Methods for identifying TCRs: single-cell RT-PCR
[0751] Abundance of TCRs among all paired TCRs: 95.2% (observed 40 times in 42 pairs)
[0752] TCR orientation: α-β
[0753] Expression vector: SB transposon
[0754]
[0755] The statistical data of TCR 4268-TCR4 of patient 4268 are shown in Table 36 below.
[0756] Table 36
[0757] parameter # frequency Total hole 96 100% CDR3α 43 44.8% CDR3β 53 55.2% 4268-TCR4 pair 40 41.7% Total paired TCR 42 43.8%
[0758] The sequence of 4268-TCR5 isolated from patient 4268 is shown below. Starting from the amino terminus, the first underlined region is CDR1α (SEQ ID NO: 177), the second underlined region is CDR2α (SEQ ID NO: 178), the third underlined region is CDR3α (SEQ ID NO: 179), the fourth underlined region is CDR1β (SEQ ID NO: 180), the fifth underlined region is CDR2β (SEQ ID NO: 181), and the sixth underlined region is CDR3β (SEQ ID NO: 182). The bold region is the linker (SEQ ID NO: 26). Starting from the amino terminus, the first italicized region is the α chain constant region (SEQ ID NO: 23) and the second italicized region is the β chain constant region (SEQ ID NO: 25). The α chain variable region (SEQ ID NO: 183) includes a sequence starting from the amino terminus and ending before the start of the α chain constant region. The beta chain variable region (SEQ ID NO: 184) comprises a sequence starting immediately after the linker and ending just before the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 185) comprises a sequence starting at the amino terminus and ending just before the start of the linker. The full-length beta chain (SEQ ID NO: 186) comprises a sequence starting immediately after the linker and ending at the carboxyl terminus.
[0759] Cancer reactive T cells were identified using the screening methods listed below. The method used to isolate TCRs is shown below.
[0760] TCR Name:4268-TCR5
[0761] Identification of P53 mutation: R248Q
[0762] Methods: Universal screening for p53 "hotspot" mutations
[0763] Co-culture to identify TCR: Co-culture 4268-F19 with p53-mut-TMG and sort CD4+41BB+T cells
[0764] Methods for identifying TCRs: single-cell RT-PCR
[0765] Abundance of TCR among all paired TCRs: 11.8% (observed 2 times in 17 pairs)
[0766] TCR orientation: α-β
[0767] Expression vector: SB transposon
[0768]
[0769]
[0770] The statistical data of TCR 4268-TCR5 of patient 4268 are shown in Table 37 below.
[0771] Table 37
[0772] parameter # frequency Total hole 96 100% CDR3α 2 2.1% CDR3β 87 90.6% 4268-TCR5 pair 2 2.1% Total paired TCR 17 17.7%
[0773] Example 9
[0774] This example demonstrates the identification of anti-mutated p53 T cells in patient 4266 by co-culturing autologous APCs induced to express mutated p53 within autologous T cells ("universal screening for p53 hotspot mutations"). This example also demonstrates the isolation of four anti-mutated p53 TCRs from patient 4266.
[0775] like Figure 31-34 Experiments were performed as described for patient 4266.
[0776] TIL fragments from patient 4266 (F1-F24, n=24) were co-cultured with autologous APCs electroporated with TMG consisting of irrelevant, WT p53, or mutated p53 sequences. Co-culture was performed overnight at 37°C. IFN-γ secretion was evaluated using an ELISPOT assay. Results are shown in Fig.31 After setting gates for lymphocytes → live cells (PI negative) → CD3+ (T cells), the expression of 4-1BB was evaluated by flow cytometry. The results are shown in Fig.32 middle.
[0777] TIL fragments from patient 4266 (F1-F24, n=24) were co-cultured with autologous APC pulsed with either peptide vehicle (DMSO) or purified (>95% by HPLC) 25-amino acid peptides consisting of WT p53-R248 sequence or mutated p53-R248W sequence. Co-culture was performed overnight at 37°C. IFN-γ secretion was evaluated using ELISPOT assay. Results are shown in Fig.33 After setting gates for lymphocytes → live cells (PI negative) → CD3+ (T cells), the expression of 4-1BB was evaluated by flow cytometry. The results are shown in Fig.34 middle.
[0778] Cos7 cells (2.5 x 10 per well) 4) were plated on wells of a flat-bottom 96-well plate. The next day, the cells were co-transfected with individual HLA alleles from patient 4266. The following day, the cells were pulsed with no peptide, DMSO, wild-type p53-R248 peptide SSCMGGMNRR (SEQ ID NO: 590), or mutated p53-R248W peptide SSCMGGMNWR (SEQ ID NO: 591) at 1 μg / mL for 2 hours at 37°C. TIL cultures (10 5 ) were added to the wells and co-cultured overnight at 37°C. After setting gates for lymphocytes → live cells (PI negative) → CD3+ (T cells) → CD4-CD8+, the expression of 4-1BB was evaluated by flow cytometry. The results are shown in Fig.53 middle.
[0779] T cells expressing mimics (no TCR), 4266-TCR1, 4266-TCR2, 4266-TCR3 or 4266-TCR4 with assumed specificity for p53-R248W identified from 4266-TIL were co-cultured with autologous APC pulsed with a peptide vehicle (DMSO) or a purified (>95%, by HPLC) 25 amino acid peptide consisting of the WT p53-R248 sequence or the mutated p53-R248W sequence. Separate culture medium and PMA and ionomycin were negative and positive controls, respectively. Co-culture was performed at 37°C overnight. After setting gates for lymphocytes → live cells (PI negative) → CD3+ (T cells) → CD4-CD8+, the expression of 4-1BB was evaluated by flow cytometry. The results are shown in Fig.54 middle.
[0780] The tumor cell (TC) line was established from xenograft tumor fragments resected from patient 4266 and then serially passaged through immunocompromised mice (TC#4266). TC#4266 was incubated with T cells (10 5) were co-cultured overnight at 37°C. TC#4266 cells were not incubated with anything, or TC#4266 cells were incubated with W6 / 32 pan-HLA class I specific blocking antibody, IVA12 pan-HLA class II specific blocking antibody or mutated p53-R248W peptide SSCMGGMNWR (SEQ ID NO: 591) at 37°C for 2 hours. The antibody was stored in the co-culture at a final concentration of 5μg / mL. The peptide was incubated at 1μg / mL, and the excess peptide was washed after incubation. The culture medium alone (without TC) and PMA and ionomycin were negative and positive controls, respectively. After setting the gate for lymphocytes → live cells (PI negative) → CD3+ (T cells) → CD4-CD8+, the expression of 4-1BB was evaluated by flow cytometry. The results are shown in Fig.55 middle.
[0781] The sequence of 4266-TCR1 isolated from patient 4266 is shown below. Starting from the amino terminus, the first underlined region is CDR1α (SEQ ID NO: 97), the second underlined region is CDR2α (SEQ ID NO: 98), the third underlined region is CDR3α (SEQ ID NO: 99), the fourth underlined region is CDR1β (SEQ ID NO: 100), the fifth underlined region is CDR2β (SEQ ID NO: 101), and the sixth underlined region is CDR3β (SEQ ID NO: 102). The bold region is the linker (SEQ ID NO: 26). Starting from the amino terminus, the first italicized region is the α chain constant region (SEQ ID NO: 23) and the second italicized region is the β chain constant region (SEQ ID NO: 25). The α chain variable region (SEQ ID NO: 103) includes a sequence starting from the amino terminus and ending before the start of the α chain constant region. The beta chain variable region (SEQ ID NO: 104) comprises a sequence starting immediately after the linker and ending just before the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 105) comprises a sequence starting at the amino terminus and ending just before the start of the linker. The full-length beta chain (SEQ ID NO: 106) comprises a sequence starting immediately after the linker and ending at the carboxyl terminus.
[0782] Cancer reactive T cells were identified using the screening methods listed below. The method used to isolate TCRs is shown below.
[0783] TCR Name:4266-TCR1
[0784] Identification of P53 mutation: R248W
[0785] Screening method: Universal screening for p53 "hotspot" mutations
[0786] Co-culture to identify TCRs: Co-culture 4266-F1, 4266-F3, 4266-F5, and 4266-F6 with p53mutTMG or R248W long peptide (the same TCR was tested in both co-cultures), and sort CD8+41BB+ T cells
[0787] Methods for identifying TCRs: single-cell RT-PCR
[0788] Abundance of TCR among all paired TCRs: 17.0% (observed 9 times in 53 pairs)
[0789] TCR orientation: α-β
[0790] Expression vector: SB transposon
[0791]
[0792]
[0793] The statistical data of TCR 4266-TCR1 of patient 4266 are shown in Table 38 below.
[0794] Table 38
[0795] parameter # frequency Total hole 96 100% CDR3α 9 9.4% CDR3β 10 10.4% 4266-TCR1 pair 9 9.4% Total paired TCR 53 55.2%
[0796] The sequence of 4266-TCR2 isolated from patient 4266 is shown below. Starting from the amino terminus, the first underlined region is CDR1α (SEQ ID NO: 107), the second underlined region is CDR2α (SEQ ID NO: 108), the third underlined region is CDR3α (SEQ ID NO: 109), the fourth underlined region is CDR1β (SEQ ID NO: 110), the fifth underlined region is CDR2β (SEQ ID NO: 111), and the sixth underlined region is CDR3β (SEQ ID NO: 112). The bold region is the linker (SEQ ID NO: 26). Starting from the amino terminus, the first italicized region is the α chain constant region (SEQ ID NO: 23) and the second italicized region is the β chain constant region (SEQ ID NO: 25). The α chain variable region (SEQ ID NO: 113) includes a sequence starting from the amino terminus and ending before the start of the α chain constant region. The beta chain variable region (SEQ ID NO: 114) comprises a sequence starting immediately after the linker and ending just before the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 115) comprises a sequence starting at the amino terminus and ending just before the start of the linker. The full-length beta chain (SEQ ID NO: 116) comprises a sequence starting immediately after the linker and ending at the carboxyl terminus.
[0797] Cancer reactive T cells were identified using the screening methods listed below. The method used to isolate TCRs is shown below.
[0798] TCR Name:4266-TCR2
[0799] Identification of P53 mutation: R248W
[0800] Screening method: Universal screening for p53 "hotspot" mutations
[0801] Co-culture to identify TCRs: Co-culture 4266-F1, 4266-F3, 4266-F5, and 4266-F6 with p53mutTMG or R248W long peptide (the same TCR was tested in both co-cultures), and sort CD8+41BB+ T cells
[0802] Methods for identifying TCRs: single-cell RT-PCR
[0803] Abundance of TCR among all paired TCRs: 24.5% (observed 13 times in 53 pairs)
[0804] TCR orientation: α-β
[0805] Expression vector: SB transposon
[0806]
[0807] The statistical data of TCR 4266-TCR2 of patient 4266 are shown in Table 39 below.
[0808] Table 39
[0809] parameter # frequency Total hole 96 100% CDR3α 21 21.9% CDR3β 18 18.8% 4266-TCR2 pair 13 13.5% Total paired TCR 53 55.2%
[0810] The sequence of 4266-TCR3 isolated from patient 4266 is shown below. Starting from the amino terminus, the first underlined region is CDR1α (SEQ ID NO: 117), the second underlined region is CDR2α (SEQ ID NO: 118), the third underlined region is CDR3α (SEQ ID NO: 119), the fourth underlined region is CDR1β (SEQ ID NO: 120), the fifth underlined region is CDR2β (SEQ ID NO: 121), and the sixth underlined region is CDR3β (SEQ ID NO: 122). The bold region is the linker (SEQ ID NO: 26). Starting from the amino terminus, the first italicized region is the α chain constant region (SEQ ID NO: 23) and the second italicized region is the β chain constant region (SEQ ID NO: 25). The α chain variable region (SEQ ID NO: 123) includes a sequence starting from the amino terminus and ending before the start of the α chain constant region. The beta chain variable region (SEQ ID NO: 124) comprises a sequence starting immediately after the linker and ending just before the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 125) comprises a sequence starting at the amino terminus and ending just before the start of the linker. The full-length beta chain (SEQ ID NO: 126) comprises a sequence starting immediately after the linker and ending at the carboxyl terminus.
[0811] Cancer reactive T cells were identified using the screening methods listed below. The method used to isolate TCRs is shown below.
[0812] TCR Name:4266-TCR3
[0813] Identification of P53 mutation: R248W
[0814] Screening method: Universal screening for p53 "hotspot" mutations
[0815] Co-culture to identify TCRs: Co-culture 4266-F1, 4266-F3, 4266-F5, and 4266-F6 with p53mutTMG or R248W long peptide (the same TCR was tested in both co-cultures), and sort CD8+41BB+ T cells
[0816] Methods for identifying TCRs: single-cell RT-PCR
[0817] Abundance of TCR among all paired TCRs: 34.0% (observed 18 times in 53 pairs)
[0818] TCR orientation: α-β
[0819] Expression vector: SB transposon
[0820]
[0821] The statistical data of TCR 4266-TCR3 of patient 4266 are shown in Table 40 below.
[0822] Table 40
[0823] parameter # frequency Total hole 96 100% CDR3α 19 19.8% CDR3β 26 27.1 4266-TCR3 pairs 18 18.8% Total paired TCR 53 55.2%
[0824] The sequence of 4266-TCR4 isolated from patient 4266 is shown below. Starting from the amino terminus, the first underlined region is CDR1α (SEQ ID NO: 127), the second underlined region is CDR2α (SEQ ID NO: 128), the third underlined region is CDR3α (SEQ ID NO: 129), the fourth underlined region is CDR1β (SEQ ID NO: 130), the fifth underlined region is CDR2β (SEQ ID NO: 131), and the sixth underlined region is CDR3β (SEQ ID NO: 132). The bold region is the linker (SEQ ID NO: 26). Starting from the amino terminus, the first italicized region is the α chain constant region (SEQ ID NO: 23) and the second italicized region is the β chain constant region (SEQ ID NO: 25). The α chain variable region (SEQ ID NO: 133) includes a sequence starting from the amino terminus and ending just before the start of the α chain constant region. The beta chain variable region (SEQ ID NO: 134) comprises a sequence starting immediately after the linker and ending just before the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 135) comprises a sequence starting at the amino terminus and ending just before the start of the linker. The full-length beta chain (SEQ ID NO: 136) comprises a sequence starting immediately after the linker and ending at the carboxyl terminus.
[0825] Cancer reactive T cells were identified using the screening methods listed below. The method used to isolate TCRs is shown below.
[0826] TCR Name:4266-TCR4
[0827] Identification of P53 mutation: R248W
[0828] Screening method: Universal screening for p53 "hotspot" mutations
[0829] Co-culture to identify TCRs: Co-culture 4266-F1, 4266-F3, 4266-F5, and 4266-F6 with p53mutTMG or R248W long peptide (the same TCR was tested in both co-cultures), and sort CD8+41BB+ T cells
[0830] Methods for identifying TCRs: single-cell RT-PCR
[0831] Abundance of TCR among all paired TCRs: 9.4% (observed 5 times in 53 pairs)
[0832] TCR orientation: α-β
[0833] Expression vector: SB transposon
[0834]
[0835]
[0836] The statistical data of TCR 4266-TCR4 of patient 4266 are shown in Table 41 below.
[0837] Table 41
[0838] parameter # frequency Total hole 96 100% CDR3α 5 5.2% CDR3β 13 13.5 4266-TCR3 pairs 5 5.2% Total paired TCR 53 55.2%
[0839] Example 10
[0840] This example demonstrates an overview of T cell responses to p53 "hotspot" mutations.
[0841] Table 42 provides an overview of T cell responses to p53 "hotspot" mutations. Table 42, Nos. 1-15, is a retrospective study. Table 42, Nos. 16-33, is a prospective study.
[0842] Table 42
[0843]
[0844]
[0845] n / a = not applicable; N = negative; Y = confirmed reactive; TBS = to be screened.
[0846] Embodiment 11
[0847] This example demonstrates treatment of patients with p53 mutation-reactive TILs.
[0848] Table 43 provides an overview of patients treated with p53 mutation-reactive TILs.
[0849] Table 43
[0850]
[0851] NT = not treated; TBS = to be screened; NR = no response; PR = partial response; **patients have not been treated yet.
[0852] Example 12
[0853] This example demonstrates the isolation and specific reactivity of the TCR from patient 4141.
[0854] Autologous APCs were transfected with TMG encoding an unrelated mutation, a WT p53 sequence, or a mutated p53 sequence containing R175H. Culture medium alone and PMA and ionomycin were used as negative and positive controls, respectively. The next day, TILs (fragment culture 12) from patient 4141 were co-cultured with TMG-transfected APCs at 37°C overnight. IFN-γ secretion was evaluated by ELISPOT. After gating for lymphocytes → live cells (PI negative) → CD3+ (T cells) → CD4-CD8+, the expression of 4-1BB was evaluated by flow cytometry. The results are shown in Fig.38 middle.
[0855] Cos7 cells (2.5 x 10 per well) 4 The next day, cells were co-transfected with individual HLA alleles from patient 4141 and either WT TP53TMG or mutated TP53TMG containing the p53-R175H sequence. The next day, TILs from patient 4141 specific for p53-R175H (fragment culture 12) were co-cultured with transfected Cos7 cells and incubated overnight at 37°C. IFN-γ secretion was evaluated by ELISPOT. The results are shown in Fig.39 middle.
[0856] T cells expressing mock (no TCR) or 4141-TCR1a2 were co-cultured with T2 tumor cells (expressing HLA-A*02:01). T2 cells were pulsed with peptide vehicle (DMSO) or purified (>95% by HPLC) peptides consisting of WT p53-R175 peptide HMTEVVRRC (SEQ ID NO:532) or mutated p53-R175H peptide HMTEVVRHC (SEQ ID NO:530) at 37°C. Culture medium alone and PMA and ionomycin were negative and positive controls, respectively. Co-culture was performed overnight at 37°C. IFN-γ secretion was evaluated by ELISA. The results are shown in Fig.40 middle.
[0857] T cells expressing 4141-TCR1a2 were co-cultured overnight at 37°C with Saos2 cells (p53-NULL and HLA-A*02:01+) that were either untreated or made to overexpress the full-length p53-R175H protein. Inhibitors of secretion (monensin and brefeldin A) were added to the co-cultures to capture cytokines within the T cells. After 6 hours of co-culture, the cells were fixed and permeabilized and then stained for IL-2, CD107a, IFN-γ, and tumor necrosis factor-α (TNFα). Flow cytometry was used to analyze the co-cultures based on lymphocyte gating. The results are shown in Fig.41 middle.
[0858] The sequence of TCR 4141-TCR1a2 isolated from patient 4141 is shown below. Starting from the amino terminus, the first underlined region is CDR1α (SEQ ID NO: 467), the second underlined region is CDR2α (SEQ ID NO: 468), the third underlined region is CDR3α (SEQ ID NO: 469), the fourth underlined region is CDR1β (SEQ ID NO: 470), the fifth underlined region is CDR2β (SEQ ID NO: 471), and the sixth underlined region is CDR3β (SEQ ID NO: 472). The bold region is the linker (SEQ ID NO: 26). Starting from the amino terminus, the first italic region is the α chain constant region (SEQ ID NO: 23) and the second italic region is the β chain constant region (SEQ ID NO: 25). The α chain variable region (SEQ ID NO: 473) includes a sequence starting from the amino terminus and ending just before the start of the α chain constant region. The beta chain variable region (SEQ ID NO: 474) comprises a sequence starting immediately after the linker and ending just before the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 475) comprises a sequence starting at the amino terminus and ending just before the start of the linker. The full-length beta chain (SEQ ID NO: 476) comprises a sequence starting immediately after the linker and ending at the carboxyl terminus.
[0859] Cancer reactive T cells were identified as follows. TCRs were isolated as follows.
[0860] TCR Name:4141-TCR1a2
[0861] Identification of P53 mutation: R175H
[0862] Screening method: Universal screening for p53 "hotspot" mutations
[0863] Co-culture to identify TCR: co-culture 4141 infusion bag TIL with p53mutTMG, and sort CD8+41BB+ T cells
[0864] Methods for identifying TCRs: Single-cell RT-PCR followed by TA TOPO cloning kit (Thermo Fisher Scientific, Waltham, MA) for α chain
[0865] TCR orientation: α-β
[0866] Expression vector: SB transposon
[0867]
[0868] The statistical data of 4141-TCR1a2 from patient 4141 are shown in Table 44 below.
[0869] Table 44
[0870] parameter # frequency Total hole 96 100% CDR3α Unknown (TATOPO clone) not applicable CDR3β 58 60.4%
[0871] Example 13
[0872] This example demonstrates the isolation and specific reactivity of the TCR isolated from patient 4259.
[0873] TIL fragment cultures from patient 4259 (no. 6) were co-cultured with autologous APCs, which were 1) electroporated with TMG consisting of irrelevant, WT p53 or mutated p53 sequences or 2) pulsed with a peptide vehicle (DMSO) or a purified (>95%, by HPLC) 25 amino acid peptide consisting of WT p53-Y220 sequence or mutated p53-Y220 sequence. Co-culture was performed overnight at 37°C. After gating on lymphocytes → live cells (PI negative) → CD3+ (T cells), the expression of 4-1BB was evaluated by flow cytometry. The results are shown in Fig.42 middle.
[0874] Autologous APCs were pulsed with decreasing concentrations of a 25-amino acid peptide (corresponding to WT p53-Y220 or mutated p53-Y220C sequence) at 37°C for 2 hours. TIL fragment cultures from patient 4259 (no. 6) were co-cultured with peptide-pulsed APCs. The expression of 4-1BB was determined by flow cytometry after gating on lymphocytes → live cells (PI negative) → CD3+ (T cells). The results are shown in Fig.43 middle.
[0875] Autologous antigen presenting cells were pulsed with DMSO, WT p53-Y220 peptide RNTFRHSVVVPYE (SEQ ID NO: 533) or mutated p53-Y220C peptide RNTFRHSVVVPCE (SEQ ID NO: 534) at 37°C for 2 hours. Excess peptide was washed away. TILs specific for p53-Y220C from patient 4259 were co-cultured with peptide-pulsed APCs at 37°C overnight. After setting gates for lymphocytes → live cells (PI negative) → CD3+ (T cells), the expression of 4-1BB was evaluated by flow cytometry. The results are shown in Fig.44 middle.
[0876] Cos7 cells (2.5 x 10 per well) 4 ) were plated on the wells of a flat-bottom 96-well plate. The following day, the cells were co-transfected with individual HLA alleles from patient 4259. The following day, DMSO or p53-Y220C peptide RNTFRHSVVVPCE (SEQ ID NO: 534) was pulsed on the transfected Cos7 cells for 2 hours. Excess peptide was washed away. TIL fragment culture no. 6 (10 5 The co-culture was incubated at 37°C overnight. After setting gates for lymphocytes → live → CD3+ (T cells) → CD8-CD4+, the expression of 4-1BB was determined by flow cytometry. The results are shown in Fig.45 middle.
[0877] The autologous APCs of patient 4259 were pulsed with a peptide corresponding to 25-amino acids of WT p53-Y220 or mutated p53-Y220C sequence at 37 ° C for 2 hours. Excess peptide was washed away. T cells expressing 4259-F6-TCR were co-cultured with peptide-pulsed APCs at 37 ° C overnight. After setting gates for lymphocytes → live cells (PI negative) → CD3+ (T cells), the expression of 4-1BB was evaluated by flow cytometry. The imported TCR was measured by mouse TCRβ (mTCR). The results are shown in Table 45.
[0878] Table 45
[0879] WTp53-Y220 Mutp53-Y220C 4-1BB+ / mTCR+ 0.27 5.22 4-1BB- / mTCR- 68.5 73.7 4-1BB+ / mTCR- 0.18 1.59 4-1BB- / mTCR+ 31.0 19.5
[0880] The tumor cell (TC) line was established from xenograft tumor fragments resected from patient 4259 and then serially passaged through immunocompromised mice (TC#4259). TC#4259 was incubated with T cells (10 5) were co-cultured overnight at 37°C. TC#4259 cells alone or TC#4259 cells were incubated with W6 / 32 pan-HLA class I specific blocking antibody, IVA12 pan-HLA class II specific blocking antibody or mutated p53-Y220C peptide RNTFRHSVVVPCE (SEQ ID NO: 534) at 37°C for 2 hours. The antibody was stored in the co-culture at a final concentration of 5 μg / mL. The peptide was incubated at 10 μg / mL, and the excess peptide was washed after incubation. The culture medium alone (without TC) and PMA and ionomycin were negative and positive controls, respectively. After setting the gate for lymphocytes → live cells (PI negative) → CD3+ (T cells), the expression of 4-1BB was evaluated by flow cytometry. The results are shown in Fig.46 middle.
[0881] The sequence of TCR 4259-F6-TCR isolated from patient 4259 is shown below. Starting from the amino terminus, the first underlined region is CDR1α (SEQ ID NO: 477), the second underlined region is CDR2α (SEQ ID NO: 478), the third underlined region is CDR3α (SEQ ID NO: 479), the fourth underlined region is CDR1β (SEQ ID NO: 480), the fifth underlined region is CDR2β (SEQ ID NO: 481), and the sixth underlined region is CDR3β (SEQ ID NO: 482). The bold region is the linker (SEQ ID NO: 26). Starting from the amino terminus, the first italic region is the α chain constant region (SEQ ID NO: 23) and the second italic region is the β chain constant region (SEQ ID NO: 25). The α chain variable region (SEQ ID NO: 483) includes a sequence starting from the amino terminus and ending just before the start of the α chain constant region. The beta chain variable region (SEQ ID NO: 484) includes a sequence starting immediately after the linker and ending just before the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 485) includes a sequence starting from the amino terminus and ending just before the start of the linker. The full-length beta chain (SEQ ID NO: 486) includes a sequence starting immediately after the linker and ending at the carboxyl terminus.
[0882] Cancer reactive T cells were identified as follows. TCRs were isolated as follows.
[0883] TCR Name:4259-F6-TCR
[0884] Identification of P53 mutation: Y220C
[0885] Screening method: Universal screening for p53 "hotspot" mutations
[0886] Co-culture to identify TCR: co-culture 4259-F6 with p53-Y220C peptide and sorting CD4+41BB+ T cells
[0887] Methods for identifying TCRs: single-cell RT-PCR
[0888] Abundance of TCRs among all paired TCRs: 81.1% (observed 36 times in 44 pairs)
[0889] TCR orientation: α-β
[0890] Expression vector: SB transposon
[0891]
[0892]
[0893] The statistical data of 4259-F6-TCR from patient 4259 are shown in Table 46 below.
[0894] Table 46
[0895] parameter # frequency Total hole 96 100% CDR3α 41 42.7% CDR3β 47 49.0% 4259-F6-TCR Pair 36 37.5% Total paired TCR 44 45.8%
[0896] Embodiment 14
[0897] This example demonstrates the isolation and specific reactivity of the TCR from patient 4285.
[0898] TIL fragments from patient 4285 (F1-F22 and F24, n=23) were co-cultured with autologous APCs electroporated with TMG consisting of irrelevant, WT p53 or mutated p53 sequences. Co-culture was performed overnight at 37°C. IFN-γ secretion was evaluated using an ELISPOT assay. Results are shown in Fig.47 After setting gates for lymphocytes → live cells (PI negative) → CD3+ (T cells), the expression of 4-1BB was evaluated by flow cytometry. The results are shown in Fig.49 middle.
[0899] TIL fragments from patient 4285 (F1-F22 and F24, n=23) were co-cultured with autologous APCs pulsed with either peptide vehicle (DMSO) or purified (>95% by HPLC) 25 amino acid peptides consisting of the WT p53-R175 sequence or the mutated p53-R175H sequence. Co-culture was performed overnight at 37°C. IFN-γ secretion was evaluated using an ELISPOT assay. Results are shown in Fig.48 After setting gates for lymphocytes → live cells (PI negative) → CD3+ (T cells), the expression of 4-1BB was evaluated by flow cytometry. The results are shown in Fig.50 Middle. TIL fragment F6 is the source of 4285-TCR1 after sorting CD4+41BB+ T cells.
[0900] Autologous APCs were pulsed with a 15 amino acid peptide overlapping 14 amino acids from the p53-R175H sequence (amino acid substitutions underlined in Table 45). TILs from patient 4285 (fragment cultures 10, 6, and 9) specific for p53-R175H were co-cultured with peptide-pulsed APCs overnight at 37°C. DMSO was the peptide vehicle. IFN-γ secretion was evaluated using an ELISPOT assay. The results are shown in Table 47.
[0901] Table 47
[0902]
[0903] Cos7 cells (2.5 x 10 per well) 4 ) were spread on the wells of a flat-bottom 96-well plate. The next day, the cells were co-transfected with individual HLA alleles from patient 4285. The next day, the cells were pulsed with DMSO or the mutated p53-R175H peptide YKQSQHMTEVVRHCPHHERCSDSDG (SEQ ID NO: 2) at 10 μg / mL for 2 hours at 37 ° C. Selected TIL fragment cultures (4285-F6, 4285-F9 and 4285-F10) specific for p53-R175H from patient 4285 were co-cultured with transfected Cos7 cells at 37 ° C overnight. After setting the gate for lymphocytes → live → CD3+ (T cells) → CD8-CD4+, the expression of 4-1BB was determined by flow cytometry. The results are shown in Fig.51 middle.
[0904] Autologous APCs were pulsed with decreasing concentrations of 25- or 15-amino acid peptides corresponding to WT or mutant p53-R175H sequences at 37°C for 2 hours. 4285-TCR1 transposed T cells from patient 4285 were co-cultured with peptide-pulsed APCs at 37°C overnight. Expression of 4-1BB was determined by flow cytometry after gating for lymphocytes → live → CD3+ (T cells) → CD8-CD4+. Results are shown in Fig.52 middle.
[0905] The sequence of 4285-TCR1 isolated from patient 4285 is shown below. Starting from the amino terminus, the first underlined region is CDR1α (SEQ ID NO: 487), the second underlined region is CDR2α (SEQ ID NO: 488), the third underlined region is CDR3α (SEQ ID NO: 489), the fourth underlined region is CDR1β (SEQ ID NO: 490), the fifth underlined region is CDR2β (SEQ ID NO: 491), and the sixth underlined region is CDR3β (SEQ ID NO: 492). The bold region is the linker (SEQ ID NO: 26). Starting from the amino terminus, the first italicized region is the α chain constant region (SEQ ID NO: 23) and the second italicized region is the β chain constant region (SEQ ID NO: 25). The α chain variable region (SEQ ID NO: 493) includes a sequence starting from the amino terminus and ending just before the start of the α chain constant region. The beta chain variable region (SEQ ID NO: 494) comprises a sequence starting immediately after the linker and ending just before the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 495) comprises a sequence starting at the amino terminus and ending just before the start of the linker. The full-length beta chain (SEQ ID NO: 496) comprises a sequence starting immediately after the linker and ending at the carboxyl terminus.
[0906] Cancer-reactive T cells were identified as described below. TCRs were isolated as described below.
[0907] TCR Name:4285-TCR1
[0908] Identification of P53 mutation: R175H
[0909] Screening method: Universal screening for p53 "hotspot" mutations
[0910] Co-culture to identify TCR: co-culture 4285-F6 with p53-R175H peptide and sorting CD4+41BB+ T cells
[0911] Methods for identifying TCRs: single-cell RT-PCR
[0912] Abundance of TCRs among all paired TCRs: 81.8% (observed 36 times in 44 pairs)
[0913] TCR orientation: α-β
[0914] Expression vector: SB transposon
[0915]
[0916] The statistical data of 4285-TCR1 of patient 4285 are shown in Table 48 below.
[0917] Table 48
[0918] parameter # frequency Total hole 96 100% CDR3α 37 39.8% CDR3β 39 40.6% 4285-TCR1 pair 36 37.5% Total paired TCR 44 45.8%
[0919] Embodiment 15
[0920] This example demonstrates the specific reactivity of three anti-mutant p53 TCRs from patient 4196 from Example 2.
[0921] The expression of HLA-A*0201 and p53 R 175H in different target cell lines is shown in Table 49.
[0922] Table 49
[0923]
[0924] The target cells in Table 49 were co-cultured with cells transduced with one of the TCRs in Example 2. Mock transduced cells (no TCR) were used as control effector cells. IFN-γ secretion (pg / mL) (Table 50) and 4-1BB expression (% 4-1BB (mTCRβ+)) (Table 51) were measured.
[0925] Table 50
[0926]
[0927]
[0928] Table 51
[0929]
[0930] Example 16
[0931] This example demonstrates the overview of the reactivity of the TCRs of Examples 1-15.
[0932] The TCRs of Table 52 were isolated, expressed in T cells and tested against relevant antigens. The results are summarized in Table 52.
[0933] Table 52
[0934]
[0935]
[0936] All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein.
[0937] In the context of describing the present invention (especially in the context of the appended claims), the use of the terms "one" and "a kind of" and "the" and "at least one" and similar references should be interpreted as covering both the singular and the plural, unless otherwise specified herein or clearly contradicted by the context. The use of the term "at least one" followed by a list of one or more items (e.g., "at least one of A and B") should be understood to mean any combination of one or more of the listed items (A or B) or the listed items (A and B), unless otherwise specified herein or clearly contradicted by the context. Unless otherwise specified, the terms "comprising", "having", "including" and "containing" should be interpreted as open terms (i.e., meaning "including but not limited to"). Unless otherwise specified herein, the description of the numerical range herein is intended only to be used as a shorthand method for referring to each individual value falling within the range, respectively, and each individual value is incorporated into the specification as if it were individually narrated herein. Unless otherwise specified herein or clearly contradicted by the context, all methods described herein can be performed in any suitable order. Unless otherwise claimed, the use of any and all examples or exemplary language (e.g., "such as") provided herein is intended only to better illustrate the present invention and is not intended to limit the scope of the present invention. No language in the specification should be construed as indicating that any unclaimed element is essential to the implementation of the present invention.
[0938] Preferred embodiments of the present invention are described herein, including the best mode known to the inventor for implementing the present invention. After reading the foregoing description, variations of those preferred embodiments will become apparent to those of ordinary skill in the art. The inventor expects that such variations will be appropriately adopted by a skilled person, and the inventor intends to practice the present invention in a manner different from that specifically described herein. Therefore, the present invention includes all modifications and equivalents of the subject matter recorded in the appended claims as allowed by applicable law. In addition, unless otherwise noted herein or otherwise clearly contradictory to the context, the present invention encompasses any combination of the above-mentioned elements in all possible variations thereof.
Claims
1. An isolated or purified T cell receptor (TCR) having antigenic specificity for mutant human p53.
2. The TCR of claim 1, wherein the TCR has antigenic specificity for human p53 having a mutation at position 175, 245, 220 or 248 of SEQ ID NO:
1.
3. The TCR of claim 1, wherein the TCR is antigenically specific for human p53 having one of the following human p53 mutations: R175H, G245S, Y220C, R248Q or R248W.
4. The TCR of any one of claims 1-3, wherein the TCR comprises the following amino acid sequence: (1) all SEQ ID NOs: 27-32; (2) all SEQ ID NOs: 37-42; (3) all SEQ ID NOs: 47-52; (4) all SEQ ID NOs: 57-62; (5) all SEQ ID NOs: 67-72; (6) all SEQ ID NOs: 77-82; (7) all SEQ ID NOs: 97-102; (8) all SEQ ID NOs: 107-112; (9) all SEQ ID NOs: 117-122; (10) all SEQ ID NOs: 127-132; (11) all SEQ ID NOs: 137-142; (12) all SEQ ID NOs: 147-152; (13) all SEQ ID NOs: 157-162; (14) all SEQ ID NOs: 167-172; (15) all SEQ ID NOs: 177-182; (16) all SEQ ID NOs: 187-192; (17) all SEQ ID NOs: 197-202; (18) all SEQ ID NOs: 207-212; (19) all SEQ ID NOs: 217-222; (20) all SEQ ID NOs: 227-232; (21) all SEQ ID NOs: 237-242; (22) all SEQ ID NOs: 247-252; (23) all SEQ ID NOs: 257-262; (24) all SEQ ID NOs: 267-272; (25) all SEQ ID NOs: 277-282; (26) all SEQ ID NOs: 287-292; (27) all SEQ ID NOs: 297-302; (28) all SEQ ID NOs: 307-312; (29) all SEQ ID NOs: 317-322; (30) all SEQ ID NOs: 327-332; (31) all SEQ ID NOs: 337-342; (32) all SEQ ID NOs: 347-352; (33) all SEQ ID NOs: 357-362; (34) all SEQ ID NOs: 367-372; (35) all SEQ ID NOs: 377-382; (36) all SEQ ID NOs: 387-392; (37) all SEQ ID NOs: 397-402; (38) all SEQ ID NOs: 407-412; (39) all SEQ ID NOs: 417-422; (40) all SEQ ID NOs: 427-432; (41) All SEQ ID NOs: 437-442; (42) all SEQ ID NOs: 447-452; (43) all SEQ ID NOs: 457-462; (44) all SEQ ID NOs: 477-482; or (45) all SEQ ID NOs: 487-492.
5. The TCR of any one of claims 1-3, wherein the TCR comprises the following amino acid sequence: (1) both SEQ ID NOs: 33-34; (2) both SEQ ID NOs:43-44; (3) both SEQ ID NOs: 53-54; (4) both SEQ ID NOs: 63-64; (5) both SEQ ID NOs:73-74; (6) both SEQ ID NOs:83-84; (7) both SEQ ID NOs: 103-104; (8) both SEQ ID NOs: 113-114; (9) both SEQ ID NOs: 123-124; (10) both SEQ ID NOs: 133-134; (11) both SEQ ID NOs: 143-144; (12) both SEQ ID NOs: 153-154; (13) both SEQ ID NOs: 163-164; (14) both SEQ ID NOs: 173-174; (15) both SEQ ID NOs: 183-184; (16) both SEQ ID NOs: 193-194; (17) both SEQ ID NOs: 203-204; (18) both SEQ ID NOs: 213-214; (19) both SEQ ID NOs: 223-224; (20) both SEQ ID NOs: 233-234; (21) both SEQ ID NOs: 243-244; (22) both SEQ ID NOs:253-254; (23) both SEQ ID NOs: 263-264; (24) both SEQ ID NOs: 273-274; (25) both SEQ ID NOs: 283-284; (26) both SEQ ID NOs: 293-294; (27) both SEQ ID NOs:303-304; (28) both SEQ ID NOs:313-314; (29) both SEQ ID NOs:323-324; (30) both SEQ ID NOs: 333-334; (31) both SEQ ID NOs:343-344; (32) both SEQ ID NOs:353-354; (33) both SEQ ID NOs:363-364; (34) both SEQ ID NOs:373-374; (35) both SEQ ID NOs:383-384; (36) both SEQ ID NOs:393-394; (37) both SEQ ID NOs:403-404; (38) SEQ ID NO: 413-414; (39) SEQ ID NO: 423-424; (40) both SEQ ID NOs:433-434; (41) both SEQ ID NOs:443-444; (42) both SEQ ID NOs:453-454; (43) both SEQ ID NOs:463-464; (44) both of SEQ ID NOs:483-484; or (45) Both SEQ ID NOs:493-494.
6. The TCR of any one of claims 1-3, wherein the TCR comprises the following amino acid sequence: (1) both SEQ ID NOs: 35-36; (2) both SEQ ID NOs:45-46; (3) both SEQ ID NOs: 55-56; (4) both SEQ ID NOs: 65-66; (5) both SEQ ID NOs:75-76; (6) both SEQ ID NOs:85-86; (7) both SEQ ID NOs: 105-106; (8) both SEQ ID NOs: 115-116; (9) both SEQ ID NOs: 125-126; (10) both SEQ ID NOs: 135-136; (11) both SEQ ID NOs:145-146; (12) both SEQ ID NOs:155-156; (13) both SEQ ID NOs:165-166; (14) both SEQ ID NOs:175-176; (15) both SEQ ID NOs:185-186; (16) both SEQ ID NOs:195-196; (17) both SEQ ID NOs:205-206; (18) both SEQ ID NOs:215-216; (19) both SEQ ID NOs:225-226; (20) both SEQ ID NOs:235-236; (21) both SEQ ID NOs:245-246; (22) both SEQ ID NOs:255-256; (23) both SEQ ID NOs:265-266; (24) both SEQ ID NOs:275-276; (25) SEQ ID NOs:285-286; (26) SEQ ID NOs:295-296; (27) SEQ ID NOs:305-306; (28) SEQ ID NOs:315-316; (29) SEQ ID NOs:325-326; (30) SEQ ID NOs:335-336; (31) SEQ ID NOs:345-346; (32) SEQ ID NOs:355-356; (33) SEQ ID NOs:365-366; (34) SEQ ID NOs:375-376; (35) SEQ ID NOs:385-386; (36) SEQ ID NOs:395-396; (37) SEQ ID NOs:405-406; (38) SEQ ID NOs:415-416; (39) SEQ ID NOs:416-417; NO: 425-426; (40) SEQ ID NO: 435-436; (41) both SEQ ID NOs:445-446; (42) both SEQ ID NOs:455-456; (43) both SEQ ID NOs:465-466; (44) both of SEQ ID NOs:485-486; or (45) Both SEQ ID NOs:495-496.
7. An isolated or purified polypeptide comprising a functional portion of the TCR according to any one of claims 1 to 3, wherein the polypeptide comprises the following amino acid sequence: (1) all SEQ ID NOs: 27-32; (2) all SEQ ID NOs: 37-42; (3) all SEQ ID NOs: 47-52; (4) all SEQ ID NOs: 57-62; (5) all SEQ ID NOs: 67-72; (6) all SEQ ID NOs: 77-82; (7) all SEQ ID NOs: 97-102; (8) all SEQ ID NOs: 107-112; (9) all SEQ ID NOs: 117-122; (10) all SEQ ID NOs: 127-132; (11) all SEQ ID NOs: 137-142; (12) all SEQ ID NOs: 147-152; (13) all SEQ ID NOs: 157-162; (14) all SEQ ID NOs: 167-172; (15) all SEQ ID NOs: 177-182; (16) all SEQ ID NOs: 187-192; (17) all SEQ ID NOs: 197-202; (18) all SEQ ID NOs: 207-212; (19) all SEQ ID NOs: 217-222; (20) all SEQ ID NOs: 227-232; (21) all SEQ ID NOs: 237-242; (22) all SEQ ID NOs: 247-252; (23) all SEQ ID NOs: 257-262; (24) all SEQ ID NOs: 267-272; (25) all SEQ ID NOs: 277-282; (26) all SEQ ID NOs: 287-292; (27) all SEQ ID NOs: 297-302; (28) all SEQ ID NOs: 307-312; (29) all SEQ ID NOs: 317-322; (30) all SEQ ID NOs: 327-332; (31) all SEQ ID NOs: 337-342; (32) all SEQ ID NOs: 347-352; (33) all SEQ ID NOs: 357-362; (34) all SEQ ID NOs: 367-372; (35) all SEQ ID NOs: 377-382; (36) all SEQ ID NOs: 387-392; (37) all SEQ ID NOs: 397-402; (38) all SEQ ID NOs: 407-412; (39) all SEQ ID NOs: 417-422; (40) all SEQ ID NOs: 427-432; (41) All SEQ ID NOs: 437-442; (42) all SEQ ID NOs: 447-452; (43) all SEQ ID NOs: 457-462; (44) all of SEQ ID NOs: 477-482; or (45) All SEQ ID NOs:487-492.
8. The polypeptide of claim 7, wherein the polypeptide comprises the following amino acid sequences: (1) both of SEQ ID NOs: 33-34; (2) both SEQ ID NOs:43-44; (3) both SEQ ID NOs: 53-54; (4) both SEQ ID NOs: 63-64; (5) both SEQ ID NOs:73-74; (6) both SEQ ID NOs:83-84; (7) both SEQ ID NOs:103-104; (8) both SEQ ID NOs:113-114; (9) both SEQ ID NOs:123-124; (10) both SEQ ID NOs:133-134; (11) both SEQ ID NOs:143-144; (12) both SEQ ID NOs:153-154; (13) both SEQ ID NOs:163-164; (14) both SEQ ID NOs:173-174; (15) both SEQ ID NOs:183-184; (16) both SEQ ID NOs:193-194; (17) both SEQ ID NOs:203-204; (18) both SEQ ID NOs:213-214; (19) both SEQ ID NOs:223-224; (20) NO:233-234; (21) SEQ ID NO:243-244; (22) SEQ ID NO:253-254; (23) SEQ ID NO:263-264; (24) SEQ ID NO:273-274; (25) SEQ ID NO:283-284; (26) SEQ ID NO:293-294; (27) SEQ ID NO:303-304; (28) SEQ ID NO:313-314; (29) SEQ ID NO:323-324; (30) SEQ ID NO:333-334; (31) SEQ ID NO:343-344; (32) SEQ ID NO:353-354; (33) SEQ ID NO:363-364; (34) SEQ ID NO:373-374 both; (35) SEQ ID NO:383-384 both; (36) SEQ ID NO:393-394 both; (37) both SEQ ID NOs:403-404; (38) SEQ ID NO: 413-414; (39) SEQ ID NO: 423-424; (40) both SEQ ID NOs:433-434; (41) both SEQ ID NOs:443-444; (42) both SEQ ID NOs:453-454; (43) both SEQ ID NOs:463-464; (44) both of SEQ ID NOs:483-484; or (45) Both SEQ ID NOs:493-494.
9. The polypeptide of claim 7, wherein the polypeptide comprises the following amino acid sequences: (1) both of SEQ ID NOs: 35-36; (2) both SEQ ID NOs:45-46; (3) both SEQ ID NOs: 55-56; (4) both SEQ ID NOs: 65-66; (5) both SEQ ID NOs:75-76; (6) both SEQ ID NOs:85-86; (7) both SEQ ID NOs: 105-106; (8) both SEQ ID NOs: 115-116; (9) both SEQ ID NOs: 125-126; (10) both SEQ ID NOs: 135-136; (11) both SEQ ID NOs: 145-146; (12) both SEQ ID NOs: 155-156; (13) both SEQ ID NOs: 165-166; (14) both SEQ ID NOs: 175-176; (15) both SEQ ID NOs: 185-186; (16) both SEQ ID NOs: 195-196; (17) both SEQ ID NOs: 205-206; (18) both SEQ ID NOs:215-216; (19) both SEQ ID NOs: 225-226; (20) both SEQ ID NOs: 235-236; (21) both SEQ ID NOs: 245-246; (22) both SEQ ID NOs:255-256; (23) both SEQ ID NOs: 265-266; (24) both SEQ ID NOs: 275-276; (25) both SEQ ID NOs: 285-286; (26) both SEQ ID NOs: 295-296; (27) both SEQ ID NOs:305-306; (28) both SEQ ID NOs:315-316; (29) both SEQ ID NOs:325-326; (30) both SEQ ID NOs:335-336; (31) both SEQ ID NOs:345-346; (32) both SEQ ID NOs:355-356; (33) both SEQ ID NOs:365-366; (34) both SEQ ID NOs:375-376; (35) both SEQ ID NOs:385-386; (36) both SEQ ID NOs:395-396; (37) both SEQ ID NOs:405-406; (38) both SEQ ID NOs:415-416; (39) both SEQ ID NOs:425-426; (40) both SEQ ID NOs:435-436; (41) both SEQ ID NOs:445-446; (42) both SEQ ID NOs:455-456; (43) both SEQ ID NOs:465-466; (44) both of SEQ ID NOs:485-486; or (45) Both SEQ ID NOs:495-496.
10. An isolated or purified protein comprising: (1) a first polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 27-29 and a second polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 30-32; (2) a first polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 37-39 and a second polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 40-42; (3) a first polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 47-49 and a second polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 50-52; (4) a first polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 57-59 and a second polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 60-62; (5) a first polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 67-69 and a second polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 70-72; (6) a first polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 77-79 and a second polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 80-82; (7) a first polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 97-99 and a second polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 100-102; (8) a first polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 107-109 and a second polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 110-112; (9) a first polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 117-119 and a second polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 120-122; (10) a first polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 127-129 and a second polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 130-132; (11) a first polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 137-139 and a second polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 140-142; (12) a first polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 147-149 and a second polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 150-152; (13) a first polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 157-159 and a second polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 160-162; (14) a first polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 167-169 and a second polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 170-172; (15) a first polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 177-179 and a second polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 180-182; (16) a first polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 187-189 and a second polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 190-192; (17) a first polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 197-199 and a second polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 200-202; (18) a first polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 207-209 and a second polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 210-212; (19) a first polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 217-219 and a second polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 220-222; (20) a first polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 227-229 and a second polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 230-232; (21) a first polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 237-239 and a second polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 240-242; (22) a first polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 247-249 and a second polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 250-252; (23) a first polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 257-259 and a second polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 260-262; (24) a first polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 267-269 and a second polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 270-272; (25) a first polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 277-279 and a second polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 280-282; (26) a first polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 287-289 and a second polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 290-292; (27) a first polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 297-299 and a second polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 300-302; (28) a first polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 307-309 and a second polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 310-312; (29) a first polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 317-319 and a second polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 320-322; (30) a first polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 327-329 and a second polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 330-332; (31) a first polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 337-339 and a second polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 340-342; (32) a first polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 347-349 and a second polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 350-352; (33) a first polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 357-359 and a second polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 360-362; (34) a first polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 367-369 and a second polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 370-372; (35) a first polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 377-379 and a second polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 380-382; (36) a first polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 387-389 and a second polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 390-392; (37) a first polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 397-399 and a second polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 400-402; (38) a first polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 407-409 and a second polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 410-412; (39) a first polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 417-419 and a second polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 420-422; (40) a first polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 427-429 and a second polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 430-432; (41) a first polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 437-439 and a second polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 440-442; (42) a first polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 447-449 and a second polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 450-452; (43) a first polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 457-459 and a second polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 460-462; (44) a first polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 477 to 479 and a second polypeptide chain comprising the amino acid sequence of all of SEQ ID NOs: 480 to 482; or (45) A first polypeptide chain comprising the amino acid sequence of all SEQ ID NOs: 487-489 and a second polypeptide chain comprising the amino acid sequence of all SEQ ID NOs: 490-492.
11. The protein of claim 10, wherein: (1) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 33, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 34; (2) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:43, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:44; (3) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:53, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:54; (4) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 63, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 64; (5) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 73, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 74; (6) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 83, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 84; (7) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 103, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 104; (8) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 113, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 114; (9) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 123, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 124; (10) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 133, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 134; (11) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 143, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 144; (12) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 153, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 154; (13) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 163, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 164; (14) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 173, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 174; (15) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 183, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 184; (16) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 193, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 194; (17) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 203, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 204; (18) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 213, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 214; (19) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 223, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 224; (20) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 233, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 234; (21) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 243, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 244; (22) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 253, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 254; (23) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 263, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 264; (24) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 273, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 274; (25) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 283, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 284; (26) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 293, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 294; (27) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 303, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 304; (28) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 313, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 314; (29) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 323, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 324; (30) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 333, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 334; (31) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 343, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 344; (32) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 353, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 354; (33) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 363, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 364; (34) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 373, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 374; (35) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 383, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 384; (36) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 393, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 394; (37) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 403, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 404; (38) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:413, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:414; (39) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 423, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 424; (40) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 433, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 434; (41) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 443, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 444; (42) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 453, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 454; (43) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 463, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 464; (44) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 483, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 484; or (45) The first polypeptide chain comprises the amino acid sequence of SEQ ID NO:493, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:
494.
12. The protein of claim 10 or 11, wherein: (1) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 35, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 36; (2) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:45, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:46; (3) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:55, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:56; (4) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 65, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 66; (5) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 75, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 76; (6) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 85, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 86; (7) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 105, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 106; (8) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 115, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 116; (9) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 125, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 126; (10) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 135, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 136; (11) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 145, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 146; (12) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 155, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 156; (13) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 165, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 166; (14) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 175, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 176; (15) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 185, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 186; (16) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 195, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 196; (17) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 205, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 206; (18) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 215, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 216; (19) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 225, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 226; (20) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 235, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 236; (21) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 245, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 246; (22) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 255, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 256; (23) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 265, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 266; (24) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 275, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 276; (25) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 285, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 286; (26) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 295, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 296; (27) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 305, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 306; (28) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 315, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 316; (29) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 325, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 326; (30) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 335, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 336; (31) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 345, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 346; (32) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 355, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 356; (33) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 365, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 366; (34) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 375, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 376; (35) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 385, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 386; (36) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 395, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 396; (37) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:405, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:406; (38) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:415, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:416; (39) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:425, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:426; (40) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 435, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 436; (41) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 445, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 446; (42) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 455, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 456; (43) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 465, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 466; (44) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 485, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 486; or (45) The first polypeptide chain comprises the amino acid sequence of SEQ ID NO:495, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:
496.
13. An isolated or purified nucleic acid comprising a nucleotide sequence encoding a TCR as claimed in any one of claims 1 to 6, a polypeptide as claimed in any one of claims 7 to 9, or a protein as claimed in any one of claims 10 to 12. A recombinant expression vector comprising the nucleic acid of claim 13 .
15. An isolated or purified host cell comprising the recombinant expression vector according to claim 14.
16. An isolated or purified cell population comprising the host cell of claim 15.
17. A pharmaceutical composition comprising (a) the TCR of any one of claims 1-6, the polypeptide of any one of claims 7-9, the protein of any one of claims 10-12, the nucleic acid of claim 13, the recombinant expression vector of claim 14, the host cell of claim 15 or the cell population of claim 16, and (b) a pharmaceutically acceptable carrier.
18. A method for detecting the presence of cancer in a mammal, the method comprising: (a) contacting a sample containing cells of the cancer with the TCR of any one of claims 1 to 6, the polypeptide of any one of claims 7 to 9, the protein of any one of claims 10 to 12, the nucleic acid of claim 13, the recombinant expression vector of claim 14, the host cell of claim 15, the cell population of claim 16, or the pharmaceutical composition of claim 17, thereby forming a complex; and (b) detecting the complex. in, Detection of the complex indicates the presence of cancer in the mammal.
19. Use of the TCR of any one of claims 1-6, the polypeptide of any one of claims 7-9, the protein of any one of claims 10-12, the nucleic acid of claim 13, the recombinant expression vector of claim 14, the host cell of claim 15, the cell population of claim 16 or the pharmaceutical composition of claim 17 in the preparation of a medicament for treating or preventing cancer in a mammal.
20. The use of claim 19, wherein the cell population is autologous to the mammal.
21. The use of claim 19, wherein the cell population is allogeneic to the mammal.
22. The use according to any one of claims 19 to 21, wherein the cancer is an epithelial cancer.
23. The use according to any one of claims 19 to 21, wherein the cancer is bile duct cancer, melanoma, colon cancer, rectal cancer, ovarian cancer, endometrial cancer, non-small cell lung cancer (NSCLC), glioblastoma, cervical cancer, head and neck cancer, breast cancer, pancreatic cancer or bladder cancer.
